PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25316809-4	2014	RESULTS: We demonstrate in vitro that SGI-110 resensitized a range of platinum-resistant ovarian cancer cells to cisplatin (CDDP) and induced significant demethylation and reexpression of TSG, differentiation-associated genes, and putative drivers of ovarian cancer cisplatin resistance.	cddp	124-128	chromogranin B	Homo sapiens	38-41
25473899-4	2015	We showed evidence that increased ZHX2 levels correlated with reduced MDR1 expression and enhanced the cytotoxicity of CDDP and ADM in different HCC cell lines.	cddp	119-123	zinc fingers and homeoboxes 2	Homo sapiens	34-38
25473899-5	2015	Consistently, elevated ZHX2 significantly reduced ADM efflux in HepG2 cells and greatly increased the CDDP-mediated suppression of liver tumor growth in vivo.	cddp	102-106	zinc fingers and homeoboxes 2	Homo sapiens	23-27
26004625-6	2015	Mechanism of copper-lowering agents in enhancing hCtr1-mediated cis-diamminedichloroplatinum (II) (cisplatin, cDDP) transport is reviewed.	cddp	110-114	solute carrier family 31 member 1	Homo sapiens	49-54
26004625-7	2015	Applications of copper chelation strategy in overcoming cDDP resistance through enhanced hCtr1 expression are evaluated.	cddp	56-60	solute carrier family 31 member 1	Homo sapiens	89-94
25352209-10	2015	Furthermore, CDDP (4, 10, 15 microg/ml)-resistant human non-small lung cancer cells A549 (A549-CDDPr-4, 10, 15) expressed significant amounts of Merm1/Wbscr22 protein, as compared with the parental A549 cells.	cddp	13-17	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	145-150
25352209-10	2015	Furthermore, CDDP (4, 10, 15 microg/ml)-resistant human non-small lung cancer cells A549 (A549-CDDPr-4, 10, 15) expressed significant amounts of Merm1/Wbscr22 protein, as compared with the parental A549 cells.	cddp	13-17	BUD23 rRNA methyltransferase and ribosome maturation factor	Homo sapiens	151-158
25316809-7	2014	Furthermore, DNA damage induced by CDDP in ovarian cancer cells was increased by SGI-110, as measured by inductively coupled plasma-mass spectrometry analysis of DNA adduct formation and repair of cisplatin-induced DNA damage.	cddp	35-39	chromogranin B	Homo sapiens	81-84
25731522-11	2014	The present case suggests that capecitabine/CDDP therapy may be an effective treatment for S-1 pretreated patients with advanced or metastatic gastric cancer.	cddp	44-48	proteasome 26S subunit, non-ATPase 1	Homo sapiens	91-94
25281617-9	2014	Significant reductions in Ki-67 indices were seen in all treatment groups, whereas significant increases in caspase-3 activity were only seen in the CDDP treatment groups.	cddp	149-153	caspase 3	Homo sapiens	108-117
25246592-4	2014	cis-Diammine dichloroplatinium (II) (CDDP)-induced GSN down-regulation is associated with its cleavage and apoptosis.	cddp	37-41	gelsolin	Homo sapiens	51-54
25352299-7	2014	Throughout the study, CDDP patients had a lower erythropoietin resistance index, lower beta2 microglobulin levels and lower need for cinacalcet of phosphate binders than THD, and stable parameters of nutritional status.	cddp	22-26	erythropoietin	Homo sapiens	48-62
25352299-7	2014	Throughout the study, CDDP patients had a lower erythropoietin resistance index, lower beta2 microglobulin levels and lower need for cinacalcet of phosphate binders than THD, and stable parameters of nutritional status.	cddp	22-26	beta-2-microglobulin	Homo sapiens	87-106
25352299-11	2014	CDDP also blunted the rapid beta2 microglobulin increase and resulted in better control of anemia and calcium-phosphate abnormalities.	cddp	0-4	beta-2-microglobulin	Homo sapiens	28-47
25352299-12	2014	CDDP was also associated with a lower hospitalization rate and reduced need of erythropoietin, as well as of drugs used for treatment of calcium-phosphate abnormalities, thus leading to a significant cost-saving.	cddp	0-4	erythropoietin	Homo sapiens	79-93
25063739-0	2014	MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG.	cddp	99-103	microRNA 370	Homo sapiens	0-12
25063739-0	2014	MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG.	cddp	99-103	endoglin	Homo sapiens	129-132
25063739-4	2014	miR-370 also enhanced endometrioid ovarian cancer cell chemosensitivity to cDDP.	cddp	75-79	microRNA 370	Homo sapiens	0-7
25246592-6	2014	GSN silencing also facilitated CDDP-induced apoptosis in chemoresistant cells.	cddp	31-35	gelsolin	Homo sapiens	0-3
25246592-7	2014	In contrast, intact GSN (I-GSN) was prosurvival in the presence of CDDP through a FLICE-like inhibitory protein (FLIP)-Itch interaction.	cddp	67-71	gelsolin	Homo sapiens	20-23
25246592-7	2014	In contrast, intact GSN (I-GSN) was prosurvival in the presence of CDDP through a FLICE-like inhibitory protein (FLIP)-Itch interaction.	cddp	67-71	gelsolin	Homo sapiens	27-30
25246592-7	2014	In contrast, intact GSN (I-GSN) was prosurvival in the presence of CDDP through a FLICE-like inhibitory protein (FLIP)-Itch interaction.	cddp	67-71	itchy E3 ubiquitin protein ligase	Homo sapiens	119-123
24865317-4	2014	cDDP treatment reduced concentration of GSH and increased TBARS, parameters that were ameliorated in treatment associated with LT. cDDP altered the expression of 32 genes, increasing the expression of GPx2, APC, Nqo1 and CCs.	cddp	0-4	glutathione peroxidase 2	Mus musculus	201-205
25248902-5	2014	S-1/CDDP plus trastuzumab therapy as NAC for HER2-positive, advanced gastric cancer appears to be an effective treatment.	cddp	4-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49
25078298-2	2014	The aim of the present study is to fabricate cis-dichlorodiamminoplatinum (II) (CDDP) loaded glyconanoparticles using hyaluronic acid (HA) which is also known as the endogenous substrate for CD44 in vivo.	cddp	80-84	CD44 molecule (Indian blood group)	Homo sapiens	191-195
25895391-6	2014	Finally, homology modeling and molecular docking were employed to simulate their interaction between the P2Y purinoceptor 12 (P2Y12) target and bioactive compounds contained in CDDP.	cddp	177-181	purinergic receptor P2Y12	Rattus norvegicus	105-124
25895391-6	2014	Finally, homology modeling and molecular docking were employed to simulate their interaction between the P2Y purinoceptor 12 (P2Y12) target and bioactive compounds contained in CDDP.	cddp	177-181	purinergic receptor P2Y12	Rattus norvegicus	126-131
25895391-9	2014	The molecular docking showed that bioactive compounds contained in CDDP was able to inhibit target P2Y12.	cddp	67-71	purinergic receptor P2Y12	Rattus norvegicus	99-104
25087851-9	2014	The suppression of major vault protein (MVP) by RNA interference restored the sensitivity to CDDP.	cddp	93-97	major vault protein	Homo sapiens	40-43
25087851-12	2014	Furthermore, we found that the synergistic effect of ECyd and CDDP was correlated with the MVP expression level when the effect was analyzed in additional cancer cell lines.	cddp	62-66	major vault protein	Homo sapiens	91-94
24865317-4	2014	cDDP treatment reduced concentration of GSH and increased TBARS, parameters that were ameliorated in treatment associated with LT. cDDP altered the expression of 32 genes, increasing the expression of GPx2, APC, Nqo1 and CCs.	cddp	0-4	NAD(P)H dehydrogenase, quinone 1	Mus musculus	212-216
24865317-4	2014	cDDP treatment reduced concentration of GSH and increased TBARS, parameters that were ameliorated in treatment associated with LT. cDDP altered the expression of 32 genes, increasing the expression of GPx2, APC, Nqo1 and CCs.	cddp	131-135	glutathione peroxidase 2	Mus musculus	201-205
24865317-4	2014	cDDP treatment reduced concentration of GSH and increased TBARS, parameters that were ameliorated in treatment associated with LT. cDDP altered the expression of 32 genes, increasing the expression of GPx2, APC, Nqo1 and CCs.	cddp	131-135	NAD(P)H dehydrogenase, quinone 1	Mus musculus	212-216
24464223-3	2014	Here, we demonstrate that CDDP-resistant non-small lung cancer cells undergo profound remodeling of their endoplasmic reticulum (ER) proteome (>80 proteins identified by proteomics) and exhibit a dramatic overexpression of two protein disulfide isomerases, PDIA4 and PDIA6, without any alteration in ER-cytosol Ca(2+) fluxes.	cddp	26-30	protein disulfide isomerase family A member 4	Homo sapiens	260-265
25024611-13	2014	Furthermore, cells treated with ZnPP IX plus CDDP exhibited marked production of intracellular ROS and caspase-3 activity, which paralleled the incidence of cell apoptosis, whereas hemin decreased cellular ROS and caspase-3 activity induced by CDDP.	cddp	45-49	caspase 3	Mus musculus	103-112
25024611-13	2014	Furthermore, cells treated with ZnPP IX plus CDDP exhibited marked production of intracellular ROS and caspase-3 activity, which paralleled the incidence of cell apoptosis, whereas hemin decreased cellular ROS and caspase-3 activity induced by CDDP.	cddp	45-49	caspase 3	Mus musculus	214-223
25024611-13	2014	Furthermore, cells treated with ZnPP IX plus CDDP exhibited marked production of intracellular ROS and caspase-3 activity, which paralleled the incidence of cell apoptosis, whereas hemin decreased cellular ROS and caspase-3 activity induced by CDDP.	cddp	244-248	caspase 3	Mus musculus	214-223
24038379-6	2014	The drug sensitivity assay indicated that miR-495 enhanced the cell response to cisplatin (CDDP) in NSCLC cells, while inhibition of miR-495 led to the opposite effects.	cddp	91-95	microRNA 495	Homo sapiens	42-49
24038379-8	2014	We also demonstrated that miR-495 increased the intracellular CDDP accumulation and overexpression of ATP7A can reduce the increased drug concentration induced by miR-495.	cddp	62-66	microRNA 495	Homo sapiens	26-33
24038379-9	2014	Finally, we discovered that there was a converse relationship between miR-495 and ATP7A levels in NSCLC tissues sensitive or resistant to CDDP.	cddp	138-142	microRNA 495	Homo sapiens	70-77
24038379-9	2014	Finally, we discovered that there was a converse relationship between miR-495 and ATP7A levels in NSCLC tissues sensitive or resistant to CDDP.	cddp	138-142	ATPase copper transporting alpha	Homo sapiens	82-87
24464223-3	2014	Here, we demonstrate that CDDP-resistant non-small lung cancer cells undergo profound remodeling of their endoplasmic reticulum (ER) proteome (>80 proteins identified by proteomics) and exhibit a dramatic overexpression of two protein disulfide isomerases, PDIA4 and PDIA6, without any alteration in ER-cytosol Ca(2+) fluxes.	cddp	26-30	protein disulfide isomerase family A member 6	Homo sapiens	270-275
24402872-10	2014	In contrast, CDDP-treated group showed a significant down regulation in the expression levels of Bcl-2 mRNA as compared to untreated control group.	cddp	13-17	BCL2 apoptosis regulator	Homo sapiens	97-102
25594011-3	2014	In this study, we found that down-regulation of alphaV sensitized human M21 cells to cisplatin (cDDP) through up-regulation of the copper influx transporter CTR1.	cddp	96-100	solute carrier family 31 member 1	Homo sapiens	157-161
25594011-8	2014	These results indicate that the alphaV integrin modulates sensitivity of human cells to the cytotoxic effect of cDDP by regulating expression of the Cu transporter CTR1, and introduce the concept that alphaV expression is linked to Cu homeostasis.	cddp	112-116	solute carrier family 31 member 1	Homo sapiens	164-168
24710469-5	2014	This study suggests that CDDP protects against CVDs potentially by attenuation of leukocytes-endothelium adhesion cascade via lessening endothelial cell adhesion molecules expression and NF-kappaB signaling pathway activity.	cddp	25-29	nuclear factor kappa B subunit 1	Homo sapiens	187-196
24396470-0	2014	miR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis.	cddp	43-47	caspase 3	Homo sapiens	62-71
24396470-4	2014	We demonstrated that overexpression of miR-101 sensitized A549 cells to CDDP, one of the most frequently used agents in curing or controlling NSCLC and enhanced CDDP-induced cell death and caspase 3-dependent apoptosis.	cddp	72-76	caspase 3	Homo sapiens	189-198
24396470-6	2014	Overall, the results of the present study demonstrated that miR-101 sensitizes the A549 NSCLC cell line to CDDP via the activation of caspase 3-dependent apoptosis.	cddp	107-111	caspase 3	Homo sapiens	134-143
24199607-5	2014	The genes LMNB1 and CENPF, within the cytoskeletal part GS, were functionally validated with siRNA knockdown experiments, where the knockdown of LMNB1 and CENPF resulted in CDDP resistance in multiple cancer cell lines.	cddp	173-177	lamin B1	Homo sapiens	10-15
25580427-8	2014	The emodin-enhanced cDDP cytotoxicity was attributable to downregulation of multidrug resistance-related protein 1 (MRP1) expression.	cddp	20-24	ATP binding cassette subfamily C member 1	Homo sapiens	76-114
25580427-8	2014	The emodin-enhanced cDDP cytotoxicity was attributable to downregulation of multidrug resistance-related protein 1 (MRP1) expression.	cddp	20-24	ATP binding cassette subfamily C member 1	Homo sapiens	116-120
25580427-9	2014	Together, these results suggest that emodin could act as an adjunct to enhance the anticancer effect of cDDP likely through ROS-related downregulation of MRP1 expression, and may be of therapeutic potential in cDDP-refractory ovarian carcinomas.	cddp	104-108	ATP binding cassette subfamily C member 1	Homo sapiens	154-158
24199607-5	2014	The genes LMNB1 and CENPF, within the cytoskeletal part GS, were functionally validated with siRNA knockdown experiments, where the knockdown of LMNB1 and CENPF resulted in CDDP resistance in multiple cancer cell lines.	cddp	173-177	centromere protein F	Homo sapiens	20-25
24199607-5	2014	The genes LMNB1 and CENPF, within the cytoskeletal part GS, were functionally validated with siRNA knockdown experiments, where the knockdown of LMNB1 and CENPF resulted in CDDP resistance in multiple cancer cell lines.	cddp	173-177	lamin B1	Homo sapiens	145-150
24199607-5	2014	The genes LMNB1 and CENPF, within the cytoskeletal part GS, were functionally validated with siRNA knockdown experiments, where the knockdown of LMNB1 and CENPF resulted in CDDP resistance in multiple cancer cell lines.	cddp	173-177	centromere protein F	Homo sapiens	155-160
23543413-3	2013	It has been claimed that human copper transporter 1 (hCTR1), the human high-affinity copper transporter, is the major entry pathway for cDDP and related drugs via a mechanism that mimics copper.	cddp	136-140	solute carrier family 31 member 1	Homo sapiens	31-51
23969950-5	2013	The data showed that the expression of ING4 mRNA and protein was dramatically downregulated (or lost) in gastric carcinoma SGC7901/CDDP cells after CDDP-induced MDR phenotype and in the parental SGC7901 cells.	cddp	131-135	inhibitor of growth family member 4	Homo sapiens	39-43
23997830-2	2013	Recently, two randomized phase III trials of S-1 combined with cisplatin (CDDP) or carboplatin (CBDCA) compared with the standard platinum doublet chemotherapy were reported.	cddp	74-78	proteasome 26S subunit, non-ATPase 1	Homo sapiens	45-48
23296900-9	2013	Furthermore, miR-182 reduced the chemosensitivity of ovarian cancer cells to CDDP and Taxol, possibly by its anti-apoptosis activity.	cddp	77-81	microRNA 182	Homo sapiens	13-20
24483116-1	2013	OBJECTIVE: To investigate effect of Compound Danshen Dripping Pill (CDDP) on the inflammatory response of the myocardium of acute myocardial infarction (AMI) rabbits, to observe the therapeutic effect of CDDP combined intravenous transplantation of human umbilical cord blood mononuclear cells (HUCBMCs) on inflammatory response, pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha) , and heart function in the myocardium of AMI rabbits, and to explore the possible protective mechanisms of the combined therapy.	cddp	68-72	tumor necrosis factor	Homo sapiens	356-383
24483116-1	2013	OBJECTIVE: To investigate effect of Compound Danshen Dripping Pill (CDDP) on the inflammatory response of the myocardium of acute myocardial infarction (AMI) rabbits, to observe the therapeutic effect of CDDP combined intravenous transplantation of human umbilical cord blood mononuclear cells (HUCBMCs) on inflammatory response, pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha) , and heart function in the myocardium of AMI rabbits, and to explore the possible protective mechanisms of the combined therapy.	cddp	68-72	tumor necrosis factor	Homo sapiens	385-394
24483116-12	2013	(2) Compared with the control group, the number of white blood cells and the expression of TNF-alpha protein decreased significantly in the CDDP, transplantation, and combined groups at week 1 and 4 respectively after treatment.	cddp	140-144	tumor necrosis factor	Oryctolagus cuniculus	91-100
24122978-3	2013	The human high-affinity copper (Cu) transporter-1 (hCtr1) can also transport Pt-based drugs including cisplatin (cDDP) and carboplatin.	cddp	113-117	solute carrier family 31 member 1	Homo sapiens	51-56
24122978-4	2013	Reduced hCtr1 expression frequently occurs in cDDP-resistant cell lines and in cancer in patients who failed chemotherapy with these drugs.	cddp	46-50	solute carrier family 31 member 1	Homo sapiens	8-13
24122978-8	2013	Indeed, we found that cDDP resistance can be overcome by Cu-lowering agents through enhanced hCtr1 expression by up-regulation of Sp1 in cultured cells.	cddp	22-26	solute carrier family 31 member 1	Homo sapiens	93-98
23543413-3	2013	It has been claimed that human copper transporter 1 (hCTR1), the human high-affinity copper transporter, is the major entry pathway for cDDP and related drugs via a mechanism that mimics copper.	cddp	136-140	solute carrier family 31 member 1	Homo sapiens	53-58
23012319-2	2013	It was revealed that both ACA and CDDP induced dose- and time-dependent cytotoxicity when used as a stand-alone agent, while synergistic effects were observed when used in combination with a combination index (CI) value of 0.74 +- 0.01 and 0.85 +- 0.01 in Ca Ski and HeLa cells, respectively.	cddp	34-38	SKI proto-oncogene	Homo sapiens	259-262
23848022-6	2013	After starting S-1 + CDDP + trastuzumab, the AFP was normalized immediately (7.	cddp	21-25	alpha fetoprotein	Homo sapiens	45-48
23246440-6	2013	Transfection with either YY1 or BclXL siRNA resulted in the inhibition of both YY1 and BclXL expressions and sensitized the cells to CDDP apoptosis.	cddp	133-137	YY1 transcription factor	Homo sapiens	25-28
23452395-10	2013	At the cytological level, SSX2IP stimulates the wound healing, metastasis and invasion of hepatoma cells, and reduces the sensitivity of hepatoma cells to 5-Fu and CDDP.	cddp	164-168	synovial sarcoma, X 2 interacting protein	Mus musculus	26-32
23246440-6	2013	Transfection with either YY1 or BclXL siRNA resulted in the inhibition of both YY1 and BclXL expressions and sensitized the cells to CDDP apoptosis.	cddp	133-137	BCL2 like 1	Homo sapiens	32-37
23246440-10	2013	Overall, the above findings suggest that one mechanism of DETANONOate-induced sensitization of resistant tumor cells to CDDP correlated with the inhibition of NF-kappaB and its targets YY1 and BclXL.	cddp	120-124	YY1 transcription factor	Homo sapiens	185-188
23246440-10	2013	Overall, the above findings suggest that one mechanism of DETANONOate-induced sensitization of resistant tumor cells to CDDP correlated with the inhibition of NF-kappaB and its targets YY1 and BclXL.	cddp	120-124	BCL2 like 1	Homo sapiens	193-198
24133631-8	2013	After CDDP-HAI, 15 HCCs shrunk and 27 HCCs grew.	cddp	6-10	holocytochrome c synthase	Homo sapiens	19-23
23429295-7	2013	RXN markedly attenuated CDDP-induced intracellular ROS and significantly reduced CDDP-activated expression of p-extracellular regulated kinase (ERK), BAX, cytochrome c, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase, but increased BCL-XL expression.	cddp	81-85	Eph receptor B1	Rattus norvegicus	110-142
23429295-7	2013	RXN markedly attenuated CDDP-induced intracellular ROS and significantly reduced CDDP-activated expression of p-extracellular regulated kinase (ERK), BAX, cytochrome c, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase, but increased BCL-XL expression.	cddp	81-85	Eph receptor B1	Rattus norvegicus	144-147
23429295-7	2013	RXN markedly attenuated CDDP-induced intracellular ROS and significantly reduced CDDP-activated expression of p-extracellular regulated kinase (ERK), BAX, cytochrome c, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase, but increased BCL-XL expression.	cddp	81-85	BCL2 associated X, apoptosis regulator	Rattus norvegicus	150-153
23429295-7	2013	RXN markedly attenuated CDDP-induced intracellular ROS and significantly reduced CDDP-activated expression of p-extracellular regulated kinase (ERK), BAX, cytochrome c, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase, but increased BCL-XL expression.	cddp	81-85	Bcl2-like 1	Rattus norvegicus	243-249
23287530-2	2013	Thus, the siRNA-mediated downregulation of pyridoxal kinase (PDXK), the enzyme that generates the bioactive form of vitamin B6, protects NSCLC cells (as well as a large collection of human and murine malignant cells of distinct histological derivation) from the cytotoxic effects of CDDP.	cddp	283-287	pyridoxal kinase	Homo sapiens	43-59
23287530-2	2013	Thus, the siRNA-mediated downregulation of pyridoxal kinase (PDXK), the enzyme that generates the bioactive form of vitamin B6, protects NSCLC cells (as well as a large collection of human and murine malignant cells of distinct histological derivation) from the cytotoxic effects of CDDP.	cddp	283-287	pyridoxal kinase	Homo sapiens	61-65
24133631-10	2013	On the other hand, the growth rate of the enlarged HCCs was significantly correlated with CDDP dose after normalization with creatinine clearance.	cddp	90-94	holocytochrome c synthase	Homo sapiens	51-55
23053666-2	2013	We found that knockdown of the expression of either CLDN3 or CLDN4 produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to cisplatin (cDDP).	cddp	183-187	claudin 4	Homo sapiens	61-66
23229154-6	2013	Verapamil/CDDP co-treatment inhibited tumor xenograft growth via             the downregulation of MRP1 expression.	cddp	10-14	ATP binding cassette subfamily C member 1	Homo sapiens	99-103
23311997-9	2013	More importantly, the proportions of early/late apoptosis in AGS cells were enhanced with cis-diaminedichloroplatinum (cisplatin, CDDP) treatment, but to a higher extent with cisplatin plus CAC1-siRNA.	cddp	130-134	milk fat globule EGF and factor V/VIII domain containing	Rattus norvegicus	61-64
23493492-6	2013	To test this hypothesis, we exposed cDDP-treated cells to extracellular copper in order to hinder the human cell copper transporter (hCTR1)-mediated active transport of cDDP.	cddp	36-40	solute carrier family 31 member 1	Homo sapiens	133-138
23493492-6	2013	To test this hypothesis, we exposed cDDP-treated cells to extracellular copper in order to hinder the human cell copper transporter (hCTR1)-mediated active transport of cDDP.	cddp	169-173	solute carrier family 31 member 1	Homo sapiens	133-138
23053666-2	2013	We found that knockdown of the expression of either CLDN3 or CLDN4 produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to cisplatin (cDDP).	cddp	183-187	claudin 3	Homo sapiens	52-57
23053666-4	2013	Knockdown of CLDN3 or CLDN4 rendered human ovarian carcinoma 2008 cells resistant to cDDP in both in vitro culture and in vivo xenograft model.	cddp	85-89	claudin 3	Homo sapiens	13-18
23053666-4	2013	Knockdown of CLDN3 or CLDN4 rendered human ovarian carcinoma 2008 cells resistant to cDDP in both in vitro culture and in vivo xenograft model.	cddp	85-89	claudin 4	Homo sapiens	22-27
23053666-6	2013	The endogenous mRNA levels of copper influx transporter CTR1 were found to be significantly reduced in the knockdown cells, and exogenous expression of CTR1 restored their sensitivity to cDDP.	cddp	187-191	solute carrier family 31 member 1	Homo sapiens	152-156
23053666-7	2013	Reexpression of an shRNAi-resistant CLDN3 or CLDN4 up-regulated CTR1 levels, reversed the cDDP resistance, and enhanced TJ formation in the knockdown cells.	cddp	90-94	claudin 3	Homo sapiens	36-41
23053666-7	2013	Reexpression of an shRNAi-resistant CLDN3 or CLDN4 up-regulated CTR1 levels, reversed the cDDP resistance, and enhanced TJ formation in the knockdown cells.	cddp	90-94	claudin 4	Homo sapiens	45-50
23053666-10	2013	These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the Cu transporter CTR1.	cddp	118-122	claudin 3	Homo sapiens	28-33
23053666-10	2013	These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the Cu transporter CTR1.	cddp	118-122	claudin 4	Homo sapiens	38-43
23053666-10	2013	These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the Cu transporter CTR1.	cddp	118-122	solute carrier family 31 member 1	Homo sapiens	170-174
23098063-4	2012	Initial screening to explorer association of IC(50) values of CDDP obtained by MTT assay and gene expression levels measured with oligonucleotide microarray and real-time RT-PCR provided 6 candidate genes, namely, NUBPL, C9orf30, ZNF12, TMEM158, GSK3B, and FBLP1 using 9 lung cancer cells consisting of 3 small and 6 NSCLC cells.	cddp	62-66	NUBP iron-sulfur cluster assembly factor, mitochondrial	Homo sapiens	214-219
23098063-4	2012	Initial screening to explorer association of IC(50) values of CDDP obtained by MTT assay and gene expression levels measured with oligonucleotide microarray and real-time RT-PCR provided 6 candidate genes, namely, NUBPL, C9orf30, ZNF12, TMEM158, GSK3B, and FBLP1 using 9 lung cancer cells consisting of 3 small and 6 NSCLC cells.	cddp	62-66	Myb/SANT DNA binding domain containing 3	Homo sapiens	221-228
23098063-4	2012	Initial screening to explorer association of IC(50) values of CDDP obtained by MTT assay and gene expression levels measured with oligonucleotide microarray and real-time RT-PCR provided 6 candidate genes, namely, NUBPL, C9orf30, ZNF12, TMEM158, GSK3B, and FBLP1 using 9 lung cancer cells consisting of 3 small and 6 NSCLC cells.	cddp	62-66	zinc finger protein 12	Homo sapiens	230-235
21377848-0	2012	Urinary cystatin C as a biomarker for acute kidney injury and its immunohistochemical localization in kidney in the CDDP-treated rats.	cddp	116-120	cystatin C	Rattus norvegicus	8-18
21377848-2	2012	In the present study, we examined the urinary and plasma levels of cystatin C and how useful they are for the early detection of acute kidney injury (AKI) in CDDP-treated rats in comparison with other biomarkers (beta2-microglobulin, calbindin, clusterin, EGF, GST-alpha, GST-mu, KIM-1, NGAL, osteopontin, TIMP-1, and VEGF).	cddp	158-162	cystatin C	Rattus norvegicus	67-77
23098063-4	2012	Initial screening to explorer association of IC(50) values of CDDP obtained by MTT assay and gene expression levels measured with oligonucleotide microarray and real-time RT-PCR provided 6 candidate genes, namely, NUBPL, C9orf30, ZNF12, TMEM158, GSK3B, and FBLP1 using 9 lung cancer cells consisting of 3 small and 6 NSCLC cells.	cddp	62-66	transmembrane protein 158	Homo sapiens	237-244
21377848-8	2012	In conclusion, urinary cystatin C measurements can detect CDDP-induced AKI as early as KIM-1, GST-alpha, and EGF in rats, although the change ratio of the cystatin C was smaller than others.	cddp	58-62	cystatin C	Rattus norvegicus	23-33
21377848-8	2012	In conclusion, urinary cystatin C measurements can detect CDDP-induced AKI as early as KIM-1, GST-alpha, and EGF in rats, although the change ratio of the cystatin C was smaller than others.	cddp	58-62	cystatin C	Rattus norvegicus	155-165
23098063-4	2012	Initial screening to explorer association of IC(50) values of CDDP obtained by MTT assay and gene expression levels measured with oligonucleotide microarray and real-time RT-PCR provided 6 candidate genes, namely, NUBPL, C9orf30, ZNF12, TMEM158, GSK3B, and FBLP1 using 9 lung cancer cells consisting of 3 small and 6 NSCLC cells.	cddp	62-66	glycogen synthase kinase 3 beta	Homo sapiens	246-251
21377848-9	2012	Immunohistochemical cystatin C expression in the proximal tubule of the kidney was hardly changed by the CDDP treatment, but it was newly observed in the renal tubule lumen after CDDP treatment.	cddp	105-109	cystatin C	Rattus norvegicus	20-30
21377848-9	2012	Immunohistochemical cystatin C expression in the proximal tubule of the kidney was hardly changed by the CDDP treatment, but it was newly observed in the renal tubule lumen after CDDP treatment.	cddp	179-183	cystatin C	Rattus norvegicus	20-30
23098063-4	2012	Initial screening to explorer association of IC(50) values of CDDP obtained by MTT assay and gene expression levels measured with oligonucleotide microarray and real-time RT-PCR provided 6 candidate genes, namely, NUBPL, C9orf30, ZNF12, TMEM158, GSK3B, and FBLP1 using 9 lung cancer cells consisting of 3 small and 6 NSCLC cells.	cddp	62-66	filamin binding LIM protein 1	Homo sapiens	257-262
23098063-6	2012	The biological significance of these genes was explored by in vitro experiments: Knockdown experiments in PC-9/CDDP cells revealed that the reduced expression of TMEM158 significantly decreased the chemo-resistance against CDDP (P <.0001), while 2 transformants of PC-6 cells stably over-expressing FBLP1 resulted in an enhanced resistance to CDDP (P = .004 and P = .001).	cddp	111-115	transmembrane protein 158	Homo sapiens	162-169
23098063-6	2012	The biological significance of these genes was explored by in vitro experiments: Knockdown experiments in PC-9/CDDP cells revealed that the reduced expression of TMEM158 significantly decreased the chemo-resistance against CDDP (P <.0001), while 2 transformants of PC-6 cells stably over-expressing FBLP1 resulted in an enhanced resistance to CDDP (P = .004 and P = .001).	cddp	223-227	transmembrane protein 158	Homo sapiens	162-169
23098063-6	2012	The biological significance of these genes was explored by in vitro experiments: Knockdown experiments in PC-9/CDDP cells revealed that the reduced expression of TMEM158 significantly decreased the chemo-resistance against CDDP (P <.0001), while 2 transformants of PC-6 cells stably over-expressing FBLP1 resulted in an enhanced resistance to CDDP (P = .004 and P = .001).	cddp	223-227	transmembrane protein 158	Homo sapiens	162-169
23098063-8	2012	TMEM158 and FBLP1 may be powerful predictive biomarkers for CDDP therapy in NSCLC.	cddp	60-64	transmembrane protein 158	Homo sapiens	0-7
23098063-8	2012	TMEM158 and FBLP1 may be powerful predictive biomarkers for CDDP therapy in NSCLC.	cddp	60-64	filamin binding LIM protein 1	Homo sapiens	12-17
22914438-4	2012	In supporting this clinical study, using three pairs of cisplatin (cDDP)-resistant cell lines and two ovarian cancer cell lines derived from patients who had failed in platinum-based chemotherapy, we showed that cDDP resistance associated with reduced expression of the high-affinity copper transporter (hCtr1), which is also a cDDP transporter, can be preferentially resensitized by copper-lowering agents because of enhanced hCtr1 expression, as compared with their drug-sensitive counterparts.	cddp	212-216	solute carrier family 31 member 1	Homo sapiens	304-309
22914438-4	2012	In supporting this clinical study, using three pairs of cisplatin (cDDP)-resistant cell lines and two ovarian cancer cell lines derived from patients who had failed in platinum-based chemotherapy, we showed that cDDP resistance associated with reduced expression of the high-affinity copper transporter (hCtr1), which is also a cDDP transporter, can be preferentially resensitized by copper-lowering agents because of enhanced hCtr1 expression, as compared with their drug-sensitive counterparts.	cddp	212-216	solute carrier family 31 member 1	Homo sapiens	427-432
22914438-5	2012	Such a preferential induction of hCtr1 expression in cDDP-resistant variants by copper chelation can be explained by the mammalian copper homeostasis regulatory mechanism.	cddp	53-57	solute carrier family 31 member 1	Homo sapiens	33-38
22784015-2	2012	We reported previously that irreversible targeting by cDDP [cis-diamminedichloroplatinum(II) or cisplatin] of the Sec residue in TrxR1 (thioredoxin reductase 1) contributes to cDDP cytotoxicity.	cddp	54-58	thioredoxin reductase 1	Mus musculus	129-134
22784015-2	2012	We reported previously that irreversible targeting by cDDP [cis-diamminedichloroplatinum(II) or cisplatin] of the Sec residue in TrxR1 (thioredoxin reductase 1) contributes to cDDP cytotoxicity.	cddp	54-58	thioredoxin reductase 1	Mus musculus	136-159
22784015-2	2012	We reported previously that irreversible targeting by cDDP [cis-diamminedichloroplatinum(II) or cisplatin] of the Sec residue in TrxR1 (thioredoxin reductase 1) contributes to cDDP cytotoxicity.	cddp	176-180	thioredoxin reductase 1	Mus musculus	129-134
22784015-2	2012	We reported previously that irreversible targeting by cDDP [cis-diamminedichloroplatinum(II) or cisplatin] of the Sec residue in TrxR1 (thioredoxin reductase 1) contributes to cDDP cytotoxicity.	cddp	176-180	thioredoxin reductase 1	Mus musculus	136-159
22784015-5	2012	We found that cDDP became less cytotoxic after incubation of A549 or HCT116 cells with lower SPO(3) concentrations (100-300 muM), whereas higher SPO(3) (>300 muM) had pronounced direct cytotoxicity.	cddp	14-18	latexin	Homo sapiens	124-127
22784015-5	2012	We found that cDDP became less cytotoxic after incubation of A549 or HCT116 cells with lower SPO(3) concentrations (100-300 muM), whereas higher SPO(3) (>300 muM) had pronounced direct cytotoxicity.	cddp	14-18	latexin	Homo sapiens	161-164
22459168-1	2012	The copper (Cu) exporter ATP7B mediates resistance to cisplatin (cDDP) but details of the mechanism are unknown.	cddp	65-69	ATPase copper transporting beta	Homo sapiens	25-30
22895565-6	2012	In addition, knockdown of MMS22L expression also enhanced the apoptosis of cancer cells that were exposed to DNA-damaging agents including 5-FU and CDDP.	cddp	148-152	MMS22 like, DNA repair protein	Homo sapiens	26-32
22672985-1	2012	OBJECTIVE: This study was aimed to elucidate the roles of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3"-kinase (PI3K)/Akt pathways in regulating cytotoxicity induced by cisplatin (CDDP) in ovarian carcinoma cells.	cddp	256-260	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
22672985-1	2012	OBJECTIVE: This study was aimed to elucidate the roles of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3"-kinase (PI3K)/Akt pathways in regulating cytotoxicity induced by cisplatin (CDDP) in ovarian carcinoma cells.	cddp	256-260	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	156-186
22710939-4	2012	Sec61beta knockdown (KD) resulted in 8-, 16.8-, and 9-fold resistance to cisplatin (cDDP), carboplatin, and oxaliplatin, respectively.	cddp	84-88	SEC61 translocon subunit beta	Homo sapiens	0-9
22710939-5	2012	Sec61beta KD reduced the cellular accumulation of cDDP to 67% of that in parental cells.	cddp	50-54	SEC61 translocon subunit beta	Homo sapiens	0-9
22672985-8	2012	In CDDP-resistant cells, CDDP and PMA dramatically suppressed the cell growth, up-regulated the expression of phosphorylated ERK and cleaved caspase-9, down-regulated the expression of checkpoint kinases, and increased the proportion of cells in the synthesis-phase fraction and apoptotic cells.	cddp	3-7	mitogen-activated protein kinase 1	Homo sapiens	125-128
22672985-8	2012	In CDDP-resistant cells, CDDP and PMA dramatically suppressed the cell growth, up-regulated the expression of phosphorylated ERK and cleaved caspase-9, down-regulated the expression of checkpoint kinases, and increased the proportion of cells in the synthesis-phase fraction and apoptotic cells.	cddp	3-7	caspase 9	Homo sapiens	141-150
22672985-8	2012	In CDDP-resistant cells, CDDP and PMA dramatically suppressed the cell growth, up-regulated the expression of phosphorylated ERK and cleaved caspase-9, down-regulated the expression of checkpoint kinases, and increased the proportion of cells in the synthesis-phase fraction and apoptotic cells.	cddp	25-29	mitogen-activated protein kinase 1	Homo sapiens	125-128
22672985-8	2012	In CDDP-resistant cells, CDDP and PMA dramatically suppressed the cell growth, up-regulated the expression of phosphorylated ERK and cleaved caspase-9, down-regulated the expression of checkpoint kinases, and increased the proportion of cells in the synthesis-phase fraction and apoptotic cells.	cddp	25-29	caspase 9	Homo sapiens	141-150
22459168-2	2012	We explored the role of the CXXC motifs in the metal binding domains (MBDs) of ATP7B by investigating binding of cDDP to the sixth metal binding domain (MBD6) or a variant in which the CXXC motif was converted to SXXS.	cddp	113-117	ATPase copper transporting beta	Homo sapiens	79-84
22459168-3	2012	Platinum measurement showed that cDDP bound to wild type MBD6 but not to the SXXS variant.	cddp	33-37	methyl-CpG binding domain protein 6	Homo sapiens	57-61
22459168-4	2012	Wild type ATP7B rendered ovarian 2008 cells resistant to cDDP.	cddp	57-61	ATPase copper transporting beta	Homo sapiens	10-15
22459168-5	2012	In 2008 and in HEK293T cells, wild type ATP7B trafficked from TGN to peripheral locations in response to Cu or cDDP.	cddp	111-115	ATPase copper transporting beta	Homo sapiens	40-45
22459168-9	2012	We conclude that cDDP binds to the CXXC motifs of ATP7B and that this interaction is essential to the trafficking of ATP7B and to its ability to mediate resistance to cDDP.	cddp	17-21	ATPase copper transporting beta	Homo sapiens	50-55
22459168-9	2012	We conclude that cDDP binds to the CXXC motifs of ATP7B and that this interaction is essential to the trafficking of ATP7B and to its ability to mediate resistance to cDDP.	cddp	17-21	ATPase copper transporting beta	Homo sapiens	117-122
22459168-9	2012	We conclude that cDDP binds to the CXXC motifs of ATP7B and that this interaction is essential to the trafficking of ATP7B and to its ability to mediate resistance to cDDP.	cddp	167-171	ATPase copper transporting beta	Homo sapiens	50-55
22459168-9	2012	We conclude that cDDP binds to the CXXC motifs of ATP7B and that this interaction is essential to the trafficking of ATP7B and to its ability to mediate resistance to cDDP.	cddp	167-171	ATPase copper transporting beta	Homo sapiens	117-122
21674241-4	2011	Thrombospondin-1 (TSP-1), bone morphogenetic protein-4 (BMP-4), endothelin-1, and placental growth factor-2 were statistically significantly induced by CDDP.	cddp	152-156	thrombospondin 1	Homo sapiens	0-16
22389470-4	2012	We found that human epidermal growth factor receptor 2 (HER2) expressions are also upregulated in chemoresistant SBC-3/ETP, SBC-3/SN-38, and SBC-3/CDDP cells, compared with chemosensitive SBC-3 cells.	cddp	147-151	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-54
22389470-4	2012	We found that human epidermal growth factor receptor 2 (HER2) expressions are also upregulated in chemoresistant SBC-3/ETP, SBC-3/SN-38, and SBC-3/CDDP cells, compared with chemosensitive SBC-3 cells.	cddp	147-151	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
21970881-8	2011	CONCLUSION: Our findings indicate a new molecular mechanism for upregulated AT1R signalling through increased ROS when tumours progressed after the CDDP-based regimens, and shed light on the importance of AT1R blockade for platinum-resistant bladder cancers.	cddp	148-152	angiotensin II receptor type 1	Homo sapiens	76-80
22192357-2	2012	Here, we found that stably enhanced 14-3-3sigma expression strengthened the effects of 5-Fu, Mitoxantrone and cDDP.	cddp	110-114	stratifin	Homo sapiens	36-47
21674241-4	2011	Thrombospondin-1 (TSP-1), bone morphogenetic protein-4 (BMP-4), endothelin-1, and placental growth factor-2 were statistically significantly induced by CDDP.	cddp	152-156	thrombospondin 1	Homo sapiens	18-23
21674241-4	2011	Thrombospondin-1 (TSP-1), bone morphogenetic protein-4 (BMP-4), endothelin-1, and placental growth factor-2 were statistically significantly induced by CDDP.	cddp	152-156	bone morphogenetic protein 4	Homo sapiens	26-54
21674241-4	2011	Thrombospondin-1 (TSP-1), bone morphogenetic protein-4 (BMP-4), endothelin-1, and placental growth factor-2 were statistically significantly induced by CDDP.	cddp	152-156	bone morphogenetic protein 4	Homo sapiens	56-61
21674241-4	2011	Thrombospondin-1 (TSP-1), bone morphogenetic protein-4 (BMP-4), endothelin-1, and placental growth factor-2 were statistically significantly induced by CDDP.	cddp	152-156	endothelin 1	Homo sapiens	64-76
21674241-5	2011	At protein level, CDDP also induced hypoxia-inducible factor-1alpha but not vascular endothelial growth factor.	cddp	18-22	hypoxia inducible factor 1 subunit alpha	Homo sapiens	36-67
21674241-6	2011	In carcinoma samples taken before and after platinum-based neoadjuvant chemotherapy from 28 patients with advanced, high-grade serous ovarian carcinoma, CD105 and factors most induced by CDDP (TSP-1 and BMP-4) were analyzed by immunohistochemistry.	cddp	187-191	thrombospondin 1	Homo sapiens	193-198
20935673-10	2011	Furthermore, drug-resistance upon CD40-ligand stimulation, a model for the protective stimuli provided in lymph nodes, could also be overcome by CDDP/F-ara-A.	cddp	145-149	CD40 molecule	Homo sapiens	34-38
21383688-7	2011	Genetic suppression of KiSS1 in CDDP-sensitive cell lines rendered them CR, an observation that was mechanistically linked to alterations in glutathione S-transferase-pi expression and function.	cddp	32-36	KiSS-1 metastasis suppressor	Homo sapiens	23-28
21383688-9	2011	Genetic reconstitution of KiSS1 in CR cells abrogated cellular migration and induced CDDP sensitivity.	cddp	85-89	KiSS-1 metastasis suppressor	Homo sapiens	26-31
21383688-11	2011	Mechanistically, alterations in apoptotic pathways and CDDP metabolism contributed to KiSS1-associated chemotherapy sensitization.	cddp	55-59	KiSS-1 metastasis suppressor	Homo sapiens	86-91
21334806-4	2011	Furthermore, suppression of 14-3-3zeta enhanced the anti-cancer effect of cis-diammined dichloridoplatium (CDDP) in hepatoma cell lines.	cddp	107-111	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	28-38
21224584-1	2010	PURPOSE: The aim of this study was to determine whether the expressions of excision repair cross-complementing-1 (ERCC1) and thymidylate synthase (TS) predict the clinical outcome of patients with esophageal squamous cell carcinoma treated with CDDP/5-FU chemoradiotherapy.	cddp	245-249	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	75-112
21634054-1	2011	OBJECTIVES: The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status.	cddp	74-78	MAX dimerization protein MGA	Homo sapiens	147-150
21152118-5	2010	This study aimed to investigate the effects of selective opener (Atractyloside glycoside, ATR) and inhibitor (Cyclosporine A, CsA) of mitochondrial permeability transition pore (mPTP) on a CDDP-resistant HCC cell line (SK-Hep1 cells).	cddp	189-193	ATR serine/threonine kinase	Homo sapiens	90-93
21152118-5	2010	This study aimed to investigate the effects of selective opener (Atractyloside glycoside, ATR) and inhibitor (Cyclosporine A, CsA) of mitochondrial permeability transition pore (mPTP) on a CDDP-resistant HCC cell line (SK-Hep1 cells).	cddp	189-193	protein tyrosine phosphatase, receptor type, U	Mus musculus	178-182
21152118-5	2010	This study aimed to investigate the effects of selective opener (Atractyloside glycoside, ATR) and inhibitor (Cyclosporine A, CsA) of mitochondrial permeability transition pore (mPTP) on a CDDP-resistant HCC cell line (SK-Hep1 cells).	cddp	189-193	DNL-type zinc finger	Homo sapiens	222-226
21368468-0	2011	[A case of AFP-producing gastric cancer resected after efficient S-1/CDDP combination chemotherapy].	cddp	69-73	alpha fetoprotein	Homo sapiens	11-14
21224584-1	2010	PURPOSE: The aim of this study was to determine whether the expressions of excision repair cross-complementing-1 (ERCC1) and thymidylate synthase (TS) predict the clinical outcome of patients with esophageal squamous cell carcinoma treated with CDDP/5-FU chemoradiotherapy.	cddp	245-249	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	114-119
21224584-1	2010	PURPOSE: The aim of this study was to determine whether the expressions of excision repair cross-complementing-1 (ERCC1) and thymidylate synthase (TS) predict the clinical outcome of patients with esophageal squamous cell carcinoma treated with CDDP/5-FU chemoradiotherapy.	cddp	245-249	thymidylate synthetase	Homo sapiens	147-149
22966390-4	2010	The relationship between the ATP7A expression levels and the in vitro CDDP sensitivity was then evaluated.	cddp	70-74	ATPase copper transporting alpha	Homo sapiens	29-34
20978160-1	2010	We previously reported that angiotensin II type 1 receptor (AT1R) antagonists enhanced the cytotoxity of cis-dichlorodiammineplatinum (CDDP) in a bladder cancer xenograft model.	cddp	135-139	angiotensin II receptor type 1	Homo sapiens	28-58
20978160-1	2010	We previously reported that angiotensin II type 1 receptor (AT1R) antagonists enhanced the cytotoxity of cis-dichlorodiammineplatinum (CDDP) in a bladder cancer xenograft model.	cddp	135-139	angiotensin II receptor type 1	Homo sapiens	60-64
20978160-2	2010	To elucidate the synergistic mechanism, we investigated whether reactive oxygen species (ROS) generation induced by CDDP may affect the regulation of AT1R expression.	cddp	116-120	angiotensin II receptor type 1	Homo sapiens	150-154
20978160-6	2010	The in vitro study showed that AT1R expression was significantly upregulated by CDDP in T24, KU-1, and KU-19-19 cells.	cddp	80-84	angiotensin II receptor type 1	Homo sapiens	31-35
20978160-9	2010	The upregulation of AT1R expression induced by CDDP was significantly suppressed by scavenging free radicals.	cddp	47-51	angiotensin II receptor type 1	Homo sapiens	20-24
20978160-10	2010	Angiotensin II induced VEGF production in CDDP-treated cells; however, the AT1R antagonist significantly inhibited the increase in VEGF.	cddp	42-46	angiotensinogen	Homo sapiens	0-14
20978160-10	2010	Angiotensin II induced VEGF production in CDDP-treated cells; however, the AT1R antagonist significantly inhibited the increase in VEGF.	cddp	42-46	vascular endothelial growth factor A	Homo sapiens	23-27
20978160-10	2010	Angiotensin II induced VEGF production in CDDP-treated cells; however, the AT1R antagonist significantly inhibited the increase in VEGF.	cddp	42-46	angiotensin II receptor type 1	Homo sapiens	75-79
20978160-11	2010	The in vivo study results also showed that CDDP treatment upregulated AT1R expression, resulting in increased VEGF.	cddp	43-47	angiotensin II receptor type 1	Homo sapiens	70-74
20978160-11	2010	The in vivo study results also showed that CDDP treatment upregulated AT1R expression, resulting in increased VEGF.	cddp	43-47	vascular endothelial growth factor A	Homo sapiens	110-114
20978160-12	2010	Clinical specimens from patients who underwent cystectomy after neoadjuvant CDDP-based chemotherapy showed significantly higher AT1R and VEGF expression than corresponding transurethral resection specimens.	cddp	76-80	angiotensin II receptor type 1	Homo sapiens	128-132
20978160-12	2010	Clinical specimens from patients who underwent cystectomy after neoadjuvant CDDP-based chemotherapy showed significantly higher AT1R and VEGF expression than corresponding transurethral resection specimens.	cddp	76-80	vascular endothelial growth factor A	Homo sapiens	137-141
20978160-13	2010	Our findings indicate that CDDP upregulates AT1R expression though ROS generation and enhances VEGF production.	cddp	27-31	angiotensin II receptor type 1	Homo sapiens	44-48
20978160-13	2010	Our findings indicate that CDDP upregulates AT1R expression though ROS generation and enhances VEGF production.	cddp	27-31	vascular endothelial growth factor A	Homo sapiens	95-99
20700687-6	2010	RESULTS: Drug resistance of MCF-7/5-FU cells to 5-FU, MX, cDDP, ADM, TAXOL all increased significantly compared with MCF-7 cells and that maybe related to BCRP, but not MDR1 and MRP1.	cddp	58-62	BCR pseudogene 1	Homo sapiens	155-159
20700687-9	2010	Enforced 14-3-3sigma expression can increase the sensitivity of MCF-7/5-FU cells to 5-FU and cDDP.	cddp	93-97	stratifin	Homo sapiens	9-20
20519567-1	2010	Mammalian copper transporter 1 (CTR1) is a high-affinity copper influx transporter that also mediates the uptake of platinum-containing chemotherapeutic agents including cisplatin (cDDP).	cddp	181-185	solute carrier family 31 member 1	Homo sapiens	10-30
20519567-1	2010	Mammalian copper transporter 1 (CTR1) is a high-affinity copper influx transporter that also mediates the uptake of platinum-containing chemotherapeutic agents including cisplatin (cDDP).	cddp	181-185	solute carrier family 31 member 1	Homo sapiens	32-36
20519567-3	2010	To examine the mechanism by which hCTR1 also transports cDDP, variant forms of hCTR1 in which methionines 150 and 154 were converted to isoleucines or in which histidine 139 was converted to alanine were re-expressed in cells in which both alleles of CTR1 had been knocked out.	cddp	56-60	solute carrier family 31 member 1	Homo sapiens	34-39
20519567-3	2010	To examine the mechanism by which hCTR1 also transports cDDP, variant forms of hCTR1 in which methionines 150 and 154 were converted to isoleucines or in which histidine 139 was converted to alanine were re-expressed in cells in which both alleles of CTR1 had been knocked out.	cddp	56-60	solute carrier family 31 member 1	Homo sapiens	35-39
20519567-5	2010	In contrast, conversion of the methionines increased the uptake and cytotoxicity of cDDP well above that attained with wild-type hCTR1.	cddp	84-88	solute carrier family 31 member 1	Homo sapiens	129-134
20519567-9	2010	Although both copper and cDDP may rely on a series of transchelation reactions to pass through the hCTR1 trimeric complex, the details of the molecular interactions must be different, which provides a potential basis for selective pharmacological modulation of copper versus cDDP cytotoxicity.	cddp	25-29	solute carrier family 31 member 1	Homo sapiens	99-104
20519567-9	2010	Although both copper and cDDP may rely on a series of transchelation reactions to pass through the hCTR1 trimeric complex, the details of the molecular interactions must be different, which provides a potential basis for selective pharmacological modulation of copper versus cDDP cytotoxicity.	cddp	275-279	solute carrier family 31 member 1	Homo sapiens	99-104
22966390-5	2010	The ATP7A mRNA expression levels in the CDDP-resistant tumors were significantly higher than those in the CDDP-sensitive tumors (p=0.0167, Mann-Whitney U test).	cddp	40-44	ATPase copper transporting alpha	Homo sapiens	4-9
20438795-4	2010	Conversely, based on its early and time-dependent increase, its large magnitude of alteration and its high accuracy and sensitivity of detection, (KIM-1) in urine appeared to be the best biomarker for detection of CDDP-induced proximal tubular injury.	cddp	214-218	hepatitis A virus cellular receptor 1	Rattus norvegicus	147-152
20376536-5	2010	Results showed that lentivirus-mediated shRNA targeting IGF-1R combined with chemotherapy (CDDP or DTX) could lead to growth suppression of osteosarcoma cells not only in vitro but also in vivo.	cddp	91-95	insulin like growth factor 1 receptor	Homo sapiens	56-62
20451502-5	2010	Neither of these structural changes prevented cDDP from triggering the rapid degradation of hCTR1.	cddp	46-50	solute carrier family 31 member 1	Homo sapiens	92-97
20451502-6	2010	However, they did alter the potency of the cDDP that achieved cell entry, possibly reflecting the fact that hCTR1 may mediate the transport of cDDP both through the pore it forms in the plasma membrane and via endocytosis.	cddp	43-47	solute carrier family 31 member 1	Homo sapiens	108-113
20451502-6	2010	However, they did alter the potency of the cDDP that achieved cell entry, possibly reflecting the fact that hCTR1 may mediate the transport of cDDP both through the pore it forms in the plasma membrane and via endocytosis.	cddp	143-147	solute carrier family 31 member 1	Homo sapiens	108-113
20451502-7	2010	We conclude that cDDP interacts with hCTR1 both at (40)MXXM(45) and at sites outside the N-terminal domain that produce the conformational changes that trigger degradation.	cddp	17-21	solute carrier family 31 member 1	Homo sapiens	37-42
20372780-5	2010	Treatment with CDDP and 5-FU led to phosphorylation of H2AX preferentially in S-phase cells, consistent with the induction of replication stress.	cddp	15-19	H2A.X variant histone	Homo sapiens	55-59
20567123-1	2010	We experienced a case of primary gastric choriocarcinoma(PGC)treated by curative operation after neoadjuvant chemotherapy with S-1/CDDP.	cddp	131-135	progastricsin	Homo sapiens	57-60
19698702-7	2010	l-Buthionine-S,R-sulfoximine, an inhibitor of GCL (glutamate-cysteine ligase), resensitised in part UKF-NB-3(r)CDDP(1000) cells to artesunate.	cddp	111-115	glutamate-cysteine ligase catalytic subunit	Homo sapiens	46-49
22966294-5	2010	The relationship between ATP7B expression and in vitro CDDP sensitivity was then evaluated.	cddp	55-59	ATPase copper transporting beta	Homo sapiens	25-30
22966294-6	2010	The ATP7B mRNA expression levels in CDDP-resistant tumors were significantly higher than those in the CDDP-sensitive group (p=0.015; Mann-Whitney U test).	cddp	36-40	ATPase copper transporting beta	Homo sapiens	4-9
22966294-6	2010	The ATP7B mRNA expression levels in CDDP-resistant tumors were significantly higher than those in the CDDP-sensitive group (p=0.015; Mann-Whitney U test).	cddp	102-106	ATPase copper transporting beta	Homo sapiens	4-9
20332681-15	2010	CONCLUSION: These results suggest that NAC with S-1+CDDP is promising against resectable advanced gastric cancer; however, its true value will only emerge after completion of the ongoing phase III study of NAC plus surgery and postoperative chemotherapy for resectable large type 3/type 4 advanced gastric cancer (JCOG0501).	cddp	52-56	synuclein alpha	Homo sapiens	39-42
19698702-7	2010	l-Buthionine-S,R-sulfoximine, an inhibitor of GCL (glutamate-cysteine ligase), resensitised in part UKF-NB-3(r)CDDP(1000) cells to artesunate.	cddp	111-115	glutamate-cysteine ligase catalytic subunit	Homo sapiens	51-76
21475919-1	2009	Low excision repair cross-complementing 1 (ERCC1) has been associated with a favorable response to cisplatin (CDDP) in several types of malignancies.	cddp	110-114	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-41
19622016-3	2009	TRX knockdown did not significantly increase the basal level of cell death without exposure to stress, but CDDP-induced cell death was enhanced.	cddp	107-111	thioredoxin	Homo sapiens	0-3
19629622-9	2009	Immunoblotting revealed up-regulation of the organic cation transporter rOCT2 in hypomagnesemic rats before CDDP administration, but not of rOCT1 or rat multidrug and toxin-extrusion 1.	cddp	108-112	solute carrier family 22 member 2	Rattus norvegicus	72-77
19629622-12	2009	CONCLUSION: These results suggest that hypomagnesemia could cause dehydration and up-regulation of rOCT2, enhancing renal accumulation of CDDP and the deterioration of AKI.	cddp	138-142	solute carrier family 22 member 2	Rattus norvegicus	99-104
19920383-1	2009	S-1/CDDP combination chemotherapy is conducted in many institutions, but most patients are hospitalized at the time of CDDP administration.	cddp	119-123	proteasome 26S subunit, non-ATPase 1	Homo sapiens	0-3
20037412-5	2009	Moreover, S-1 and CDDP combined chemotherapy (S-1: 120 mg/day, day 1-21/ 35 days, CDDP: 60 mg/m2, day 8/35 days) was performed as the second-line chemotherapy, nevertheless the diameter of liver metastasis enlarged to 26 mm.	cddp	18-22	proteasome 26S subunit, non-ATPase 1	Homo sapiens	46-49
21475919-1	2009	Low excision repair cross-complementing 1 (ERCC1) has been associated with a favorable response to cisplatin (CDDP) in several types of malignancies.	cddp	110-114	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	43-48
21475919-2	2009	The present study aimed to investigate whether ERCC1 predicts the response to CDDP-based chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) and to evaluate the association between ERCC1 and platinum drug sensitivity in ESCC cell lines.	cddp	78-82	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
21475919-5	2009	Responses to CDDP and oxaliplatin (OXA) in ESCC cell lines were evaluated using the WST-8 colorimetric assay by comparing ERCC1 levels.	cddp	13-17	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	122-127
21475919-9	2009	ESCC cell lines with lower ERCC1 showed significantly greater sensitivity to clinically relevant concentrations of CDDP and OXA compared to lines with higher ERCC1 (p<0.01).	cddp	115-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	27-32
20723345-7	2009	The p53 expression levels were higher in Anip973/CDDP than in Anip973 (P<0.01).	cddp	49-53	tumor protein p53	Homo sapiens	4-7
20723345-10	2009	CONCLUSIONS: Clusterin is associated with resistance to CDDP in NSCLC.	cddp	56-60	clusterin	Homo sapiens	13-22
19570948-2	2009	hCtr1 is involved in the transport of platinum-based antitumor agents such as cisplatin (CDDP); however, the mechanisms that regulate hCtr1-mediated transport of these agents have not been well elucidated.	cddp	89-93	solute carrier family 31 member 1	Homo sapiens	0-5
19570948-4	2009	We found that replacements of several methionine residues that are essential for hCtr1-mediated copper transport conferred a dominant-negative effect on the endogenous hCtr1"s function, resulting in reduced rates of Cu(I) and CDDP transport and increased resistance to the toxicities of copper and CDDP treatments.	cddp	226-230	solute carrier family 31 member 1	Homo sapiens	81-86
19570948-4	2009	We found that replacements of several methionine residues that are essential for hCtr1-mediated copper transport conferred a dominant-negative effect on the endogenous hCtr1"s function, resulting in reduced rates of Cu(I) and CDDP transport and increased resistance to the toxicities of copper and CDDP treatments.	cddp	226-230	solute carrier family 31 member 1	Homo sapiens	168-173
19570948-4	2009	We found that replacements of several methionine residues that are essential for hCtr1-mediated copper transport conferred a dominant-negative effect on the endogenous hCtr1"s function, resulting in reduced rates of Cu(I) and CDDP transport and increased resistance to the toxicities of copper and CDDP treatments.	cddp	298-302	solute carrier family 31 member 1	Homo sapiens	81-86
19570948-3	2009	We compared the mechanisms of hCtr1-mediated transport of copper and CDDP.	cddp	69-73	solute carrier family 31 member 1	Homo sapiens	30-35
19570948-4	2009	We found that replacements of several methionine residues that are essential for hCtr1-mediated copper transport conferred a dominant-negative effect on the endogenous hCtr1"s function, resulting in reduced rates of Cu(I) and CDDP transport and increased resistance to the toxicities of copper and CDDP treatments.	cddp	298-302	solute carrier family 31 member 1	Homo sapiens	168-173
19381033-6	2009	All ERCC1-negative specimens were sensitive for CDDP in HDRA, and all CDDP-resistant specimens in HDRA showed positive ERCC1 staining.	cddp	48-52	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9
19105980-0	2009	In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF.	cddp	77-81	apoptosis inducing factor mitochondria associated 1	Homo sapiens	154-157
19620807-3	2009	Afterwards a rise of tumor marker (CEA) occurred accompanying taste disorder and edema of the lower limbs, so we changed to combination chemotherapy for PTX/CDDP.	cddp	157-161	CEA cell adhesion molecule 3	Homo sapiens	35-38
19435660-1	2009	PC-1 (NPP-1) inhibitors may be useful as therapeutics for the treatment of CDDP (calcium pyrophosphate dehydrate) deposition disease and osteoarthritis.	cddp	75-79	ectonucleotide pyrophosphatase/phosphodiesterase 1	Homo sapiens	0-4
19435660-1	2009	PC-1 (NPP-1) inhibitors may be useful as therapeutics for the treatment of CDDP (calcium pyrophosphate dehydrate) deposition disease and osteoarthritis.	cddp	75-79	ectonucleotide pyrophosphatase/phosphodiesterase 1	Homo sapiens	6-11
19333003-3	2009	RESULTS: CDDP induced almost complete growth inhibition of BRCA1-defective HBCXs, while BRCA1-reconstituted HBCXs were only partially inhibited.	cddp	9-13	BRCA1 DNA repair associated	Homo sapiens	59-64
19381033-6	2009	All ERCC1-negative specimens were sensitive for CDDP in HDRA, and all CDDP-resistant specimens in HDRA showed positive ERCC1 staining.	cddp	70-74	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	119-124
19381033-7	2009	ERCC1 status was significantly correlated with CDDP sensitivity(p=0.01).	cddp	47-51	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
19381033-9	2009	CONCLUSION: HDRA may provide effective non-platinum adjuvant chemotherapy protocols for patients with ERCC1-positive, i.e. CDDP resistant, NSCLC.	cddp	123-127	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	102-107
19396019-13	2009	These observations indicate that somatic promoter hypermethylation and impaired ERK signaling are associated with decreased GSTP1 expression and CDDP sensitivity in gastric cancer cell lines.	cddp	145-149	mitogen-activated protein kinase 1	Homo sapiens	80-83
19148521-1	2009	We previously established H-1R cells, a cisplatin (CDDP)-resistant cell line, from H-1 cells, a CDDP-sensitive oral carcinoma cell line.	cddp	51-55	H1.5 linker histone, cluster member	Homo sapiens	26-29
19203502-5	2009	RESULTS: The mean level of U-Alb during the 5 - 8 day period after CDDP treatment was significantly higher than before treatment (p < 0.01).	cddp	67-71	albumin	Homo sapiens	29-32
19203502-7	2009	U-Alb, U-C5b-9 and U-fH clearly increased on Days 4 - 10 after CDDP treatment.	cddp	63-67	albumin	Homo sapiens	2-5
19148521-1	2009	We previously established H-1R cells, a cisplatin (CDDP)-resistant cell line, from H-1 cells, a CDDP-sensitive oral carcinoma cell line.	cddp	96-100	H1.5 linker histone, cluster member	Homo sapiens	26-29
19139770-9	2009	In QGY/CDDP cells, intracellular platinum accumulation decreased and GST-pi expression increased, but P-gp expression kept stable.	cddp	7-11	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
20213395-9	2009	The third study 80961 investigated interval compression i.e. if the CDDP/DOX when given every 2 weeks with GCSF superior to the same two drugs given every 3 weeks.	cddp	68-72	colony stimulating factor 3	Homo sapiens	107-111
19106520-8	2008	However, despite NSE turning normal, CEA rose that CDDP was added to the regimen.	cddp	51-55	CEA cell adhesion molecule 3	Homo sapiens	37-40
19020749-7	2008	Since BRCA1 depletion has been found to decrease DNA damage repair and cell survival in MDA-MB-468 cells when treated with DNA-damaging drugs, we employed ELISA-based quantitative analyses to measure BRCA1 protein levels in CDDP+/- cetuximab-treated cells.	cddp	224-228	BRCA1 DNA repair associated	Homo sapiens	6-11
19020749-7	2008	Since BRCA1 depletion has been found to decrease DNA damage repair and cell survival in MDA-MB-468 cells when treated with DNA-damaging drugs, we employed ELISA-based quantitative analyses to measure BRCA1 protein levels in CDDP+/- cetuximab-treated cells.	cddp	224-228	BRCA1 DNA repair associated	Homo sapiens	200-205
19020749-9	2008	Interestingly, cetuximab co-exposure significantly antagonized the ability of CDDP to up-regulate BRCA1 expression.	cddp	78-82	BRCA1 DNA repair associated	Homo sapiens	98-103
19020749-11	2008	Unexpectedly, ELISA-based quantitative analyses of EGFR protein content demonstrated that simultaneous exposure to cetuximab and optimal doses of CDDP completely depleted EGFR protein in MDA-MB-468 cells.	cddp	146-150	epidermal growth factor receptor	Homo sapiens	51-55
19020749-11	2008	Unexpectedly, ELISA-based quantitative analyses of EGFR protein content demonstrated that simultaneous exposure to cetuximab and optimal doses of CDDP completely depleted EGFR protein in MDA-MB-468 cells.	cddp	146-150	epidermal growth factor receptor	Homo sapiens	171-175
18523133-1	2008	Previous studies have demonstrated that treating cultured cells with cisplatin (CDDP) up-regulated the expression of glutathione (GSH) and its de novo rate-limiting enzyme glutamate-cysteine ligase (GCL), which consists of a catalytic (GCLC) and a modifier (GCLM) subunit.	cddp	80-84	glutamate-cysteine ligase catalytic subunit	Homo sapiens	172-197
18509599-8	2008	DDAP also induced more apoptosis than CDDP did in the 2008.C13 subline, which was partially mediated by the caspase 3-dependent pathway.	cddp	38-42	caspase 3	Homo sapiens	108-117
18523133-1	2008	Previous studies have demonstrated that treating cultured cells with cisplatin (CDDP) up-regulated the expression of glutathione (GSH) and its de novo rate-limiting enzyme glutamate-cysteine ligase (GCL), which consists of a catalytic (GCLC) and a modifier (GCLM) subunit.	cddp	80-84	glutamate-cysteine ligase catalytic subunit	Homo sapiens	199-202
18523133-1	2008	Previous studies have demonstrated that treating cultured cells with cisplatin (CDDP) up-regulated the expression of glutathione (GSH) and its de novo rate-limiting enzyme glutamate-cysteine ligase (GCL), which consists of a catalytic (GCLC) and a modifier (GCLM) subunit.	cddp	80-84	glutamate-cysteine ligase catalytic subunit	Homo sapiens	236-240
18523133-1	2008	Previous studies have demonstrated that treating cultured cells with cisplatin (CDDP) up-regulated the expression of glutathione (GSH) and its de novo rate-limiting enzyme glutamate-cysteine ligase (GCL), which consists of a catalytic (GCLC) and a modifier (GCLM) subunit.	cddp	80-84	glutamate-cysteine ligase modifier subunit	Homo sapiens	258-262
18523133-2	2008	It has also been shown that many CDDP-resistant cell lines exhibit high levels of GCLC/GCLM and GSH.	cddp	33-37	glutamate-cysteine ligase catalytic subunit	Homo sapiens	82-86
18523133-2	2008	It has also been shown that many CDDP-resistant cell lines exhibit high levels of GCLC/GCLM and GSH.	cddp	33-37	glutamate-cysteine ligase modifier subunit	Homo sapiens	87-91
18523133-3	2008	Because the GSH system is the major intracellular regulator of redox conditions that serve as an important detoxification cytoprotector, these results have been taken into consideration that elevated levels of GCL/GSH are responsible for the CDDP resistance.	cddp	242-246	glutamate-cysteine ligase catalytic subunit	Homo sapiens	210-213
18523133-4	2008	In contrast to this context, we demonstrated here that overexpression of GSH by transfection with an expression plasmid containing the GCLC cDNA conferred sensitization to CDDP through up-regulation of human copper transporter (hCtr) 1, which is also a transporter for CDDP.	cddp	172-176	glutamate-cysteine ligase catalytic subunit	Homo sapiens	135-139
18523133-4	2008	In contrast to this context, we demonstrated here that overexpression of GSH by transfection with an expression plasmid containing the GCLC cDNA conferred sensitization to CDDP through up-regulation of human copper transporter (hCtr) 1, which is also a transporter for CDDP.	cddp	269-273	glutamate-cysteine ligase catalytic subunit	Homo sapiens	135-139
18751380-13	2008	CONCLUSION: We established a CDDP-resistant cell line using MKN45 cells, in which ERCC1 and GST-pi were increased.	cddp	29-33	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	82-87
21479472-8	2008	Cisplatin sensitivity after hRev3 mRNA knockdown increased approximately 2-fold in UM-SCC-23 cells and approximately 3-fold in UM-SCC-23 CDDP/R cells.	cddp	137-141	REV3 like, DNA directed polymerase zeta catalytic subunit	Homo sapiens	28-33
18701855-3	2008	After two courses and a reduced regimen with S-1 64 mg/m(2) day plus CDDP 35 mg/m(2) day, the tumor lesion became CR and the serum CEA 575 ng/mL level before therapy decreased to the normal level.	cddp	69-73	CEA cell adhesion molecule 3	Homo sapiens	131-134
18701855-5	2008	The serum CEA elevated 13 months after the treatment, and the patient received a reduced course and two-course S-1/CDDP therapy.	cddp	115-119	CEA cell adhesion molecule 3	Homo sapiens	10-13
18636185-7	2008	ATP7B mRNA and protein expression levels in the CDDP-resistant xenografts were significantly higher than those in the CDDP-sensitive xenografts (p=0.0389 and p=0.0357, respectively, Mann-Whitney U test).	cddp	48-52	ATPase copper transporting beta	Homo sapiens	0-5
18636185-7	2008	ATP7B mRNA and protein expression levels in the CDDP-resistant xenografts were significantly higher than those in the CDDP-sensitive xenografts (p=0.0389 and p=0.0357, respectively, Mann-Whitney U test).	cddp	118-122	ATPase copper transporting beta	Homo sapiens	0-5
18636185-8	2008	These results suggest that ATP7B is a CDDP-resistance marker in human NSCLC xenografts in vivo.	cddp	38-42	ATPase copper transporting beta	Homo sapiens	27-32
18553227-6	2008	Simultaneously, another Japanese phase III trial comparing S-1 with S-1 plus CDDP showed a survival benefit of S-1 plus CDDP.	cddp	120-124	proteasome 26S subunit, non-ATPase 1	Homo sapiens	68-71
18553227-6	2008	Simultaneously, another Japanese phase III trial comparing S-1 with S-1 plus CDDP showed a survival benefit of S-1 plus CDDP.	cddp	120-124	proteasome 26S subunit, non-ATPase 1	Homo sapiens	59-62
18633225-1	2008	We encountered a 64-year-old UGT1A1*28 heterotype patient who received CPT-11 and CDDP chemotherapy for Stage III A small-cell lung-cancer and developed grade 4 neutropenia as assessed by CTCAE v3.0 in Pharmaceutical Management.	cddp	82-86	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	29-35
18553227-6	2008	Simultaneously, another Japanese phase III trial comparing S-1 with S-1 plus CDDP showed a survival benefit of S-1 plus CDDP.	cddp	120-124	proteasome 26S subunit, non-ATPase 1	Homo sapiens	68-71
18281772-5	2008	Twice-administered CDDP 80 mg/body and S-1 80 mg on the eighth day served to decrease CEA.	cddp	19-23	pregnancy specific beta-1-glycoprotein 2	Homo sapiens	86-89
18281772-8	2008	After CDDP 60 mg/body of day 8 was administered twice at S-1 80 mg/day, CEA became normal.	cddp	6-10	proteasome 26S subunit, non-ATPase 1	Homo sapiens	57-60
18281772-8	2008	After CDDP 60 mg/body of day 8 was administered twice at S-1 80 mg/day, CEA became normal.	cddp	6-10	pregnancy specific beta-1-glycoprotein 2	Homo sapiens	72-75
17361333-5	2007	A synergistic effect was obtained by treatment involving the association of VP-16 with ACNU or CDDP among the combinations of two drugs, and the association of ACNU, CBDCA, and VP-16 in the combination of three drugs.	cddp	95-99	host cell factor C1	Homo sapiens	76-81
18219867-14	2007	CONCLUSION: There have been numerous reports of the combination of S-1 + CDDP in esophageal cancer for NAC or in inoperable cases.	cddp	73-77	synuclein alpha	Homo sapiens	103-106
17627472-8	2007	Moreover, the internalized TRX-C35S binds to endogenous TRX, resulting in the generation of intracellular reactive oxygen species (ROS) and enhanced cis-diamine-dichloroplatinum (II) (CDDP)-induced apoptosis via a ROS-mediated pathway involving apoptosis signal-regulating kinase-1 (ASK-1) activation.	cddp	184-188	thioredoxin	Homo sapiens	27-30
17627472-8	2007	Moreover, the internalized TRX-C35S binds to endogenous TRX, resulting in the generation of intracellular reactive oxygen species (ROS) and enhanced cis-diamine-dichloroplatinum (II) (CDDP)-induced apoptosis via a ROS-mediated pathway involving apoptosis signal-regulating kinase-1 (ASK-1) activation.	cddp	184-188	thioredoxin	Homo sapiens	56-59
17695505-5	2007	ATP7A expression was markedly increased by exposure to CDDP with or without copper in KB cells but not in KBR/1.2 cells.	cddp	55-59	ATPase copper transporting alpha	Homo sapiens	0-5
17466256-3	2007	LA-12 induced apoptosis much more efficiently than did CDDP due to a combination of rapid penetration into the cell and attack on DNA, leading to fast activation of p53 and caspase-3.	cddp	55-59	caspase 3	Rattus norvegicus	173-182
17466278-2	2007	Previous study in our laboratory considered p53 mutant cell lines A431 (parental) and A431/Pt (CDDP-resistant counterpart, resistance factor R.F.=2.6).	cddp	95-99	tumor protein p53	Homo sapiens	44-47
17466278-12	2007	The presence of a wild-type p53 exalts either CDDP cytotoxicity (two-fold more active in U2-OS than in A431 cells) and CDDP resistance in comparison to a p53 mutant type.	cddp	46-50	tumor protein p53	Homo sapiens	28-31
17466278-12	2007	The presence of a wild-type p53 exalts either CDDP cytotoxicity (two-fold more active in U2-OS than in A431 cells) and CDDP resistance in comparison to a p53 mutant type.	cddp	119-123	tumor protein p53	Homo sapiens	28-31
17466256-3	2007	LA-12 induced apoptosis much more efficiently than did CDDP due to a combination of rapid penetration into the cell and attack on DNA, leading to fast activation of p53 and caspase-3.	cddp	55-59	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	165-168
17431117-5	2007	The TRAIL- and drug-resistant prostate carcinoma PC-3 cell line was treated with CDDP, VP-16, ADR, and vincristine.	cddp	81-85	TNF superfamily member 10	Homo sapiens	4-9
17510416-1	2007	We and others have shown that the copper transporters ATP7A and ATP7B play a role in cellular resistance to cis-diaminedichloroplatinum (II) (CDDP).	cddp	142-146	ATPase copper transporting alpha	Homo sapiens	54-59
17510416-1	2007	We and others have shown that the copper transporters ATP7A and ATP7B play a role in cellular resistance to cis-diaminedichloroplatinum (II) (CDDP).	cddp	142-146	ATPase copper transporting beta	Homo sapiens	64-69
17565259-6	2007	CDDP (60 mg/m2) administration was begun 8 days after the start of S-1.	cddp	0-4	proteasome 26S subunit, non-ATPase 1	Homo sapiens	67-70
17353624-10	2007	Expression of ERCC 1, a component of this complex multi-protein system, has been reported to be a determinant of prognosis in CDDP-treated non-small-cell lung cancer patients.	cddp	126-130	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	14-20
16897996-0	2006	[Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].	cddp	60-64	proteasome 26S subunit, non-ATPase 1	Homo sapiens	41-58
17212140-2	2006	Laparoscopic biopsy showed it to be Group V. Pre-operative diagnosis was T3N3P1HOM1, Stage V. Three courses of pre-operative chemotherapy (NAC) of TS-1+CDDP were performed.	cddp	152-156	X-linked Kx blood group	Homo sapiens	139-142
16777967-4	2006	The melanosomal accumulation of CDDP remarkably modulates melanogenesis through a pronounced increase in tyrosinase activity.	cddp	32-36	tyrosinase	Homo sapiens	105-115
17023760-3	2006	Systemic administration of 5FU and CDDP caused her CEA level to decrease gradually and abdominal computed tomography revealed considerable reduction of the metastatic tumors and ascites.	cddp	35-39	CEA cell adhesion molecule 3	Homo sapiens	51-54
16685392-8	2006	The inhibition rates (IRs) of CDDP and CBDCA were significantly correlated with TS/PCNA, the ratio of TS/actin and PCNA/actin, and DPD/PCNA, the ratio of DPD/actin and PCNA/actin.	cddp	30-34	proliferating cell nuclear antigen	Homo sapiens	83-87
16705697-3	2006	In the present study, we examined whether activation of JNK is induced by the chemotherapeutic agents cis-diaminedichloroplatinum (cisplatin, CDDP) or doxorubicin (DXR), and whether the ectopic expression of constitutively active (MKK7-JNK1) or dominant-negative form of JNK (dnJNK) influenced apoptosis in response to the CDDP or DXR in sarcoma cell lines MG-63 and SaOS-2.	cddp	142-146	mitogen-activated protein kinase 8	Homo sapiens	56-59
16705697-3	2006	In the present study, we examined whether activation of JNK is induced by the chemotherapeutic agents cis-diaminedichloroplatinum (cisplatin, CDDP) or doxorubicin (DXR), and whether the ectopic expression of constitutively active (MKK7-JNK1) or dominant-negative form of JNK (dnJNK) influenced apoptosis in response to the CDDP or DXR in sarcoma cell lines MG-63 and SaOS-2.	cddp	323-327	mitogen-activated protein kinase 8	Homo sapiens	56-59
16705697-4	2006	The CDDP or DXR induced JNK activation in the both cell lines, as assessed by Western blotting using phosphospecific antibodies.	cddp	4-8	mitogen-activated protein kinase 8	Homo sapiens	24-27
16705697-7	2006	Collectively, our results indicate that JNK activation is involved in apoptotic cell death in sarcoma cell lines following stimulation with CDDP or DXR.	cddp	140-144	mitogen-activated protein kinase 8	Homo sapiens	40-43
16685392-10	2006	The associations of TS/PCNA and DPD/PCNA with the IRs of CDDP, CBDCA remained significant in the 3R/3R group and H-type group.	cddp	57-61	proliferating cell nuclear antigen	Homo sapiens	23-27
16685392-8	2006	The inhibition rates (IRs) of CDDP and CBDCA were significantly correlated with TS/PCNA, the ratio of TS/actin and PCNA/actin, and DPD/PCNA, the ratio of DPD/actin and PCNA/actin.	cddp	30-34	proliferating cell nuclear antigen	Homo sapiens	115-119
16685392-10	2006	The associations of TS/PCNA and DPD/PCNA with the IRs of CDDP, CBDCA remained significant in the 3R/3R group and H-type group.	cddp	57-61	dihydropyrimidine dehydrogenase	Homo sapiens	32-35
16685392-10	2006	The associations of TS/PCNA and DPD/PCNA with the IRs of CDDP, CBDCA remained significant in the 3R/3R group and H-type group.	cddp	57-61	proliferating cell nuclear antigen	Homo sapiens	36-40
16685392-11	2006	These results suggest that in vitro sensitivity to platinum-derived drugs, CDDP and CBDCA, is associated with PCNA-normalized mRNA expression of TS and DPD in human lung cancer tissues, as affected by the TS polymorphism.	cddp	75-79	proliferating cell nuclear antigen	Homo sapiens	110-114
16685392-11	2006	These results suggest that in vitro sensitivity to platinum-derived drugs, CDDP and CBDCA, is associated with PCNA-normalized mRNA expression of TS and DPD in human lung cancer tissues, as affected by the TS polymorphism.	cddp	75-79	dihydropyrimidine dehydrogenase	Homo sapiens	152-155
16685392-8	2006	The inhibition rates (IRs) of CDDP and CBDCA were significantly correlated with TS/PCNA, the ratio of TS/actin and PCNA/actin, and DPD/PCNA, the ratio of DPD/actin and PCNA/actin.	cddp	30-34	dihydropyrimidine dehydrogenase	Homo sapiens	131-134
16685392-8	2006	The inhibition rates (IRs) of CDDP and CBDCA were significantly correlated with TS/PCNA, the ratio of TS/actin and PCNA/actin, and DPD/PCNA, the ratio of DPD/actin and PCNA/actin.	cddp	30-34	proliferating cell nuclear antigen	Homo sapiens	115-119
16685392-8	2006	The inhibition rates (IRs) of CDDP and CBDCA were significantly correlated with TS/PCNA, the ratio of TS/actin and PCNA/actin, and DPD/PCNA, the ratio of DPD/actin and PCNA/actin.	cddp	30-34	dihydropyrimidine dehydrogenase	Homo sapiens	154-157
16685392-8	2006	The inhibition rates (IRs) of CDDP and CBDCA were significantly correlated with TS/PCNA, the ratio of TS/actin and PCNA/actin, and DPD/PCNA, the ratio of DPD/actin and PCNA/actin.	cddp	30-34	proliferating cell nuclear antigen	Homo sapiens	115-119
16310931-11	2006	The transduction of 11R-p53 enhanced CDDP-dependent induction of apoptosis.	cddp	37-41	tumor protein p53	Homo sapiens	24-27
16836906-0	2006	[Inhibition effect on Tca8113/CDDP by antisense oligonucleotides of cyclin D1 combined with cis diamminedichloroplatinum].	cddp	30-34	cyclin D1	Mus musculus	68-77
16836906-1	2006	OBJECTIVE: To clarify the relationship between cyclin D1 and cisplatin resistance of Tca8113/cis diamminedichloroplatinum (CDDP) in vitro and in vivo.	cddp	123-127	cyclin D1	Mus musculus	47-56
16731744-2	2006	We showed recently that hepatocyte growth factor (HGF) enhances death of human ovarian cancer cell lines treated with cisplatin (CDDP) and that this effect is mediated by the p38 mitogen-activated protein kinase.	cddp	129-133	hepatocyte growth factor	Homo sapiens	24-48
16731744-2	2006	We showed recently that hepatocyte growth factor (HGF) enhances death of human ovarian cancer cell lines treated with cisplatin (CDDP) and that this effect is mediated by the p38 mitogen-activated protein kinase.	cddp	129-133	hepatocyte growth factor	Homo sapiens	50-53
16731744-3	2006	In this work, we integrated genome-wide expression profiling, in silico data survey, and functional assays to identify transcripts regulated in SK-OV-3 ovarian cancer cells made more responsive to CDDP by HGF.	cddp	197-201	hepatocyte growth factor	Homo sapiens	205-208
16731744-4	2006	Using oligonucleotide microarrays, we found that HGF pretreatment changes the transcriptional response to CDDP.	cddp	106-110	hepatocyte growth factor	Homo sapiens	49-52
16731744-5	2006	Quantitative reverse transcription-PCR not only validated all the 15 most differentially expressed genes but also confirmed that they were primarily modulated by the combined treatment with HGF and CDDP and reversed by suppressing p38 mitogen-activated protein kinase activity.	cddp	198-202	hepatocyte growth factor	Homo sapiens	190-193
16586549-3	2006	5-FU, MTX, CDDP of different concentrations were given after transfecting cells with cyclin D1 ASODN for 24 h the dose-effect responses were observed and IC50s were calculated.	cddp	11-15	cyclin D1	Homo sapiens	85-94
16586549-7	2006	Cyclin D1 ASODN could increase the chemosensitivity to 5-FU, MTX, CDDP in cells.	cddp	66-70	cyclin D1	Homo sapiens	0-9
16484864-5	2006	After 33 months, a high dose of CDDP was administered twice in combination with TS-1, because elevation of serum CEA levels and paraortic lymphnode swelling were observed for the first time.	cddp	32-36	CEA cell adhesion molecule 3	Homo sapiens	113-116
16315893-6	2005	However, a combination of po TS-1 (8 mg/kg x 10 days, from day 3) and ip CDDP (3.5 mg/kg, day 6 and 13) showed a significant survival improvement than that of po TS-1 or ip CDDP treatment alone.	cddp	173-177	Trichinella spiralis resistance 1	Mus musculus	29-33
16043385-3	2005	In the present study, the association between MGMT expression and the cellular sensitivity to the platinum agent, CDDP was examined in four human oral cancer cell lines.	cddp	114-118	O-6-methylguanine-DNA methyltransferase	Homo sapiens	46-50
16043385-4	2005	CDDP depleted MGMT protein and mRNA levels in all four cell lines.	cddp	0-4	O-6-methylguanine-DNA methyltransferase	Homo sapiens	14-18
16043385-5	2005	Two cell lines with low MGMT expression were sensitive to an alkylating agent, N-methyl-N"-nitro-N-nitrosoguanidine and CDDP, whereas two other cell lines with high MGMT expression were resistant to both agents.	cddp	120-124	O-6-methylguanine-DNA methyltransferase	Homo sapiens	24-28
16043385-6	2005	Furthermore, the addition of the MGMT inhibitor, O6-benzylguanine (O6-BG), invariably enhanced CDDP sensitivity.	cddp	95-99	O-6-methylguanine-DNA methyltransferase	Homo sapiens	33-37
16043385-7	2005	CDDP depleted MGMT expression, and CDDP sensitivity was enhanced by O6-BG.	cddp	0-4	O-6-methylguanine-DNA methyltransferase	Homo sapiens	14-18
16043385-8	2005	These results provide valuable information about the relationship between MGMT expression and CDDP sensitivity in oral cancer chemotherapy.	cddp	94-98	O-6-methylguanine-DNA methyltransferase	Homo sapiens	74-78
15900595-9	2005	RCN-transfectant of H69 CDDP-resistant strain showed intermediate sensitivity between the parent strain and the CDDP-resistant strain.	cddp	24-28	reticulocalbin 1	Homo sapiens	0-3
15900595-9	2005	RCN-transfectant of H69 CDDP-resistant strain showed intermediate sensitivity between the parent strain and the CDDP-resistant strain.	cddp	112-116	reticulocalbin 1	Homo sapiens	0-3
16227410-5	2005	The CDDP-resistant cells released more protein as exosomes and Western blot analysis revealed that these exosomes contained substantially more LAMP1 than those released by the CDDP-sensitive cells.	cddp	4-8	lysosomal associated membrane protein 1	Homo sapiens	143-148
16184937-2	2005	Hepatic intraarterial injection therapy with 5-FU/CDDP was not only ineffective against a liver metastasis but a lung metastasis was also found, and therefore systemic chemotherapy with CPT-11/5-FU/l-LV (IFL) was administered.	cddp	50-54	interferon alpha 1	Homo sapiens	204-207
16193384-6	2005	In contrast, p53 inactivation rendered D54 and U87MG cells significantly more resistant to cis-dichlorodiamminoplatinum (CDDP), another chemotherapeutic to which high-grade astrocytomas sometimes respond.	cddp	121-125	tumor protein p53	Homo sapiens	13-16
17022150-10	2005	There were significant correlations between the IC50 of CDDP and Bcl-2, BCRP, GST-pi, and between that of 5-FU and MRP 2.	cddp	56-60	BCL2 apoptosis regulator	Homo sapiens	65-70
15720263-5	2005	DNA repair capacity influences response to CDDP and ERCC1 gene stands out as a predictive marker of CDDP sensitivity.	cddp	100-104	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	52-57
15856183-4	2005	CDDP treatment markedly increased urinary excretion of NAG, gamma-GTP, LDH and protein, with peaks on day 4 and complete or partial recovery on day 7; NDP increased NAG, LDH and protein excretion, but to a lesser extent, and these elevations were generally more marked for females.	cddp	0-4	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	55-58
15856183-4	2005	CDDP treatment markedly increased urinary excretion of NAG, gamma-GTP, LDH and protein, with peaks on day 4 and complete or partial recovery on day 7; NDP increased NAG, LDH and protein excretion, but to a lesser extent, and these elevations were generally more marked for females.	cddp	0-4	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	165-168
16020127-13	2005	In a mixed HB, both chemosensitizers combined with DOXO or CDDP produced a significant reduction of tumor growth (p = .0001-.00063) and AFP levels (p = .0006-.0128) compared to tumors treated with DOXO or CDDP only.	cddp	59-63	alpha fetoprotein	Homo sapiens	136-139
16020127-16	2005	MDR1 modulators improve the efficiency of DOXO and CDDP treatment in xenotransplanted HB.	cddp	51-55	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
16170037-5	2005	The evaluation of molecular pathways involved in apoptosis indicates that the Bcl-2 but not the caspases may be involved in the CDDP protection of paclitaxel-induced apoptosis.	cddp	128-132	BCL2 apoptosis regulator	Homo sapiens	78-83
16170037-6	2005	The increase in p53 protein and its nuclear accumulation suggests a possible involvement of p53 in CDDP protection.	cddp	99-103	tumor protein p53	Homo sapiens	16-19
16170037-6	2005	The increase in p53 protein and its nuclear accumulation suggests a possible involvement of p53 in CDDP protection.	cddp	99-103	tumor protein p53	Homo sapiens	92-95
15770730-5	2005	IFN-alpha is also able to prevent the increase in proliferation rate and VEGF secretion of CDDP resistant cells.	cddp	91-95	interferon alpha 1	Homo sapiens	0-9
15770730-5	2005	IFN-alpha is also able to prevent the increase in proliferation rate and VEGF secretion of CDDP resistant cells.	cddp	91-95	vascular endothelial growth factor A	Homo sapiens	73-77
15770730-8	2005	CONCLUSION: In conclusion, IFN-alpha has direct cytotoxic effects, acts as a radiosensitizer and circumvents tumor cell-regrowth after CDDP treatment.	cddp	135-139	interferon alpha 1	Homo sapiens	27-36
15389812-3	2005	RESULTS: CDDP and DACH-Ac-Pt were equiactive against mutant p53 and androgen-independent DU-145 or PC-3 tumor cells.	cddp	9-13	tumor protein p53	Homo sapiens	60-63
15389812-4	2005	In wild-type p53 cells, CDDP was threefold more potent against androgen-dependent LNCaP than isogenic androgen-independent LNCaP-LN3 cells.	cddp	24-28	tumor protein p53	Homo sapiens	13-16
15389812-6	2005	The greater potency of DACH-Ac-Pt than CDDP in wild-type p53 cells was not due to increased cellular drug uptake or increased adduct levels, but correlated with a lower tolerance to DNA damage.	cddp	39-43	tumor protein p53	Homo sapiens	57-60
15389812-11	2005	The differential induction of p21(WAF1/CIP1) and increase in Bax/Bcl-2 ratios with CDDP and DACH-Ac-Pt in LNCaP-LN3 cells appear to be linked to the relative activity of the two agents against this model.	cddp	83-87	cyclin dependent kinase inhibitor 1A	Homo sapiens	30-33
15389812-11	2005	The differential induction of p21(WAF1/CIP1) and increase in Bax/Bcl-2 ratios with CDDP and DACH-Ac-Pt in LNCaP-LN3 cells appear to be linked to the relative activity of the two agents against this model.	cddp	83-87	BCL2 associated X, apoptosis regulator	Homo sapiens	61-64
15389812-11	2005	The differential induction of p21(WAF1/CIP1) and increase in Bax/Bcl-2 ratios with CDDP and DACH-Ac-Pt in LNCaP-LN3 cells appear to be linked to the relative activity of the two agents against this model.	cddp	83-87	BCL2 apoptosis regulator	Homo sapiens	65-70
15492509-7	2004	These studies support the role of BRCA1 in the CDDP-induced and MMS-induced DNA damage and repair by p53-independent pathways.	cddp	47-51	breast cancer 1, early onset	Mus musculus	34-39
15507242-9	2004	In the duodenum, the numbers of secretin-immunoreactive cells and somatostatin-immunoreactive cells were dramatically increased 5 days after CDDP treatment.	cddp	141-145	somatostatin	Rattus norvegicus	66-78
15507242-10	2004	In the jejunum, the number of CCK-immunoreactive cells was increased 1 day after CDDP treatment and those of secretin-immunoreactive cells and CCK-immunoreactive cells were increased 5 days after CDDP treatment.	cddp	81-85	cholecystokinin	Rattus norvegicus	30-33
15507242-11	2004	In the ileum, the number of CCK-immunoreactive cells was increased 1 day after CDDP treatment.	cddp	79-83	cholecystokinin	Rattus norvegicus	28-31
15507242-12	2004	The change in the secretin-immunoreactive cell count may be caused by metabolic inhibition of gastrin following CDDP-induced nephrotoxicity.	cddp	112-116	gastrin	Rattus norvegicus	94-101
15505427-0	2004	Sensitization by glycerol for CDDP-therapy against human cultured cancer cells and tumors bearing mutated p53 gene.	cddp	30-34	tumor protein p53	Homo sapiens	106-109
15505427-2	2004	Human tongue cell carcinoma (SAS) cells transfected with mutated p53 gene (SAS/m p53) showed CDDP-resistance compared with the cells with neo control gene (SAS/ neo).	cddp	93-97	tetraspanin 31	Homo sapiens	29-32
15505427-2	2004	Human tongue cell carcinoma (SAS) cells transfected with mutated p53 gene (SAS/m p53) showed CDDP-resistance compared with the cells with neo control gene (SAS/ neo).	cddp	93-97	tumor protein p53	Homo sapiens	65-68
15505427-2	2004	Human tongue cell carcinoma (SAS) cells transfected with mutated p53 gene (SAS/m p53) showed CDDP-resistance compared with the cells with neo control gene (SAS/ neo).	cddp	93-97	tetraspanin 31	Homo sapiens	75-78
15505427-2	2004	Human tongue cell carcinoma (SAS) cells transfected with mutated p53 gene (SAS/m p53) showed CDDP-resistance compared with the cells with neo control gene (SAS/ neo).	cddp	93-97	tumor protein p53	Homo sapiens	81-84
15505427-2	2004	Human tongue cell carcinoma (SAS) cells transfected with mutated p53 gene (SAS/m p53) showed CDDP-resistance compared with the cells with neo control gene (SAS/ neo).	cddp	93-97	tetraspanin 31	Homo sapiens	75-78
15505427-3	2004	When those cultured cells were pre-treated with glycerol, CDDP-induced apoptosis was enhanced by glycerol in SAS/m p53 cells but not in SAS/ neo cells.	cddp	58-62	tetraspanin 31	Homo sapiens	109-112
15505427-3	2004	When those cultured cells were pre-treated with glycerol, CDDP-induced apoptosis was enhanced by glycerol in SAS/m p53 cells but not in SAS/ neo cells.	cddp	58-62	tumor protein p53	Homo sapiens	115-118
15505427-4	2004	In tumor-transplanted mice, the glycerol treatment to tumors enhanced growth delay induced by CDDP in mp53 tumors transplanted with SAS/m p53 cells, but not in wtp53 tumors transplanted with SAS/ neo cells.	cddp	94-98	tetraspanin 31	Mus musculus	132-135
15505427-4	2004	In tumor-transplanted mice, the glycerol treatment to tumors enhanced growth delay induced by CDDP in mp53 tumors transplanted with SAS/m p53 cells, but not in wtp53 tumors transplanted with SAS/ neo cells.	cddp	94-98	transformation related protein 53, pseudogene	Mus musculus	103-106
15505427-5	2004	When transplanted tumors were treated with CDDP alone, the cells positive for active caspase-3, 85 kDa PARP and apoptosis were observed by immunohistochemical staining in wtp53 tumors but not in mp53 tumors.	cddp	43-47	caspase 3	Homo sapiens	85-94
15505427-5	2004	When transplanted tumors were treated with CDDP alone, the cells positive for active caspase-3, 85 kDa PARP and apoptosis were observed by immunohistochemical staining in wtp53 tumors but not in mp53 tumors.	cddp	43-47	poly(ADP-ribose) polymerase 1	Homo sapiens	103-107
15505427-7	2004	These results showed that the CDDP-induced growth inhibition of the tumors is p53 -dependent and that the enhanced growth delay by glycerol may be due to the increased apoptosis.	cddp	30-34	tumor protein p53	Homo sapiens	78-81
15492509-7	2004	These studies support the role of BRCA1 in the CDDP-induced and MMS-induced DNA damage and repair by p53-independent pathways.	cddp	47-51	transformation related protein 53, pseudogene	Mus musculus	101-104
15077178-7	2004	Inhibition of the Src PTKs, MAPK, and NF-kappaB activities by Rituximab or by specific chemical inhibitors sensitized the cells to CDDP-mediated apoptosis.	cddp	131-135	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	18-21
15298732-8	2004	To explain these findings, messenger RNA (mRNA) levels for multidrug resistance-associated protein-1 (MRP-1), the ATP-dependent pump for Pt-GSH complexes, were quantified in CDDP-treated MKN-45 cells with and without DOC pretreatment.	cddp	174-178	ATP binding cassette subfamily C member 1	Homo sapiens	59-100
15298732-8	2004	To explain these findings, messenger RNA (mRNA) levels for multidrug resistance-associated protein-1 (MRP-1), the ATP-dependent pump for Pt-GSH complexes, were quantified in CDDP-treated MKN-45 cells with and without DOC pretreatment.	cddp	174-178	ATP binding cassette subfamily C member 1	Homo sapiens	102-107
15298732-9	2004	While CDDP administration increased MRP-1 mRNA expression in MKN-45 cells, MRP-1 was not up-regulated after CDDP administration in DOC pretreated MKN-45 cells.	cddp	6-10	ATP binding cassette subfamily C member 1	Homo sapiens	36-41
15298732-10	2004	Our results suggested that the enhanced CDDP toxicity due to DOC pretreatment may be related to the accumulation of intracellular Pt-GSH complexes, because DOC appears to suppress the MRP-1 up-regulation induced by CDDP exposure in gastric cancer cells.	cddp	40-44	ATP binding cassette subfamily C member 1	Homo sapiens	184-189
15298732-10	2004	Our results suggested that the enhanced CDDP toxicity due to DOC pretreatment may be related to the accumulation of intracellular Pt-GSH complexes, because DOC appears to suppress the MRP-1 up-regulation induced by CDDP exposure in gastric cancer cells.	cddp	215-219	ATP binding cassette subfamily C member 1	Homo sapiens	184-189
15330188-3	2004	Because direct invasion of the thoracic aorta was suspected, FAP therapy (CDDP, 5-FU and ADM) was given as neoadjuvant chemotherapy.	cddp	74-78	fibroblast activation protein alpha	Homo sapiens	61-64
15010879-0	2004	Glycerol enhances CDDP-induced growth inhibition of thyroid anaplastic carcinoma tumor carrying mutated p53 gene.	cddp	18-22	transformation related protein 53, pseudogene	Mus musculus	104-107
15010879-7	2004	Cells positive for cleavage to active caspase-3 and 85 kDa PARP, and apoptosis were hardly observed in the tumors when they were treated with glycerol or CDDP alone.	cddp	154-158	caspase 3	Mus musculus	38-47
15010879-9	2004	It has been shown that glycerol synergistically enhanced the effects of CDDP as a tumor suppressive agent through the induction of caspase-3-mediated apoptosis in 8305c tumors.	cddp	72-76	caspase 3	Mus musculus	131-140
14601052-3	2003	Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells.	cddp	41-45	TNF superfamily member 10	Homo sapiens	151-156
14601052-3	2003	Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells.	cddp	41-45	TNF superfamily member 10	Homo sapiens	157-162
14601052-3	2003	Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells.	cddp	41-45	TNF superfamily member 10	Homo sapiens	222-227
14601052-3	2003	Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells.	cddp	41-45	TNF superfamily member 10	Homo sapiens	228-233
14601052-7	2003	However, ActD, DOX and CDDP downregulated expression of cFLIP in OS cells as well as expression of p21 in normal hOBs.	cddp	23-27	CASP8 and FADD like apoptosis regulator	Homo sapiens	56-61
14654070-8	2003	The increased expression of Trx 1 is completely blocked with an inhibitor of Trx 1, CDDP, which also abolished cardioprotection afforded by ischemic adaptation.	cddp	84-88	thioredoxin 1	Mus musculus	28-33
14654070-8	2003	The increased expression of Trx 1 is completely blocked with an inhibitor of Trx 1, CDDP, which also abolished cardioprotection afforded by ischemic adaptation.	cddp	84-88	thioredoxin 1	Mus musculus	77-82
14513366-9	2003	Wortmannin, a PI3-kinase (PI3-K) inhibitor, caused a dose-dependent inhibition of total p53 accumulation, Ser-15 phosphorylation and p21(WAF1/CIP1) transactivation in response to both CDDP and DACH-Ac-Pt, indicating that members of the PI3-K family are involved in phosphorylation of p53 and that transactivation of p21(WAF1/CIP1) is p53 dependent.	cddp	184-188	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	14-24
14582698-12	2003	The use of CDDP with arterial injection of AdCMV-p53 resulted in more extensive apoptosis in the rat liver tumors without any deterioration in liver function.	cddp	11-15	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	49-52
14564514-7	2003	Combined treatment with 5-FU and CDDP gave additional effect on CEA expression in COLO201 cells.	cddp	33-37	CEA cell adhesion molecule 3	Homo sapiens	64-67
14513366-4	2003	RESULTS: In response to CDDP and DACH-Ac-Pt, both CDDP-sensitive and CDDP-resistant models demonstrated time- and dose-dependent inductions of total p53 protein and an increase in Ser-15 phosphorylation, which was more pronounced with CDDP.	cddp	24-28	tumor protein p53	Homo sapiens	149-152
14513366-4	2003	RESULTS: In response to CDDP and DACH-Ac-Pt, both CDDP-sensitive and CDDP-resistant models demonstrated time- and dose-dependent inductions of total p53 protein and an increase in Ser-15 phosphorylation, which was more pronounced with CDDP.	cddp	50-54	tumor protein p53	Homo sapiens	149-152
14513366-4	2003	RESULTS: In response to CDDP and DACH-Ac-Pt, both CDDP-sensitive and CDDP-resistant models demonstrated time- and dose-dependent inductions of total p53 protein and an increase in Ser-15 phosphorylation, which was more pronounced with CDDP.	cddp	50-54	tumor protein p53	Homo sapiens	149-152
14513366-4	2003	RESULTS: In response to CDDP and DACH-Ac-Pt, both CDDP-sensitive and CDDP-resistant models demonstrated time- and dose-dependent inductions of total p53 protein and an increase in Ser-15 phosphorylation, which was more pronounced with CDDP.	cddp	50-54	tumor protein p53	Homo sapiens	149-152
14513366-5	2003	Although phosphorylation of p53 at Ser-392 was also observed in CDDP-treated sensitive and resistant cells, it was weak or absent in response to DACH-Ac-Pt.	cddp	64-68	tumor protein p53	Homo sapiens	28-31
14614026-6	2003	These two schemes were selected from the observation that tumor cells in vitro show an increased activity of GST 48 h after cDDP treatment.	cddp	124-128	hematopoietic prostaglandin D synthase	Mus musculus	109-112
14614026-12	2003	RESULTS: In line with the increased GST activity observed after treatment with cDDP, the cDDP/brostallicin interaction was sequence-dependent, leading to a more than additive antitumor effect, without additional toxicity, only when cDDP was given before brostallicin.	cddp	79-83	hematopoietic prostaglandin D synthase	Mus musculus	36-39
12516089-2	2003	The intracellular NO and O2(-) levels were increased up to about 110-120% and 140-180% of the control levels, respectively, after the treatment of OSC-4 cells with 5-FU (100 microg/ml), PLM (10 microg/ml), CDDP (10 microg/ml), or gamma-rays (20 Gy).	cddp	206-210	FXYD domain containing ion transport regulator 1	Homo sapiens	186-189
12898755-6	2003	RESULTS: Using pCMV-NEO-BAM system to keep stable expression of nm23-H1, the significant difference of NDPKA expression between transfected and non-transfected Tca8113 line cells was discovered; The metastases ability of transfected Tca8113 line cells decreased significantly; The chemo-sensitivity of transfected Tca8113 line cells to CDDP increased significantly.	cddp	336-340	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	64-71
12898755-7	2003	CONCLUSION: nm23-H1 can inhibit the metastases of Tca8113 line cells and increase the chemo-sensitivity to CDDP significantly.	cddp	107-111	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	12-19
12706370-15	2003	A primary role in the protection of HK-2 cells appears to be played by cysteinyl-glycine, the proximal product of the GGT-mediated hydrolysis of GSH, which shows a high reactivity against CDDP resulting in the rapid inactivation of the drug.	cddp	188-192	inactive glutathione hydrolase 2	Homo sapiens	118-121
11777343-5	2002	All-trans-retinoic acid (ATRA) treatment of HPV-immortalized HEN-16-2 cells and transformed/MDR HEN-16-2/CDDP cells inhibited telomerase activity and downregulated expression of hTERT mRNAs containing full-length functional and a defective RT motif, but there were no changes in hTR and TP1 expression.	cddp	105-109	telomerase reverse transcriptase	Homo sapiens	178-183
12557715-0	2003	[A case of advanced gastric adenocarcinoma with mild elevation of serum SCC that responded remarkably to adjuvant chemotherapy of ADM, CDDP, ETP and 5-FU (ACVF)].	cddp	135-139	serpin family B member 3	Homo sapiens	72-75
12062498-7	2002	CDDP-CSA-2 and CDDP-CSC-2, with similar urinary excretion as CDDP, gave rise to approximately five and four-fold increase in AUC(0-3 h) values, respectively, than that was achieved with native CDDP treatment.	cddp	0-4	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	5-8
12062498-11	2002	In addition, a significantly higher accumulation in tumor tissue was found with the administration of CDDP-CSA-2 than CDDP.	cddp	102-106	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	107-110
11836567-15	2002	Although the receptor signaling pathway in apoptosis was not observed by 5-FU, Bax-induced cytochrome c and caspase 3 was also observed in a receptor-independent pathway by 5-FU and CDDP.	cddp	182-186	BCL2 associated X, apoptosis regulator	Homo sapiens	79-82
11836567-15	2002	Although the receptor signaling pathway in apoptosis was not observed by 5-FU, Bax-induced cytochrome c and caspase 3 was also observed in a receptor-independent pathway by 5-FU and CDDP.	cddp	182-186	cytochrome c, somatic	Homo sapiens	91-103
11836567-15	2002	Although the receptor signaling pathway in apoptosis was not observed by 5-FU, Bax-induced cytochrome c and caspase 3 was also observed in a receptor-independent pathway by 5-FU and CDDP.	cddp	182-186	caspase 3	Homo sapiens	108-117
12680227-8	2003	Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line.	cddp	10-14	metallothionein 3	Homo sapiens	26-33
12680227-8	2003	Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line.	cddp	71-75	metallothionein 3	Homo sapiens	26-33
12552994-2	2002	DPD activity in peripheral blood mononuclear cells of 30 esophageal cancer patients treated with 5-FU and low-dose CDDP with irradiation was determined at the beginning of each cytostatic cycle, the objective being to determine if DPD activity is related to the occurrence of side-effects and responses to therapy.	cddp	115-119	dihydropyrimidine dehydrogenase	Homo sapiens	0-3
12397465-10	2002	In contrast, FLT accumulation was significantly reduced at cytostatic concentrations of CDDP and was still decreasing in a dose-related manner at 72 h despite considerable S phase arrest.	cddp	88-92	fms related receptor tyrosine kinase 1	Homo sapiens	13-16
12397465-15	2002	By contrast, CDDP results in an early decline in FLT but not in FDG uptake.	cddp	13-17	fms related receptor tyrosine kinase 1	Homo sapiens	49-52
12101396-0	2002	Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck.	cddp	52-56	tumor protein p53	Homo sapiens	23-26
12101396-6	2002	SAS/Trp248 cells showed X-ray- and CDDP-resistance due to the dominant negative nature of mutant p53, compared with SAS/neo cells.	cddp	35-39	tetraspanin 31	Homo sapiens	0-3
12101396-6	2002	SAS/Trp248 cells showed X-ray- and CDDP-resistance due to the dominant negative nature of mutant p53, compared with SAS/neo cells.	cddp	35-39	tumor protein p53	Homo sapiens	97-100
12101396-7	2002	The incidence of DNA ladders and apoptotic bodies increased markedly in SAS/neo cells after X-ray irradiation or CDDP treatment, but increased only slightly in SAS/Trp248 cells.	cddp	113-117	tetraspanin 31	Homo sapiens	72-75
12101396-9	2002	The present results strongly suggest that the X-ray- and CDDP-sensitivities of human squamous cell carcinomas are p53-dependent, and that the sensitivities are tightly correlated with the induction of apoptosis through caspase-3 activation.	cddp	57-61	tumor protein p53	Homo sapiens	114-117
12101396-9	2002	The present results strongly suggest that the X-ray- and CDDP-sensitivities of human squamous cell carcinomas are p53-dependent, and that the sensitivities are tightly correlated with the induction of apoptosis through caspase-3 activation.	cddp	57-61	caspase 3	Homo sapiens	219-228
12101396-10	2002	The p53-dependent X-ray- or CDDP-sensitivity was supported by results from p53-null human lung cancer H1299 cells which were transfected with wild-type or mutant p53 gene.	cddp	28-32	tumor protein p53	Homo sapiens	4-7
12101396-10	2002	The p53-dependent X-ray- or CDDP-sensitivity was supported by results from p53-null human lung cancer H1299 cells which were transfected with wild-type or mutant p53 gene.	cddp	28-32	tumor protein p53	Homo sapiens	75-78
12101396-10	2002	The p53-dependent X-ray- or CDDP-sensitivity was supported by results from p53-null human lung cancer H1299 cells which were transfected with wild-type or mutant p53 gene.	cddp	28-32	tumor protein p53	Homo sapiens	75-78
12012012-5	2002	Bcl-2 over-expression inhibited both delay in S-phase exit and CDDP-induced apoptosis in ATRA-pretreated cells.	cddp	63-67	BCL2 apoptosis regulator	Homo sapiens	0-5
12012012-6	2002	The CDDP-induced S-phase accumulation of OVCCR1 cells resulted from an activation of CDK2/cyclin A activity.	cddp	4-8	cyclin dependent kinase 2	Homo sapiens	85-89
12012012-6	2002	The CDDP-induced S-phase accumulation of OVCCR1 cells resulted from an activation of CDK2/cyclin A activity.	cddp	4-8	cyclin A2	Homo sapiens	90-98
12012012-7	2002	Our results indicate that ATRA-pretreatment modified the CDDP-induced regulation of CDK2 activity by the CDK inhibitors p21 and p27.	cddp	57-61	cyclin dependent kinase 2	Homo sapiens	84-88
12012012-7	2002	Our results indicate that ATRA-pretreatment modified the CDDP-induced regulation of CDK2 activity by the CDK inhibitors p21 and p27.	cddp	57-61	cyclin dependent kinase 2	Homo sapiens	84-87
12012012-7	2002	Our results indicate that ATRA-pretreatment modified the CDDP-induced regulation of CDK2 activity by the CDK inhibitors p21 and p27.	cddp	57-61	cyclin dependent kinase inhibitor 1A	Homo sapiens	120-123
12012012-7	2002	Our results indicate that ATRA-pretreatment modified the CDDP-induced regulation of CDK2 activity by the CDK inhibitors p21 and p27.	cddp	57-61	interferon alpha inducible protein 27	Homo sapiens	128-131
12012012-8	2002	Taken together, our findings suggest that ATRA potentiates the apoptosis induced by CDDP in ovarian carcinoma cells and that this action is sustained by modulation of the activity of CDK2/cyclin A.	cddp	84-88	cyclin A2	Homo sapiens	188-196
14607648-10	2002	Antisense hTR appears to increase Pancl cell"s susceptibility to chemotherapeutic reagent cDDP, but not to differentiation reagent DMSO, COX2 inhibitor sulinbac, NS-398, curcumin, and chemotherapeutic reagent adriamycin (ADM).	cddp	90-94	telomerase RNA component	Homo sapiens	10-13
14607648-11	2002	CONCLUSIONS: These data indicate that hTR is probably a critical component of human telomerase activity and that downregulation of the RNA component of human telomerase is an effective target for anticancer strategy and antisense hTR can increase Pancl cell"s susceptibility to cDDP.	cddp	278-282	telomerase RNA component	Homo sapiens	230-233
11791389-0	2001	[A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy].	cddp	83-87	alpha fetoprotein	Homo sapiens	11-14
11791389-1	2001	A case of AFP producing early gastric cancer successfully treated with a small dose of CDDP and 5-FU therapy administered intermittedly is reported with a review of the literature.	cddp	87-91	alpha fetoprotein	Homo sapiens	10-13
11705695-1	2001	Several studies have demonstrated a correlation between cellular toxicity of cis-diamminedichloroplatinum (II) (cisplatin, CDDP) and inhibited intracellular activity of the thioredoxin system, i.e., thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH.	cddp	123-127	thioredoxin	Homo sapiens	173-184
11925926-2	2001	(1) Comparison of gene expression between CDDP-sensitive human ovarian serous adenocarcinoma cell lines and CDDP-resistant cell lines revealed that gamma-glutamylcysteine synthetase, glutathione peroxidase-like protein, dehydrogenase (UGDH), NAD(P)H: quinoneoxireductase, glucose-6-phosphatase, ornithine decarboxylase and dihydrodiol dehydrogenase were associated with a mechanism of CDDP-resistance.	cddp	42-46	UDP-glucose 6-dehydrogenase	Homo sapiens	235-239
11925926-2	2001	(1) Comparison of gene expression between CDDP-sensitive human ovarian serous adenocarcinoma cell lines and CDDP-resistant cell lines revealed that gamma-glutamylcysteine synthetase, glutathione peroxidase-like protein, dehydrogenase (UGDH), NAD(P)H: quinoneoxireductase, glucose-6-phosphatase, ornithine decarboxylase and dihydrodiol dehydrogenase were associated with a mechanism of CDDP-resistance.	cddp	42-46	NAD(P)H quinone dehydrogenase 1	Homo sapiens	242-270
11925926-2	2001	(1) Comparison of gene expression between CDDP-sensitive human ovarian serous adenocarcinoma cell lines and CDDP-resistant cell lines revealed that gamma-glutamylcysteine synthetase, glutathione peroxidase-like protein, dehydrogenase (UGDH), NAD(P)H: quinoneoxireductase, glucose-6-phosphatase, ornithine decarboxylase and dihydrodiol dehydrogenase were associated with a mechanism of CDDP-resistance.	cddp	42-46	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	272-293
11925926-2	2001	(1) Comparison of gene expression between CDDP-sensitive human ovarian serous adenocarcinoma cell lines and CDDP-resistant cell lines revealed that gamma-glutamylcysteine synthetase, glutathione peroxidase-like protein, dehydrogenase (UGDH), NAD(P)H: quinoneoxireductase, glucose-6-phosphatase, ornithine decarboxylase and dihydrodiol dehydrogenase were associated with a mechanism of CDDP-resistance.	cddp	42-46	ornithine decarboxylase 1	Homo sapiens	295-318
11705695-1	2001	Several studies have demonstrated a correlation between cellular toxicity of cis-diamminedichloroplatinum (II) (cisplatin, CDDP) and inhibited intracellular activity of the thioredoxin system, i.e., thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH.	cddp	123-127	thioredoxin	Homo sapiens	199-210
11705695-1	2001	Several studies have demonstrated a correlation between cellular toxicity of cis-diamminedichloroplatinum (II) (cisplatin, CDDP) and inhibited intracellular activity of the thioredoxin system, i.e., thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH.	cddp	123-127	thioredoxin	Homo sapiens	212-215
11705695-1	2001	Several studies have demonstrated a correlation between cellular toxicity of cis-diamminedichloroplatinum (II) (cisplatin, CDDP) and inhibited intracellular activity of the thioredoxin system, i.e., thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH.	cddp	123-127	peroxiredoxin 5	Homo sapiens	218-239
11705695-1	2001	Several studies have demonstrated a correlation between cellular toxicity of cis-diamminedichloroplatinum (II) (cisplatin, CDDP) and inhibited intracellular activity of the thioredoxin system, i.e., thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH.	cddp	123-127	peroxiredoxin 5	Homo sapiens	241-245
11705695-2	2001	Conversely, increased cellular activity of the Trx system confers resistance to CDDP.	cddp	80-84	thioredoxin	Homo sapiens	47-50
11705695-3	2001	In this study, we have analyzed the interaction of CDDP with Trx and TrxR in order to clarify the mechanism.	cddp	51-55	thioredoxin	Homo sapiens	61-64
11705695-3	2001	In this study, we have analyzed the interaction of CDDP with Trx and TrxR in order to clarify the mechanism.	cddp	51-55	peroxiredoxin 5	Homo sapiens	69-73
11705695-4	2001	The inhibition with time-dependent kinetics by CDDP of NADPH-reduced (but not oxidized) TrxR was irreversible, strongly suggesting covalent modification of the reduced selenocysteine-containing active site.	cddp	47-51	peroxiredoxin 5	Homo sapiens	88-92
11705695-5	2001	Assuming second order kinetics, the rate constant of TrxR inhibition by CDDP was 21 +/- 3 M(-1) x s(-1).	cddp	72-76	peroxiredoxin 5	Homo sapiens	53-57
11705695-7	2001	Escherichia coli Trx or human or bacterial glutaredoxin (Grx) activities were in comparison only slightly or not at all inhibited by either CDDP, transplatin, or carboplatin.	cddp	140-144	thioredoxin	Homo sapiens	17-20
11705695-7	2001	Escherichia coli Trx or human or bacterial glutaredoxin (Grx) activities were in comparison only slightly or not at all inhibited by either CDDP, transplatin, or carboplatin.	cddp	140-144	glutaredoxin	Homo sapiens	43-55
11705695-7	2001	Escherichia coli Trx or human or bacterial glutaredoxin (Grx) activities were in comparison only slightly or not at all inhibited by either CDDP, transplatin, or carboplatin.	cddp	140-144	glutaredoxin	Homo sapiens	57-60
11705695-11	2001	The fact that GS-Pt inhibits the mammalian Trx as well as Grx systems shows that CDDP may exert effects at several stages of its metabolism, including after conjugation with GSH, which are intimately linked with the cellular disulfide/dithiol redox regulatory systems.	cddp	81-85	thioredoxin	Homo sapiens	43-46
11705695-11	2001	The fact that GS-Pt inhibits the mammalian Trx as well as Grx systems shows that CDDP may exert effects at several stages of its metabolism, including after conjugation with GSH, which are intimately linked with the cellular disulfide/dithiol redox regulatory systems.	cddp	81-85	glutaredoxin	Homo sapiens	58-61
11265400-1	2001	Since 1986, we have applied thermochemo (CDDP) therapy combined with radiotherapy to 18 patients with 25 advanced and/or recurrent head and neck cancers (thermochemoradiotherapy: TCR).	cddp	41-45	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	179-182
11445857-6	2001	UL-3A clones with low p53 levels were more sensitive to CDDP (LD50 <8.0 microg/ml).	cddp	56-60	tumor protein p53	Canis lupus familiaris	22-25
11090055-1	2000	Both toxic exposure to cadmium and cancer therapy with cisplatin (CDDP) can induce anemia in patients owing to the insufficient production of erythropoietin (EPO).	cddp	66-70	erythropoietin	Homo sapiens	142-156
11090055-1	2000	Both toxic exposure to cadmium and cancer therapy with cisplatin (CDDP) can induce anemia in patients owing to the insufficient production of erythropoietin (EPO).	cddp	66-70	erythropoietin	Homo sapiens	158-161
11090055-2	2000	Therefore, the effects of cadmium chloride (Cd) and CDDP in the Hep3B human hepatoma cell line, which up-regulates EPO expression in response to hypoxia and cobalt (Co), were investigated.	cddp	52-56	erythropoietin	Homo sapiens	115-118
11090055-3	2000	The induction of binding activity of the HIF-1 transcription factor and EPO mRNA expression and protein production were suppressed by Cd and CDDP in a dose-dependent manner with no apparent cell damage.	cddp	141-145	hypoxia inducible factor 1 subunit alpha	Homo sapiens	41-46
11090055-3	2000	The induction of binding activity of the HIF-1 transcription factor and EPO mRNA expression and protein production were suppressed by Cd and CDDP in a dose-dependent manner with no apparent cell damage.	cddp	141-145	erythropoietin	Homo sapiens	72-75
11090055-6	2000	These results indicate that Cd and CDDP have a strong and specific inhibitory effect on hypoxia- and Co-induced signaling and EPO induction in hepatic cells.	cddp	35-39	erythropoietin	Homo sapiens	126-129
11079315-5	2000	After three courses of chemotherapy with CDDP, Bleomycin and VP-16, the mass reduced in size and the serum AFP level decreased to the normal range.	cddp	41-45	alpha fetoprotein	Homo sapiens	107-110
11163861-7	2000	Next, we examined the expression of TRX and p53 in breast cancer cell line MCF-7 cells after CDDP treatment or irradiation.	cddp	93-97	thioredoxin	Homo sapiens	36-39
11163861-7	2000	Next, we examined the expression of TRX and p53 in breast cancer cell line MCF-7 cells after CDDP treatment or irradiation.	cddp	93-97	tumor protein p53	Homo sapiens	44-47
11163861-8	2000	CDDP treatment or irradiation augmented expression of TRX and p53 in MCF-7 cells by western blotting.	cddp	0-4	thioredoxin	Homo sapiens	54-57
11163861-8	2000	CDDP treatment or irradiation augmented expression of TRX and p53 in MCF-7 cells by western blotting.	cddp	0-4	tumor protein p53	Homo sapiens	62-65
11163861-9	2000	Immunofluorescence cell analysis by confocal microscopy showed that CDDP treatment induced translocation of TRX into nuclei.	cddp	68-72	thioredoxin	Homo sapiens	108-111
10938392-0	2000	CDDP induces p53-dependent apoptosis in tongue cancer cells.	cddp	0-4	tumor protein p53	Homo sapiens	13-16
10938392-3	2000	On the other hand, overexpression of p53 in HSC-4 was observed without CDDP treatment and no elevation of Bax could be detected.	cddp	71-75	tumor protein p53	Homo sapiens	37-40
10938392-6	2000	It is suggested that p53 status may have predictive potential with regard to response to CDDP therapy.	cddp	89-93	tumor protein p53	Homo sapiens	21-24
10897215-7	2000	Furthermore, significant statistical differences in chemosensitivity to 5-FU and CDDP were revealed depending on the presence of serum p53 antibodies.	cddp	81-85	tumor protein p53	Homo sapiens	135-138
10631318-5	2000	When we examined sensitivities of these cell lines to DNA-damaging agents including UV irradiation, X-ray irradiation and cis-diamine-dichloroplatinum (CDDP), we found that higher 53BP2 mRNA expression was correlated with the sensitivity to these agents.	cddp	152-156	tumor protein p53 binding protein 2	Homo sapiens	180-185
10790998-7	2000	for 7 days, the inhibitory effects of S-1 + CDDP of liver metastasis and tumor of the spleen were remarkable compared with the S-1 alone group.	cddp	44-48	eukaryotic translation elongation factor 1 alpha 2	Mus musculus	127-130
10790998-9	2000	This study suggests that low-dose CDDP might be a modulator of S-1 for colon 26 liver metastasis.	cddp	34-38	eukaryotic translation elongation factor 1 alpha 2	Mus musculus	63-66
10741696-6	2000	To determine whether the repair inhibition contributes to the cytotoxic synergism, we examined the effect of the constitutive expression of ERCC1 antisense RNA on the interaction of dFdC and CDDP.	cddp	191-195	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	140-145
10775506-7	2000	(ii) The Src kinase inhibitor PP1 sensitizes A431 cells to CDDP-induced apoptosis.	cddp	59-63	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	9-12
10775506-7	2000	(ii) The Src kinase inhibitor PP1 sensitizes A431 cells to CDDP-induced apoptosis.	cddp	59-63	neuropeptide Y receptor Y4	Homo sapiens	30-33
10775506-8	2000	(iii) CDDP induces caspase-3-dependent cleavage of the c-Src C-terminal portion and a concomitant reduction in Bcl-X(L) levels.	cddp	6-10	caspase 3	Homo sapiens	19-28
10775506-8	2000	(iii) CDDP induces caspase-3-dependent cleavage of the c-Src C-terminal portion and a concomitant reduction in Bcl-X(L) levels.	cddp	6-10	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	55-60
10775506-8	2000	(iii) CDDP induces caspase-3-dependent cleavage of the c-Src C-terminal portion and a concomitant reduction in Bcl-X(L) levels.	cddp	6-10	BCL2 like 1	Homo sapiens	111-119
10656450-1	2000	Cell cycle regulators and signal transduction pathways can influence apoptotic sensitivity of tumor cells, and we previously described an association between EGFr overexpression, reduced DNA repair activity, and increased apoptotic sensitivity of ME-180 cervical carcinoma cells toward cis-diammedichloroplatinum (cDDP; K. Nishikawa, et al., Cancer Res., 52: 4758-4765, 1992).	cddp	314-318	epidermal growth factor receptor	Homo sapiens	158-162
10656450-3	2000	As ME-180 cells progressed from high to low cDDP sensitivity [IC50 approximately 80 ng/ml in cDDP sensitive (PT-S) to approximately 2000 ng/ml in cDDP-resistant (Pt-R) cells], there was a significant decrease in EGFr expression that paralleled the relative reduction in cDDP apoptotic responsiveness (approximately 30-fold).	cddp	44-48	epidermal growth factor receptor	Homo sapiens	212-216
10656450-6	2000	cDDP stimulated a 2-fold increase in p53 levels in both drug-sensitive and drug-resistant cells but caused a delayed reduction in p21WAF1 levels, suggesting p53-independent regulation of p21WAF1 in ME-180 cells.	cddp	0-4	tumor protein p53	Homo sapiens	37-40
10656450-6	2000	cDDP stimulated a 2-fold increase in p53 levels in both drug-sensitive and drug-resistant cells but caused a delayed reduction in p21WAF1 levels, suggesting p53-independent regulation of p21WAF1 in ME-180 cells.	cddp	0-4	tumor protein p53	Homo sapiens	157-160
10656450-7	2000	Activation of EGFr in Pt-R cells stimulated cell cycle progression (2-fold), reduced p21WAF1 levels (>2-fold), and increased sensitivity to cDDP (3-fold), suggesting that receptor signaling enhanced the efficacy of cDDP to induce cell death by relieving cell cycle restriction.	cddp	143-147	epidermal growth factor receptor	Homo sapiens	14-18
10656450-7	2000	Activation of EGFr in Pt-R cells stimulated cell cycle progression (2-fold), reduced p21WAF1 levels (>2-fold), and increased sensitivity to cDDP (3-fold), suggesting that receptor signaling enhanced the efficacy of cDDP to induce cell death by relieving cell cycle restriction.	cddp	218-222	epidermal growth factor receptor	Homo sapiens	14-18
10493958-5	1999	The introduction of bcl-Xs gene into MKN45 gastric cancer cells increased the sensitivity to VP-16 and taxotere 2-3-fold in the IC50 values, whereas the introduction of bax gene increased the sensitivity to CDDP, VP-16 and taxotere 2-5-fold in the IC50 values, as compared to that of the Neo-transfected MKN45 cells.	cddp	207-211	BCL2 associated X, apoptosis regulator	Homo sapiens	169-172
10191716-3	1999	The estrogens diethylstilbestrol (DES) and the ligand of meso-1-PtCl2 (meso-1), responsible for the hormonal effect of meso-1-PtCl2, and the cytotoxic drug cisplatin (cDDP) were used as comparative substances.	cddp	167-171	transcription factor 15	Mus musculus	119-131
10391097-8	1999	Moreover, TdT-mediated dUTP-biotin nick-end labeling (TUNEL) assay showed that CDDP-induced apoptosis (31.1+/-3.8%) was significantly inhibited by pretreatment with NAC in KU1 cells (11.2+/-2.6%).	cddp	79-83	DNA nucleotidylexotransferase	Homo sapiens	10-13
11263191-7	1999	CDDP and 5-FU increased ICAM-1 expression significantly and the sensitivity of SKOV3 cell to LAK cell lysis was well related to the ICAM-1 expression.	cddp	0-4	intercellular adhesion molecule 1	Homo sapiens	24-30
11263191-7	1999	CDDP and 5-FU increased ICAM-1 expression significantly and the sensitivity of SKOV3 cell to LAK cell lysis was well related to the ICAM-1 expression.	cddp	0-4	intercellular adhesion molecule 1	Homo sapiens	132-138
10191716-3	1999	The estrogens diethylstilbestrol (DES) and the ligand of meso-1-PtCl2 (meso-1), responsible for the hormonal effect of meso-1-PtCl2, and the cytotoxic drug cisplatin (cDDP) were used as comparative substances.	cddp	167-171	transcription factor 15	Mus musculus	57-63
10191716-3	1999	The estrogens diethylstilbestrol (DES) and the ligand of meso-1-PtCl2 (meso-1), responsible for the hormonal effect of meso-1-PtCl2, and the cytotoxic drug cisplatin (cDDP) were used as comparative substances.	cddp	167-171	transcription factor 15	Mus musculus	57-69
10191716-5	1999	DES and cDDP showed a strong and comparable activity on the ER+ MXT-M-3.2 MC in vivo, meso-1 being somewhat less inhibitory.	cddp	8-12	transcription factor 15	Mus musculus	86-92
10076573-6	1999	The intracellular platinum content of PC-14/HMG2 after exposure to 300 microM CDDP was 1.1 and 1.5 times that of PC-14 and PC-14/CMV, respectively.	cddp	78-82	high mobility group box 2	Homo sapiens	44-48
10076573-9	1999	These results suggest that HMG2 may enhance the CDDP sensitivity of cells by inhibiting repair of the DNA lesion induced by CDDP.	cddp	48-52	high mobility group box 2	Homo sapiens	27-31
10076573-1	1999	To elucidate the role of high mobility group 2 protein (HMG2) in cis-diamminedichloroplatinum (II) (cisplatin, CDDP) sensitivity, we constructed a human HMG2-transfected human non-small cell lung cancer cell line, PC-14/HMG2.	cddp	111-115	high mobility group box 2	Homo sapiens	25-54
10076573-9	1999	These results suggest that HMG2 may enhance the CDDP sensitivity of cells by inhibiting repair of the DNA lesion induced by CDDP.	cddp	124-128	high mobility group box 2	Homo sapiens	27-31
10076573-1	1999	To elucidate the role of high mobility group 2 protein (HMG2) in cis-diamminedichloroplatinum (II) (cisplatin, CDDP) sensitivity, we constructed a human HMG2-transfected human non-small cell lung cancer cell line, PC-14/HMG2.	cddp	111-115	high mobility group box 2	Homo sapiens	56-60
10076573-1	1999	To elucidate the role of high mobility group 2 protein (HMG2) in cis-diamminedichloroplatinum (II) (cisplatin, CDDP) sensitivity, we constructed a human HMG2-transfected human non-small cell lung cancer cell line, PC-14/HMG2.	cddp	111-115	high mobility group box 2	Homo sapiens	153-157
11819336-1	1998	AIM:To compare the expression level of Fas gene and Bcl-2 gene in gastric cancer cells SGC7901 and gastric cancer MDR (multidrug resistant) cells SGC7901/VCR,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/VCR cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/VCR cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/VCR and SGC7901 cells and transfectants, and drug sensitivity of transfectants for VCR, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%.	cddp	707-711	BCL2 apoptosis regulator	Homo sapiens	52-57
10076573-1	1999	To elucidate the role of high mobility group 2 protein (HMG2) in cis-diamminedichloroplatinum (II) (cisplatin, CDDP) sensitivity, we constructed a human HMG2-transfected human non-small cell lung cancer cell line, PC-14/HMG2.	cddp	111-115	high mobility group box 2	Homo sapiens	153-157
10076573-3	1999	Gel mobility shift assay revealed a CDDP-treated DNA-protein complex in the nuclear extract of PC-14/HMG2, which was not found in the extracts of PC-14 and PC-14/CMV.	cddp	36-40	high mobility group box 2	Homo sapiens	101-105
10076573-4	1999	This complex formation was subject to competition by CDDP-treated non-specific salmon sperm DNA, indicating that ectopic HMG2 recognizes CDDP-damaged DNA.	cddp	53-57	high mobility group box 2	Homo sapiens	121-125
10076573-4	1999	This complex formation was subject to competition by CDDP-treated non-specific salmon sperm DNA, indicating that ectopic HMG2 recognizes CDDP-damaged DNA.	cddp	137-141	high mobility group box 2	Homo sapiens	121-125
10076573-5	1999	PC-14/HMG2 showed more than 3-fold higher sensitivity to CDDP than PC-14 and PC-14/CMV.	cddp	57-61	high mobility group box 2	Homo sapiens	6-10
9879659-9	1998	In Ca2+ medium ATPase activity was inhibited by CDDP and stimulated by FCCP, however these effects were two to three fold less than those observed in Mg2+ medium.	cddp	48-52	dynein, axonemal, heavy chain 8	Mus musculus	15-21
9879659-10	1998	FCCP failed to stimulate ATPase activity in CDDP- supplemented medium, thus suggesting that the same ATPase activity fraction was sensitive to both CDDP and FCCP.	cddp	148-152	dynein, axonemal, heavy chain 8	Mus musculus	101-107
9673402-1	1998	A cisplatin (CDDP)-resistant human osteosarcoma cell line (OST/R) was established by continuous exposure to CDDP.	cddp	13-17	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	59-62
9652857-7	1998	CONCLUSION: Suppression of heat-induced hsp72 accumulation by CDDP contributes to an interactive hyperthermic enhancement of CDDP cytotoxicity in the cells bearing the wild-type p53 gene.	cddp	125-129	tumor protein p53	Homo sapiens	178-181
9639393-10	1998	This study demonstrated that G1 arrest induced with p16-gene expression prevents ACNU- or CDDP-induced cell death.	cddp	90-94	cyclin dependent kinase inhibitor 2A	Homo sapiens	52-55
9652857-0	1998	Suppression of heat-induced HSF activation by CDDP in human glioblastoma cells.	cddp	46-50	interleukin 6	Homo sapiens	28-31
9652857-1	1998	PURPOSE: The kinetics of the accumulation of inducible 72-kD heat shock protein (hsp72) and the activation of heat shock transcriptional factor (HSF) after hyperthermia and/or CDDP treatment in two human glioblastoma cell lines, A-172 having the wild-type p53 gene and T98G having the mutated p53 gene were evaluated.	cddp	176-180	tumor protein p53	Homo sapiens	256-259
9652857-1	1998	PURPOSE: The kinetics of the accumulation of inducible 72-kD heat shock protein (hsp72) and the activation of heat shock transcriptional factor (HSF) after hyperthermia and/or CDDP treatment in two human glioblastoma cell lines, A-172 having the wild-type p53 gene and T98G having the mutated p53 gene were evaluated.	cddp	176-180	tumor protein p53	Homo sapiens	293-296
9652857-3	1998	RESULTS: The prominent suppression of heat-induced hsp72 accumulation by CDDP was seen in A-172 cells, but not in T98G cells.	cddp	73-77	heat shock protein family A (Hsp70) member 1A	Homo sapiens	51-56
9652857-4	1998	This was due to the p53-dependent inhibition of heat-induced HSF activation by CDDP.	cddp	79-83	tumor protein p53	Homo sapiens	20-23
9652857-4	1998	This was due to the p53-dependent inhibition of heat-induced HSF activation by CDDP.	cddp	79-83	interleukin 6	Homo sapiens	61-64
9652857-7	1998	CONCLUSION: Suppression of heat-induced hsp72 accumulation by CDDP contributes to an interactive hyperthermic enhancement of CDDP cytotoxicity in the cells bearing the wild-type p53 gene.	cddp	62-66	heat shock protein family A (Hsp70) member 1A	Homo sapiens	40-45
9652857-7	1998	CONCLUSION: Suppression of heat-induced hsp72 accumulation by CDDP contributes to an interactive hyperthermic enhancement of CDDP cytotoxicity in the cells bearing the wild-type p53 gene.	cddp	62-66	tumor protein p53	Homo sapiens	178-181
9652857-7	1998	CONCLUSION: Suppression of heat-induced hsp72 accumulation by CDDP contributes to an interactive hyperthermic enhancement of CDDP cytotoxicity in the cells bearing the wild-type p53 gene.	cddp	125-129	heat shock protein family A (Hsp70) member 1A	Homo sapiens	40-45
9673402-1	1998	A cisplatin (CDDP)-resistant human osteosarcoma cell line (OST/R) was established by continuous exposure to CDDP.	cddp	108-112	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	59-62
9673402-2	1998	OST/R cells proved to be 6.73 times more resistant to CDDP compared with parental OST cells, and showed cross-resistance to carboplatin (CBDCA).	cddp	54-58	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	0-3
9673402-3	1998	The mechanism of CDDP resistance was a significant decrease of intracellular platinum accumulation which was 40% of that in OST cells.	cddp	17-21	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	124-127
9673402-4	1998	OST/R cells were exposed to CDDP for 6 hours, the platinum was released from the cytoplasm of OST/R cells without reaching a state of equilibrium.	cddp	28-32	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	0-3
9673402-4	1998	OST/R cells were exposed to CDDP for 6 hours, the platinum was released from the cytoplasm of OST/R cells without reaching a state of equilibrium.	cddp	28-32	dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	Homo sapiens	94-97
8751562-12	1996	The addition of the antioxidant butylated hydroxyanisole (BHA) inhibited CDDP-mediated cytotoxicity in both AD10 and C30 but not in A2780 ovarian tumor cells.	cddp	73-77	AD10	Homo sapiens	108-112
9435172-5	1998	Treatment with diethyldithiocarbamic acid (a drug protecting against cDDP nephrotoxicity), immediately after cDDP exposure, 1) partially lifted the cDDP-induced inhibition of the Na+/glucose cotransporter, 2) reduced platinum binding to BBM vesicles, but 3) did not modify the cDDP-induced decrease in protein-bound thiols.	cddp	69-73	sodium/nucleoside cotransporter	Oryctolagus cuniculus	179-207
9619714-5	1998	The aim of the present study was to evaluate the efficacy and tolerability of a chemo-immunotherapeutic regimen including high-dose CDDP combined with glutathione (GSH) to limit platinum-related toxicity, and natura interferon-alpha (IFN-alpha) in patients with DTIC-resistant metastatic melanoma.	cddp	132-136	interferon alpha 1	Homo sapiens	234-243
9316641-15	1997	Altogether, these findings show that drug-resistant, Fas(+)-expressing PC-3 and DU145 prostate tumor cells can be sensitized by CDDP and VP-16 to killing by Fas-L-bearing CTL, TIL, and LAK cells.	cddp	128-132	Fas ligand	Homo sapiens	157-162
9316641-15	1997	Altogether, these findings show that drug-resistant, Fas(+)-expressing PC-3 and DU145 prostate tumor cells can be sensitized by CDDP and VP-16 to killing by Fas-L-bearing CTL, TIL, and LAK cells.	cddp	128-132	toll like receptor 1	Homo sapiens	176-179
9316641-15	1997	Altogether, these findings show that drug-resistant, Fas(+)-expressing PC-3 and DU145 prostate tumor cells can be sensitized by CDDP and VP-16 to killing by Fas-L-bearing CTL, TIL, and LAK cells.	cddp	128-132	alpha kinase 1	Homo sapiens	185-188
9020952-3	1997	After arterial infusion chemotherapy consisting of CDDP, epirubicin and 5-FU, the tumor size and serum level of CEA were significantly decreased.	cddp	51-55	CEA cell adhesion molecule 3	Homo sapiens	112-115
8917706-3	1996	Compared to the parental ES cell lines or ES cells transfected with the vector lacking any HSP27 sequence, all ES cell lines overexpressing HSP27 were resistant to killing by cadmium chloride (CdCl2), mercuric chloride (HgCl2), cis-platinum(II)-diammine dichloride (cDDP), sodium arsenite (NaAsO2), and heat while ES cell lines expressing reduced HSP27 were more sensitive to metal toxicity and heat.	cddp	266-270	heat shock protein 1	Mus musculus	140-145
8917706-3	1996	Compared to the parental ES cell lines or ES cells transfected with the vector lacking any HSP27 sequence, all ES cell lines overexpressing HSP27 were resistant to killing by cadmium chloride (CdCl2), mercuric chloride (HgCl2), cis-platinum(II)-diammine dichloride (cDDP), sodium arsenite (NaAsO2), and heat while ES cell lines expressing reduced HSP27 were more sensitive to metal toxicity and heat.	cddp	266-270	heat shock protein 1	Mus musculus	140-145
9492838-3	1998	After the operation, 5-FU alone and low doses of CDDP and 5-FU were administered, but the level of serum CEA elevated and CT scanning showed multiple liver metastases.	cddp	49-53	CEA cell adhesion molecule 3	Homo sapiens	105-108
9279352-8	1997	5-FU, CDDP and Leucovorin were administered, but the CEA level became more and more elevated.	cddp	6-10	CEA cell adhesion molecule 3	Homo sapiens	53-56
8932334-2	1996	IC50 values to CDDP using MTT assay were decreased 2.1- and 4.6-fold respectively by treatment with 250 or 500 microM S-1452, for a 2 h simultaneous drug exposure, and those of PC-9/CDDP, a CDDP-resistant cell line, were decreased 3.1- and 6.1-fold.	cddp	15-19	proprotein convertase subtilisin/kexin type 9	Homo sapiens	177-181
8751562-15	1996	Since cytotoxic T lymphocytes (CTL) express Fas ligand and kill Fas+ target cells, a significant potentiation of tumor cell killing will be achieved following sensitization of tumor cells to Fas signaling by subtoxic concentrations of CDDP.	cddp	235-239	Fas ligand	Homo sapiens	44-54
8621231-1	1996	In vitro continuous stepwise exposure of HST-1 human squamous carcinoma cell line to cisplatin (CDDP) for 12 months resulted in a 3.5-fold stably resistant subline designated HST-1/CP0.2.	cddp	96-100	fibroblast growth factor 4	Homo sapiens	41-46
8621231-1	1996	In vitro continuous stepwise exposure of HST-1 human squamous carcinoma cell line to cisplatin (CDDP) for 12 months resulted in a 3.5-fold stably resistant subline designated HST-1/CP0.2.	cddp	96-100	fibroblast growth factor 4	Homo sapiens	175-180
8621231-5	1996	Pretreatment of HST-1/CP0.2 cells with 5-FU, with drug-free intervals of 24 to 48 hr before exposure to CDDP, completely reversed CDDP resistance, or even increased the sensitivity to a level greater than that of parental cells, whereas the opposite sequence had no effect on resistance.	cddp	104-108	fibroblast growth factor 4	Homo sapiens	16-21
8621231-5	1996	Pretreatment of HST-1/CP0.2 cells with 5-FU, with drug-free intervals of 24 to 48 hr before exposure to CDDP, completely reversed CDDP resistance, or even increased the sensitivity to a level greater than that of parental cells, whereas the opposite sequence had no effect on resistance.	cddp	130-134	fibroblast growth factor 4	Homo sapiens	16-21
7611790-0	1995	[Effect of low dose CDDP/5-fluorouracil therapy on PCNA labeling index and TS inhibition rate of gastric cancer].	cddp	20-24	proliferating cell nuclear antigen	Homo sapiens	51-55
7591242-1	1995	This study was undertaken to elucidate the mechanism(s) of potentiation of cisplatin (CDDP) cytotoxicity by interferon alpha-2a (IFN alpha-2a) in human squamous carcinoma cell lines SCC-25 and SCC-4.	cddp	86-90	interferon alpha 2	Homo sapiens	108-127
7591242-1	1995	This study was undertaken to elucidate the mechanism(s) of potentiation of cisplatin (CDDP) cytotoxicity by interferon alpha-2a (IFN alpha-2a) in human squamous carcinoma cell lines SCC-25 and SCC-4.	cddp	86-90	MAU2 sister chromatid cohesion factor	Homo sapiens	193-198
7591242-2	1995	IFN alpha-2a treatment significantly increased the cytotoxicity of CDDP in both cell lines in a dose-dependent manner.	cddp	67-71	interferon alpha 2	Homo sapiens	0-11
7591242-4	1995	Sensitivity of SCC-4 cells to CDDP was increased by about 3- and 7-fold, respectively, by 400 and 800 IU/ml IFN alpha-2a treatment.	cddp	30-34	MAU2 sister chromatid cohesion factor	Homo sapiens	15-20
7591242-8	1995	Our results suggest that IFN alpha-2a-mediated sensitization of SCC-25 and SCC-4 cell lines to CDDP in vitro may be due to an increase in intracellular platinum accumulation.	cddp	95-99	MAU2 sister chromatid cohesion factor	Homo sapiens	75-80
7474609-6	1995	RESULTS: We observed that tumors derived from NMB-1 and NMT-1 were very sensitive to CDDP, but ACHN derived tumors were resistant to CDDP.	cddp	85-89	N-myristoyltransferase 1	Mus musculus	56-61
7474609-8	1995	Furthermore, 24 h after CDDP administration, the levels of MT and GSH in NMB-1 and NMT-1 derived tumors were lower them or equal to those of control mice.	cddp	24-28	N-myristoyltransferase 1	Mus musculus	83-88
7794002-5	1995	With re-elevated serum CEA level, subsequent intrahepatic arterial infusion of CDDP and 5-FU the nodule size reduced with normalization of the serum CEA level.	cddp	79-83	CEA cell adhesion molecule 3	Homo sapiens	23-26
7611790-1	1995	The response of gastric cancer to intravenous application of low-dose CDDP plus 5-fluorouracil (FP) was assessed by changes in DNA indices (DIs) and PCNA labeling indices (LIs) by flow cytometry, and by the thymidylate synthetase inhibition rate (TSIR).	cddp	70-74	proliferating cell nuclear antigen	Homo sapiens	149-153
7794002-5	1995	With re-elevated serum CEA level, subsequent intrahepatic arterial infusion of CDDP and 5-FU the nodule size reduced with normalization of the serum CEA level.	cddp	79-83	CEA cell adhesion molecule 3	Homo sapiens	149-152
7850928-2	1995	SKI 2053R was highly active in vitro against both L1210 murine leukemia and its CDDP-resistant subline, L1210/DDP; the relative resistances were 20.0-, 14.5-, and 2.7-fold for CDDP, CBDCA, and SKI 2053R, respectively.	cddp	80-84	ski sarcoma viral oncogene homolog (avian)	Mus musculus	0-3
7763011-5	1995	The CDDPresistant sublines, PC-9/CDDP and PC-14/CDDP, were 18.3- and 7.7-fold more resistant to CDDP compared to the respective parent cell lines.	cddp	4-8	proprotein convertase subtilisin/kexin type 9	Homo sapiens	28-32
7763011-6	1995	The CDDP analogues were all cross-resistant to CDDP and the order of relative resistance values was CBDCA > 254-S > 1-OHP > OP for PC9/CDDP and 254-S > CBDCA > 1-OHP > OP for PC-14/CDDP.	cddp	4-8	proprotein convertase subtilisin/kexin type 9	Homo sapiens	140-143
7763011-7	1995	Although OP showed cross-resistance to CDDP, OP was the most active against the CDDP-resistant sublines with relative resistance values of 3.8 and 1.6 for PC-9/CDDP and PC-14/CDDP, respectively.	cddp	80-84	proprotein convertase subtilisin/kexin type 9	Homo sapiens	155-159
7763011-7	1995	Although OP showed cross-resistance to CDDP, OP was the most active against the CDDP-resistant sublines with relative resistance values of 3.8 and 1.6 for PC-9/CDDP and PC-14/CDDP, respectively.	cddp	80-84	proprotein convertase subtilisin/kexin type 9	Homo sapiens	155-159
7763011-7	1995	Although OP showed cross-resistance to CDDP, OP was the most active against the CDDP-resistant sublines with relative resistance values of 3.8 and 1.6 for PC-9/CDDP and PC-14/CDDP, respectively.	cddp	80-84	proprotein convertase subtilisin/kexin type 9	Homo sapiens	155-159
7850928-2	1995	SKI 2053R was highly active in vitro against both L1210 murine leukemia and its CDDP-resistant subline, L1210/DDP; the relative resistances were 20.0-, 14.5-, and 2.7-fold for CDDP, CBDCA, and SKI 2053R, respectively.	cddp	176-180	ski sarcoma viral oncogene homolog (avian)	Mus musculus	0-3
7525792-2	1994	After three courses of chemotherapy with CDDP and VP-16, the mediastinal mass reduced in size significantly but the serum AFP level did not reach within normal range.	cddp	41-45	alpha fetoprotein	Homo sapiens	122-125
7850928-8	1995	In SKI 2053R-treated groups, the time required for a mean tumor weight of 1,000 mg was 33.1 days in KATO III xenografts and 35.0 days in WiDr xenografts as compared with 30.2 and 27.2 days in CDDP-treated groups, respectively.	cddp	192-196	ski sarcoma viral oncogene homolog (avian)	Mus musculus	3-6
7923169-1	1994	We have previously demonstrated that the cytokine interleukin 1 alpha (IL-1 alpha) significantly potentiates the antitumor activity of a variety of chemotherapeutic agents, including cisplatin (cDDP).	cddp	194-198	interleukin 1 alpha	Mus musculus	50-69
7923169-1	1994	We have previously demonstrated that the cytokine interleukin 1 alpha (IL-1 alpha) significantly potentiates the antitumor activity of a variety of chemotherapeutic agents, including cisplatin (cDDP).	cddp	194-198	interleukin 1 alpha	Mus musculus	71-81
7923169-6	1994	Although pretreatment with IL-1 receptor antagonist blocked the acute tumor hemorrhagic response induced by IL-1 alpha alone, IL-1 receptor antagonist only partially blocked IL-1 alpha enhancement of CBDCA or cDDP-mediated tumor cell kill.	cddp	209-213	interleukin 1 alpha	Mus musculus	174-184
7923169-8	1994	In contrast, administration of IL-1 alpha from 24 h before or as late as 6 h after cDDP resulted in the same antitumor activity as simultaneous administration of cDDP and IL-1 alpha.	cddp	83-87	interleukin 1 alpha	Mus musculus	31-41
8033065-1	1994	We tested the ability of the collagenase-inhibitor minocycline to increase the effectiveness of CDDP, BCNU and mitomycin C +/- hyperthermia.	cddp	96-100	TIMP metallopeptidase inhibitor 1	Homo sapiens	29-50
8002635-0	1994	[Combined CDDP-THP-PEP chemotherapy (PTP therapy) for head and neck squamous cell carcinoma--a group study].	cddp	10-14	progestagen associated endometrial protein	Homo sapiens	19-22
7742604-7	1994	Analyzed in 60 patients treated by first-line chemotherapy CDDP-5FU, the longest survival was achieved for patients who had a complete response to chemotherapy and the lowest EGFR levels (P = 0.018).	cddp	59-63	epidermal growth factor receptor	Homo sapiens	175-179
8065070-14	1994	An intensive anti-cancer chemotherapy with VP-16 and CDDP was done with minor response (MR) and the serum tumor marker, LDH and NSE, decreased markedly.	cddp	53-57	enolase 2	Homo sapiens	128-131
8229131-13	1993	CONCLUSION: These results seem to indicate a possible synergy between CDDP/rIL-2 and IFN alpha in MM.	cddp	70-74	interleukin 2	Rattus norvegicus	75-80
8711347-9	1994	In animals given CDDP only, a significant increase of urine levels of all studied enzymes was proved, the maximum change was observed in NAG excretion.	cddp	17-21	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	137-140
8239690-1	1993	A 75-year-old female with skin metastasis from advanced gastric cancer (portion A, tub2, ss beta, n2, P0H0, Borrmann 3-type) was successfully treated with CDDP at a dosage of 25 mg/body every week or two.	cddp	155-159	small RNA binding exonuclease protection factor La	Homo sapiens	89-96
8342256-3	1993	Compared with cells exposed only to chemotherapy, significant inhibitory effects occurred as a result of continuous exposure to IL-3 or GM-CSF at the highest activities with CDDP and MTX in the T24 and EJ28 lines; continuous G-CSF administration (100 ng/ml) in combination with MTX led to significant growth inhibition in the EJ28 line.	cddp	174-178	interleukin 3	Homo sapiens	128-132
8391290-4	1993	Serum alpha-fetoprotein (AFP) levels decreased by more than 50% in 10 (59%) of 17 ADMOS-alone patients and in 23 (70%) of 33 ADMOS/CDDP patients whose pretreatment AFP levels were above 0.2 mg/l.	cddp	131-135	alpha fetoprotein	Homo sapiens	6-23
8391290-4	1993	Serum alpha-fetoprotein (AFP) levels decreased by more than 50% in 10 (59%) of 17 ADMOS-alone patients and in 23 (70%) of 33 ADMOS/CDDP patients whose pretreatment AFP levels were above 0.2 mg/l.	cddp	131-135	alpha fetoprotein	Homo sapiens	25-28
8390227-3	1993	Serum alpha-fetoprotein (AFP) levels decreased by more than 50% in 7/17 (59%) in the ADMOS alone group and in 23/32 (70%) in the ADMOS plus CDDP group.	cddp	140-144	alpha fetoprotein	Homo sapiens	6-23
8390227-3	1993	Serum alpha-fetoprotein (AFP) levels decreased by more than 50% in 7/17 (59%) in the ADMOS alone group and in 23/32 (70%) in the ADMOS plus CDDP group.	cddp	140-144	alpha fetoprotein	Homo sapiens	25-28
8352556-4	1993	AMB also increased the intracellular CDDP accumulation in CDDP resistant cells (NOS2CR), derived from NOS2.	cddp	37-41	nitric oxide synthase 2	Homo sapiens	80-84
8352556-4	1993	AMB also increased the intracellular CDDP accumulation in CDDP resistant cells (NOS2CR), derived from NOS2.	cddp	58-62	nitric oxide synthase 2	Homo sapiens	80-84
8342256-3	1993	Compared with cells exposed only to chemotherapy, significant inhibitory effects occurred as a result of continuous exposure to IL-3 or GM-CSF at the highest activities with CDDP and MTX in the T24 and EJ28 lines; continuous G-CSF administration (100 ng/ml) in combination with MTX led to significant growth inhibition in the EJ28 line.	cddp	174-178	colony stimulating factor 2	Homo sapiens	136-142
8434965-3	1993	(CAP 1) CDDP 7mg/sqm/8 hrs/saline 500 ml/d1-d10, ADM 35 mg/sqm/d1, CPM 350 mg/sqm/d1: 8 cases; (CAP 2) CDDP 70 mg/sqm/2 hrs/d1, ADM 35 mg/sqm/d1, CPM 350 mg/sqm/d1: 14 cases.	cddp	8-12	cyclase associated actin cytoskeleton regulatory protein 1	Homo sapiens	1-6
8476431-6	1993	Treatment with CDDP resulted in the same degree of DNA fragmentation in SBC-3 and SBC-3/Bcl2.	cddp	15-19	BCL2 apoptosis regulator	Homo sapiens	88-92
8509669-6	1993	The antitumor effect of CDDP was (but not significantly) enhanced by oral administration of PSK and the prolongation of the life span of the tumor-bearing nude mice was obtained.	cddp	24-28	TAO kinase 2	Mus musculus	92-95
8509669-11	1993	The serum immunosuppressive acid protein (IAP) value in nude mice treated with PSK alone was significantly higher than that in nude mice treated with a combination of PSK (100 mg/kg) and CDDP.	cddp	187-191	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	10-40
8509669-11	1993	The serum immunosuppressive acid protein (IAP) value in nude mice treated with PSK alone was significantly higher than that in nude mice treated with a combination of PSK (100 mg/kg) and CDDP.	cddp	187-191	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	42-45
8509669-12	1993	These results suggest that CDDP prevents the increase in serum IAP that occurs when PSK is used and that consequently combinations of PSK and CDDP result in augmentation of antitumor effects.	cddp	27-31	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	63-66
8509669-12	1993	These results suggest that CDDP prevents the increase in serum IAP that occurs when PSK is used and that consequently combinations of PSK and CDDP result in augmentation of antitumor effects.	cddp	27-31	TAO kinase 2	Mus musculus	84-87
8509669-12	1993	These results suggest that CDDP prevents the increase in serum IAP that occurs when PSK is used and that consequently combinations of PSK and CDDP result in augmentation of antitumor effects.	cddp	27-31	TAO kinase 2	Mus musculus	134-137
1427597-10	1992	Moreover, a retinoic acid-mediated K14 reduction was concomitant with a 4.0-fold transient increase in CDDP resistance in PC10.	cddp	103-107	keratin 14	Homo sapiens	35-38
8382036-6	1993	Moreover, the side effect of combination of the 1/2 MTD was less than group given MTD of CDDP in terms of body weight loss.	cddp	89-93	metallothionein 1E	Homo sapiens	82-85
8427780-4	1993	In contrast, in one of three lines with derived resistance to the platinum (IV) agent, CHIP, (PXN/951) a retention in sensitivity was observed with CDDP and CBDCA.	cddp	148-152	paxillin	Homo sapiens	94-97
8427780-6	1993	Where resistance was generated to tetraplatin (PXN/100T) there was some retention of activity by CDDP.	cddp	97-101	paxillin	Homo sapiens	47-50
1445361-8	1992	The calculated Kd of binding to CDDP-damaged DNA was 3.27 x 10(-10) for HMG1 and 1.87 x 10(-10) for HMG2.	cddp	32-36	high mobility group box 1 pseudogene 5	Homo sapiens	72-82
1445361-8	1992	The calculated Kd of binding to CDDP-damaged DNA was 3.27 x 10(-10) for HMG1 and 1.87 x 10(-10) for HMG2.	cddp	32-36	high mobility group box 2	Homo sapiens	100-104
1445361-10	1992	We also observed that HMG2 will bind to DNA modified with carboplatin and iproplatin although to a lesser extent than to DNA damaged with CDDP.	cddp	138-142	high mobility group box 2	Homo sapiens	22-26
1445361-12	1992	In addition, our findings suggest that thiol groups play an essential role in the binding of HMG1 and HMG2 to CDDP-DNA.	cddp	110-114	high mobility group box 1 pseudogene 5	Homo sapiens	93-97
1445361-12	1992	In addition, our findings suggest that thiol groups play an essential role in the binding of HMG1 and HMG2 to CDDP-DNA.	cddp	110-114	high mobility group box 2	Homo sapiens	102-106
1380890-2	1992	Culturing ME-180 cervical carcinoma cells in the presence of escalating concentrations of TNF resulted in the development of an ME-180 cell variant (ME-180R) resistant to TNF but expressing a 3-5-fold increased sensitivity to cisplatin (CDDP) when measured following continuous exposure (low doses) or short-term incubation with CDDP (high doses) and clonogenic analysis.	cddp	237-241	tumor necrosis factor	Homo sapiens	90-93
1380890-2	1992	Culturing ME-180 cervical carcinoma cells in the presence of escalating concentrations of TNF resulted in the development of an ME-180 cell variant (ME-180R) resistant to TNF but expressing a 3-5-fold increased sensitivity to cisplatin (CDDP) when measured following continuous exposure (low doses) or short-term incubation with CDDP (high doses) and clonogenic analysis.	cddp	329-333	tumor necrosis factor	Homo sapiens	90-93
1380890-6	1992	Alkaline elution studies of cross-linked DNA in CDDP-treated ME-180 cells suggested that accumulation of DNA adducts reached maximal levels 10-15 h after CDDP treatment and was similar in both TNF-resistant and parental cells.	cddp	48-52	tumor necrosis factor	Homo sapiens	193-196
1380890-11	1992	Taken together, these results suggest that TNF resistance in ME-180 cervical carcinoma cells correlates with both increased EGF receptor expression and enhanced CDDP cytotoxicity.	cddp	161-165	tumor necrosis factor	Homo sapiens	43-46
1427597-11	1992	Taken together, the reduced intracellular platinum accumulation and the marked decrease of K14 imply that they are important factors in contributing to CDDP resistance in PC10-B3.	cddp	152-156	keratin 14	Homo sapiens	91-94
1304835-4	1992	DPD activity was measured in 57 head and neck cancer patients receiving CDDP (100 mg/m2, day 1) plus 5-FU (1 g/m2/day x 5, day 2-day 6).	cddp	72-76	dihydropyrimidine dehydrogenase	Homo sapiens	0-3
1619320-2	1992	One hundred-fifty mg of CDDP/body was intraperitoneally administered while the usual systolic blood pressure was increased to 130-140% by AT-II.	cddp	24-28	angiotensinogen	Homo sapiens	138-143
1619320-5	1992	This suggests that, during renal vasoconstriction induced by AT-II, the renal blood flow as well as renal uptake of CDDP was decreased.	cddp	116-120	angiotensinogen	Homo sapiens	61-66
1619320-9	1992	The extreme vasoconstriction in the kidneys and other organs induced by AT-II might have protected these organs from the toxicities of CDDP despite the fact that STS infusion was delayed by 15 minutes after CDDP infusion.	cddp	135-139	angiotensinogen	Homo sapiens	72-77
1619320-10	1992	STS infused immediately after the cessation of AT-II could neutralize the CDDP preventing the occurrence of toxicities.	cddp	74-78	angiotensinogen	Homo sapiens	47-52
1858032-2	1991	Therefore, we hypothesized that cis-dichlorodiammine platinum (CDDP), mitomycin-C, and doxorubicin hydrochloride (Adriamycin), by the release of ROS, would increase macrophage TNF production.	cddp	63-67	tumor necrosis factor	Mus musculus	176-179
1541862-7	1992	3) The antitumor effect of CDDP was enhanced by the presence of EGF at both a concentration of 0.01 nM (except for A-431) and a concentration of 1.0 nM, in all cell lines.	cddp	27-31	epidermal growth factor	Homo sapiens	64-67
1541862-10	1992	The effect of CDDP on EGF receptors was not recognized in SKG-3a and HEC-1.	cddp	14-18	epidermal growth factor	Homo sapiens	22-25
1858032-4	1991	Both CDDP and mitomycin-C increased TNF production compared to nondrug-exposed cells.	cddp	5-9	tumor necrosis factor	Mus musculus	36-39
1858032-5	1991	Peak TNF values occurred at 10 micrograms/ml CDDP and 62.5 micrograms/ml mitomycin-C with 377 +/- 38 and 427 +/- 54 units/ml TNF produced, respectively.	cddp	45-49	tumor necrosis factor	Mus musculus	5-8
1858032-7	1991	Only CDDP-increased production of TNF from non-endotoxin-primed macrophages (0 microgram/ml CDDP - 0 +/- 0 unit/ml TNF; 50 micrograms/ml CDDP - 13 +/- 5 units/ml TNF; p2 less than 0.038).	cddp	5-9	tumor necrosis factor	Mus musculus	34-37
1858032-9	1991	By Northern blot analysis, CDDP induced transcription of the TNF gene in non-endotoxin-primed macrophages as early as 3 hours after exposure to 50 micrograms/ml CDDP, and this preceded the increase in TNF protein in kinetic studies.	cddp	27-31	tumor necrosis factor	Mus musculus	61-64
1858032-9	1991	By Northern blot analysis, CDDP induced transcription of the TNF gene in non-endotoxin-primed macrophages as early as 3 hours after exposure to 50 micrograms/ml CDDP, and this preceded the increase in TNF protein in kinetic studies.	cddp	27-31	tumor necrosis factor	Mus musculus	201-204
1858032-9	1991	By Northern blot analysis, CDDP induced transcription of the TNF gene in non-endotoxin-primed macrophages as early as 3 hours after exposure to 50 micrograms/ml CDDP, and this preceded the increase in TNF protein in kinetic studies.	cddp	161-165	tumor necrosis factor	Mus musculus	61-64
1934247-5	1991	The effect of CDDP on renal microsomal glucose-6-phosphatase activity was investigated in vivo and in vitro.	cddp	14-18	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	39-60
1934247-10	1991	In vivo, only CDDP hydrolysis products exhibited a significant inhibitory effect on renal glucose-6-phosphatase activity.	cddp	14-18	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	90-111
1934247-11	1991	In vitro, rat renal and hepatic microsomal glucose-6-phosphatase activity was decreased by CDDP both time- and concentration-dependently.	cddp	91-95	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	43-64
30428555-7	2018	We also found a significant decrease of caspase-3 and p53 expression after 48 h, accompanied by a down-regulation of NF-kappaB in cells exposed to MWCNT-COOH-CDDP system which promotes apoptosis escape and thus failing to overcome the triple negative breast cancer (TNBC) cells resistance.	cddp	158-162	caspase 3	Homo sapiens	40-49
2131048-6	1990	The same results were obtained combining TNF and CDDP, except in U20S/Pt cells in which TNF synergistically increased CDDP cytotoxicity.	cddp	118-122	tumor necrosis factor	Homo sapiens	88-91
2131048-7	1990	The combination of TNF and IFN-gamma enhanced cytotoxicity about 20-fold for DX and 6-fold for CDDP, evaluated in terms of the modification index, against LoVo/DX and U20S/Pt cells respectively.	cddp	95-99	tumor necrosis factor	Homo sapiens	19-22
2131048-7	1990	The combination of TNF and IFN-gamma enhanced cytotoxicity about 20-fold for DX and 6-fold for CDDP, evaluated in terms of the modification index, against LoVo/DX and U20S/Pt cells respectively.	cddp	95-99	interferon gamma	Homo sapiens	27-36
1690825-6	1990	As the mechanism responsible this improvement, it is felt that the CDDP attacked the metastatic tumors directly, and that this was aided by the follow-up immunotherapy with PSK.	cddp	67-71	TAO kinase 2	Homo sapiens	173-176
2169720-8	1990	CBDCA-induced MDA production was lower, compared to CDDP, which showed marked toxic effects on TEA and PAH accumulation, gluconeogenesis and glucose-6-phosphatase activity.	cddp	52-56	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	141-162
2389950-3	1990	The extreme vasoconstriction in the kidney and other organs during AT-II induced hypertension would protect these organs from CDDP induced toxicities.	cddp	126-130	angiotensinogen	Homo sapiens	67-72
2389950-4	1990	Furthermore, STS infused immediately after the cessation of AT-II could neutralize the CDDP preventing the occurrence of toxicities.	cddp	87-91	angiotensinogen	Homo sapiens	60-65
2389950-5	1990	The elevating plasma levels of CDDP might be beneficial to enhance the anticancer effects of CDDP, since the blood flow in cancer tissue was increased during AT-II induced hypertension.	cddp	31-35	angiotensinogen	Homo sapiens	158-163
2389950-5	1990	The elevating plasma levels of CDDP might be beneficial to enhance the anticancer effects of CDDP, since the blood flow in cancer tissue was increased during AT-II induced hypertension.	cddp	93-97	angiotensinogen	Homo sapiens	158-163
2116401-8	1990	Increased GSH probably also played a role in determining cadmium chloride resistance of the PC-9/CDDP, even though this cell line had a reduced metallothionein level.	cddp	97-101	proprotein convertase subtilisin/kexin type 9	Homo sapiens	92-96
2116401-9	1990	Also contributing to the cisplatin resistance phenotype was a reduced intracellular level of platinum in the PC-9/CDDP.	cddp	114-118	proprotein convertase subtilisin/kexin type 9	Homo sapiens	109-113
2346318-6	1990	The IgM/cDDP cells showed cross-resistance, in vitro and in vivo, to the currently used cis-DDP analogs carboplatin (CBDCA or JM8) and iproplatin (CHIP or JM9).	cddp	8-12	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	126-129
2346318-8	1990	In addition, the cell line IgM/cDDP was resistant to other drugs interacting with DNA, such as doxorubicin (DXR), mitomycin C (MMC) and melphalan (L-PAM).	cddp	31-35	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	149-152
2157781-5	1990	Under chemotherapy with CDDP, logarithm of alpha-fetoprotein reduced linearly.	cddp	24-28	alpha fetoprotein	Homo sapiens	43-60
2157781-7	1990	AFP reduction rate under CDDP-suspension therapy (k = -0.0097, 12/1987-6/1988) was more rapid than that under DIV therapy (k = -0.0053, 2/1987-12/1987), and AFP reduced completely in June of 1988.	cddp	25-29	alpha fetoprotein	Homo sapiens	0-3
2157781-7	1990	AFP reduction rate under CDDP-suspension therapy (k = -0.0097, 12/1987-6/1988) was more rapid than that under DIV therapy (k = -0.0053, 2/1987-12/1987), and AFP reduced completely in June of 1988.	cddp	25-29	alpha fetoprotein	Homo sapiens	157-160
30428555-7	2018	We also found a significant decrease of caspase-3 and p53 expression after 48 h, accompanied by a down-regulation of NF-kappaB in cells exposed to MWCNT-COOH-CDDP system which promotes apoptosis escape and thus failing to overcome the triple negative breast cancer (TNBC) cells resistance.	cddp	158-162	tumor protein p53	Homo sapiens	54-57
34693115-4	2021	Tan IIA may be the main active component of CDDP in the treatment of high-altitude heart disease via HIF-1/PI3K/Akt pathways.	cddp	44-48	AKT serine/threonine kinase 1	Homo sapiens	112-115
25693518-5	2015	In this study, we showed that MGMT-proficient cells were highly resistant to the cytotoxic effects of CDDP as compared to MGMT-deficient cells.	cddp	102-106	O-6-methylguanine-DNA methyltransferase	Homo sapiens	30-34
25693518-6	2015	Further studies showed that the platinum level of DNA after CDDP exposure was significantly lower in MGMT-proficient cells than in MGMT-deficient cells.	cddp	60-64	O-6-methylguanine-DNA methyltransferase	Homo sapiens	101-105
25693518-6	2015	Further studies showed that the platinum level of DNA after CDDP exposure was significantly lower in MGMT-proficient cells than in MGMT-deficient cells.	cddp	60-64	O-6-methylguanine-DNA methyltransferase	Homo sapiens	131-135
2074385-11	1990	Thereafter ADR of CDDP with regard to the renal tubulus were studied by observing urinary NAG and urinary and serum beta 2 microglobulin.	cddp	18-22	beta-2-microglobulin	Homo sapiens	116-136
34390798-10	2021	CONCLUSIONS: Our results firstly demonstrated that CDDP effectively ameliorated post ischemic myocardial inflammation through simultaneously modulating MAPK, PI3K/AKT and PPAR pathways in a multi-components synergetic manner.	cddp	51-55	AKT serine/threonine kinase 1	Rattus norvegicus	163-166
34390798-10	2021	CONCLUSIONS: Our results firstly demonstrated that CDDP effectively ameliorated post ischemic myocardial inflammation through simultaneously modulating MAPK, PI3K/AKT and PPAR pathways in a multi-components synergetic manner.	cddp	51-55	peroxisome proliferator activated receptor alpha	Rattus norvegicus	171-175
34688610-3	2021	To investigate whether and how HNRNPUL1 affects CDDP resistance of ESCC, we evaluated the expression of HNRNPUL1 and found that it was associated with recurrence in ESCC patients receiving postoperative platinum-based chemotherapy and was an independent prognostic factor for disease-free survival (DFS).	cddp	48-52	heterogeneous nuclear ribonucleoprotein U like 1	Homo sapiens	31-39
34688610-4	2021	Besides, we showed that the reduced expression of HNRNPUL1 enhanced the CDDP sensitivity of ESCC cells.	cddp	72-76	heterogeneous nuclear ribonucleoprotein U like 1	Homo sapiens	50-58
34688610-5	2021	Furthermore, RNA immunoprecipitation coupled with high-throughput sequencing (RIP-seq) were performed and a range of HNRNPUL1-binding RNAs influenced by CDDP treatment were identified followed by bioinformatics analysis.	cddp	153-157	heterogeneous nuclear ribonucleoprotein U like 1	Homo sapiens	117-125
34688610-6	2021	In terms of mechanism, we found that HNRNPUL1 inhibited CDDP sensitivity of ESCC cells by regulating the CDDP sensitivity-inhibited circular RNA (circRNA) MAN1A2 formation.	cddp	56-60	heterogeneous nuclear ribonucleoprotein U like 1	Homo sapiens	37-45
34688610-6	2021	In terms of mechanism, we found that HNRNPUL1 inhibited CDDP sensitivity of ESCC cells by regulating the CDDP sensitivity-inhibited circular RNA (circRNA) MAN1A2 formation.	cddp	56-60	mannosidase alpha class 1A member 2	Homo sapiens	155-161
34688610-6	2021	In terms of mechanism, we found that HNRNPUL1 inhibited CDDP sensitivity of ESCC cells by regulating the CDDP sensitivity-inhibited circular RNA (circRNA) MAN1A2 formation.	cddp	105-109	heterogeneous nuclear ribonucleoprotein U like 1	Homo sapiens	37-45
34688610-6	2021	In terms of mechanism, we found that HNRNPUL1 inhibited CDDP sensitivity of ESCC cells by regulating the CDDP sensitivity-inhibited circular RNA (circRNA) MAN1A2 formation.	cddp	105-109	mannosidase alpha class 1A member 2	Homo sapiens	155-161
34688610-7	2021	Taken together, our results first demonstrated the role of HNRNPUL1 in CDDP resistance of ESCC and suggested that HNRNPUL1 may be a potential target of ESCC chemotherapy.	cddp	71-75	heterogeneous nuclear ribonucleoprotein U like 1	Homo sapiens	59-67
34688610-7	2021	Taken together, our results first demonstrated the role of HNRNPUL1 in CDDP resistance of ESCC and suggested that HNRNPUL1 may be a potential target of ESCC chemotherapy.	cddp	71-75	heterogeneous nuclear ribonucleoprotein U like 1	Homo sapiens	114-122
34808069-10	2021	Mechanistically, CDDP alleviated HH-reinforced ROS by improving SOD and GPX1 while inhibiting pro-inflammatory cytokines and NF-kappaB expression.	cddp	17-21	glutathione peroxidase 1	Rattus norvegicus	72-76
34808069-11	2021	CDDP also decreased HH-evoked D-dimer, erythrocyte aggregation and blood hemorheology, promoting AQP1 and Nrf2 expression.	cddp	0-4	aquaporin 1	Rattus norvegicus	97-101
34808069-11	2021	CDDP also decreased HH-evoked D-dimer, erythrocyte aggregation and blood hemorheology, promoting AQP1 and Nrf2 expression.	cddp	0-4	NFE2 like bZIP transcription factor 2	Rattus norvegicus	106-110
34808069-13	2021	Suppressed NF-kappaB and up-regulated Nrf2 might play significant roles in the mechanism of CDDP.	cddp	92-96	NFE2 like bZIP transcription factor 2	Rattus norvegicus	38-42
25693518-7	2015	Host cell reactivation assay revealed that MGMT protected NPC cells from CDDP-induced DNA damage by enhancing DNA repair capacity.	cddp	73-77	O-6-methylguanine-DNA methyltransferase	Homo sapiens	43-47
25693518-8	2015	Importantly, we demonstrated for the first time that MGMT protein directly bound to CDDP-induced DNA damages.	cddp	84-88	O-6-methylguanine-DNA methyltransferase	Homo sapiens	53-57
25693518-9	2015	Subsequently, CDDP-bound MGMT protein became ubiquitinated and was degraded through ubiquitin-mediated proteasome system.	cddp	14-18	O-6-methylguanine-DNA methyltransferase	Homo sapiens	25-29
25693518-11	2015	NPC patients who received CDDP-based concurrent chemoradiotherapy (CCRT), with high MGMT expression level, exhibited shorter progression-free survival (PFS; p = 0.022) and overall survival (OS; p = 0.015), than patients with low MGMT expression level.	cddp	26-30	O-6-methylguanine-DNA methyltransferase	Homo sapiens	84-88
25693518-11	2015	NPC patients who received CDDP-based concurrent chemoradiotherapy (CCRT), with high MGMT expression level, exhibited shorter progression-free survival (PFS; p = 0.022) and overall survival (OS; p = 0.015), than patients with low MGMT expression level.	cddp	26-30	O-6-methylguanine-DNA methyltransferase	Homo sapiens	229-233
25693518-13	2015	Our findings suggest that MGMT protein is important to determine the efficacy of CDDP in NPC.	cddp	81-85	O-6-methylguanine-DNA methyltransferase	Homo sapiens	26-30
34390798-8	2021	Tanshinol, salvianolic acid B (Sal B), tanshinone IIA (Tan IIA) and notoginsenoside R1 (NGR1) were the pivotal anti-inflammatory ingredients in CDDP.	cddp	144-148	reticulon 4 receptor	Rattus norvegicus	88-92
34457004-6	2021	The results showed that miR-651-3p was significantly downregulated in HCC tissues and cell lines, and the decreased miR-651-3p was also observed in CDDP-induced cells.	cddp	148-152	microRNA 6513	Homo sapiens	24-34
34521054-5	2021	The effects of ZNF711 expression on CDDP resistance were studied by IC50, Annexin V, and colony formation in vitro, and in an in vivo intra-peritoneal tumor model.	cddp	36-40	zinc finger protein 711	Homo sapiens	15-21
34521054-7	2021	FINDINGS: ZNF711 down-regulation exerts a great impact on CDDP resistance for EOC patients by suppressing SLC31A1 and inhibiting CDDP influx.	cddp	58-62	zinc finger protein 711	Homo sapiens	10-16
34521054-7	2021	FINDINGS: ZNF711 down-regulation exerts a great impact on CDDP resistance for EOC patients by suppressing SLC31A1 and inhibiting CDDP influx.	cddp	58-62	solute carrier family 31 member 1	Homo sapiens	106-113
34521054-7	2021	FINDINGS: ZNF711 down-regulation exerts a great impact on CDDP resistance for EOC patients by suppressing SLC31A1 and inhibiting CDDP influx.	cddp	129-133	zinc finger protein 711	Homo sapiens	10-16
34521054-8	2021	ZNF711 down-regulation promoted, while ZNF711 overexpression drastically inhibited CDDP resistance, both in vivo and in vitro.	cddp	83-87	zinc finger protein 711	Homo sapiens	39-45
34521054-9	2021	Mechanistically, the histone demethylase JHDM2A was recruited to the SLC31A1 promoter by ZNF711 and decreased the H3K9me2 level, resulting in the activation of SLC31A1 transcription and enhancement of CDDP uptake.	cddp	201-205	lysine demethylase 3A	Homo sapiens	41-47
34521054-9	2021	Mechanistically, the histone demethylase JHDM2A was recruited to the SLC31A1 promoter by ZNF711 and decreased the H3K9me2 level, resulting in the activation of SLC31A1 transcription and enhancement of CDDP uptake.	cddp	201-205	solute carrier family 31 member 1	Homo sapiens	69-76
34521054-9	2021	Mechanistically, the histone demethylase JHDM2A was recruited to the SLC31A1 promoter by ZNF711 and decreased the H3K9me2 level, resulting in the activation of SLC31A1 transcription and enhancement of CDDP uptake.	cddp	201-205	zinc finger protein 711	Homo sapiens	89-95
34521054-10	2021	Importantly, co-treatment with the histone methylation inhibitor, BIX-01294, increased the therapeutic efficacy of CDDP treatment in ZNF711-suppressed EOC cells.	cddp	115-119	zinc finger protein 711	Homo sapiens	133-139
34521054-11	2021	INTERPRETATION: These findings both verified the clinical importance of ZNF711 in CDDP resistance and provide novel therapeutic regimens for EOC treatment.	cddp	82-86	zinc finger protein 711	Homo sapiens	72-78
34457004-6	2021	The results showed that miR-651-3p was significantly downregulated in HCC tissues and cell lines, and the decreased miR-651-3p was also observed in CDDP-induced cells.	cddp	148-152	microRNA 6513	Homo sapiens	116-126
34457004-11	2021	In conclusion, miR-651-3p could regulate the autophagy to enhance the sensitivity of HepG2 cells to CDDP via targeting ATG3.	cddp	100-104	microRNA 6513	Homo sapiens	15-25
34457004-11	2021	In conclusion, miR-651-3p could regulate the autophagy to enhance the sensitivity of HepG2 cells to CDDP via targeting ATG3.	cddp	100-104	autophagy related 3	Homo sapiens	119-123
34111474-8	2021	CDDP enhanced the expressions of CD47 in lung cancer cells.	cddp	0-4	CD47 molecule	Homo sapiens	33-37
34111474-9	2021	Interestingly, the blockage of CD47 enhanced the macrophages" phagocytic activity on the CDDP-treated tumor cells.	cddp	89-93	CD47 molecule	Homo sapiens	31-35
34111474-11	2021	Mechanistic studies revealed that the treatment of CDDP and aCD47 regulated the phagocytic activity of macrophage, percentage of CD8+ T cells, and cytokines (tumor growth factor (TGF)-beta, interleukin (IL)12p70, and interferon (IFN)-gamma) in the tumor-bearing model.	cddp	51-55	transforming growth factor alpha	Mus musculus	158-188
34111474-11	2021	Mechanistic studies revealed that the treatment of CDDP and aCD47 regulated the phagocytic activity of macrophage, percentage of CD8+ T cells, and cytokines (tumor growth factor (TGF)-beta, interleukin (IL)12p70, and interferon (IFN)-gamma) in the tumor-bearing model.	cddp	51-55	interferon gamma	Mus musculus	217-239
34367977-9	2021	These data show that TNBC models with wild type versus mutant BRCA1 exhibit differences in CDDP-induced cellular response pathways, however, the CDDP-induced signaling responses remain stable across the isogenic models of OlaR from the same lineage.	cddp	91-95	BRCA1 DNA repair associated	Homo sapiens	62-67
35614996-0	2022	Retraction Notice to: Knockdown of KCNQ1OT1 Suppresses Cell Invasion and Sensitizes Osteosarcoma Cells to CDDP by Upregulating DNMT1-Mediated Kcnq1 Expression.	cddp	106-110	KCNQ1 opposite strand/antisense transcript 1	Homo sapiens	35-43
34091590-5	2021	This study aimed to investigate whether resistance to cisplatin (CDDP), the standard treatment for OC, is due to the remodeling of the tumor immune microenvironment by the transcription factor EB (TFEB).	cddp	65-69	transcription factor EB	Homo sapiens	172-195
34091590-5	2021	This study aimed to investigate whether resistance to cisplatin (CDDP), the standard treatment for OC, is due to the remodeling of the tumor immune microenvironment by the transcription factor EB (TFEB).	cddp	65-69	transcription factor EB	Homo sapiens	197-201
34091590-6	2021	We hypothesized that TFEB is not essential for tumor survival but is associated with CDDP resistance.	cddp	85-89	transcription factor EB	Homo sapiens	21-25
34091590-10	2021	We also found that CDDP treatment induced TFEB nuclear translocation, thus increasing PD-L1 and PD-L2 expression to foster an immunosuppressive tumor microenvironment, which mediates tumor immune evasion and drug resistance.	cddp	19-23	transcription factor EB	Homo sapiens	42-46
34091590-10	2021	We also found that CDDP treatment induced TFEB nuclear translocation, thus increasing PD-L1 and PD-L2 expression to foster an immunosuppressive tumor microenvironment, which mediates tumor immune evasion and drug resistance.	cddp	19-23	CD274 molecule	Homo sapiens	86-91
34091590-10	2021	We also found that CDDP treatment induced TFEB nuclear translocation, thus increasing PD-L1 and PD-L2 expression to foster an immunosuppressive tumor microenvironment, which mediates tumor immune evasion and drug resistance.	cddp	19-23	programmed cell death 1 ligand 2	Homo sapiens	96-101
34201235-5	2021	While many mechanisms have been proposed for Pt-drug transport, the high-affinity copper transporter (hCtr1), Cu chaperone (Atox1), and Cu exporters (ATP7A and ATP7B) are also involved in cDDP transport, highlighting Cu homeostasis regulation in Pt-based cancer therapy.	cddp	188-192	solute carrier family 31 member 1	Homo sapiens	102-107
34201235-5	2021	While many mechanisms have been proposed for Pt-drug transport, the high-affinity copper transporter (hCtr1), Cu chaperone (Atox1), and Cu exporters (ATP7A and ATP7B) are also involved in cDDP transport, highlighting Cu homeostasis regulation in Pt-based cancer therapy.	cddp	188-192	antioxidant 1 copper chaperone	Homo sapiens	124-129
34201235-5	2021	While many mechanisms have been proposed for Pt-drug transport, the high-affinity copper transporter (hCtr1), Cu chaperone (Atox1), and Cu exporters (ATP7A and ATP7B) are also involved in cDDP transport, highlighting Cu homeostasis regulation in Pt-based cancer therapy.	cddp	188-192	ATPase copper transporting alpha	Homo sapiens	150-155
34201235-5	2021	While many mechanisms have been proposed for Pt-drug transport, the high-affinity copper transporter (hCtr1), Cu chaperone (Atox1), and Cu exporters (ATP7A and ATP7B) are also involved in cDDP transport, highlighting Cu homeostasis regulation in Pt-based cancer therapy.	cddp	188-192	ATPase copper transporting beta	Homo sapiens	160-165
34065942-6	2021	We found that CDDP treatment increased Orai3 expression, but not Orai1 or STIM1 expression, as well as an enhancement of CSCs markers.	cddp	14-18	ORAI calcium release-activated calcium modulator 3	Homo sapiens	39-44
34065942-7	2021	Moreover, Orai3 silencing or the reduction of extracellular calcium concentration sensitized the cells to CDDP and led to a reduction in the expression of Nanog and SOX-2.	cddp	106-110	ORAI calcium release-activated calcium modulator 3	Homo sapiens	10-15
34065942-8	2021	Orai3 contributed to SOCE (Store-operated Calcium entry) in both CDDP-treated and CD133+ subpopulation cells that overexpress Nanog and SOX-2.	cddp	65-69	ORAI calcium release-activated calcium modulator 3	Homo sapiens	0-5
34065942-12	2021	Our work reveals a link between Orai3, CSCs and resistance to CDDP in NSCLC cells.	cddp	62-66	ORAI calcium release-activated calcium modulator 3	Homo sapiens	32-37
35622184-5	2022	Cav-1 overexpression enhanced sensitivity to cisplatin (CDDP) treatment, whereas Cav-1 deficiency promoted chemoresistance in OCCC cells.	cddp	56-60	caveolin 1	Homo sapiens	0-5
35622184-6	2022	Mechanistically, although Cav-1 counteracted angiotensin-converting enzyme 2 (ACE2) expression, ACE2 positively facilitated resistance to CDDP in OCCC cells.	cddp	138-142	angiotensin converting enzyme 2	Homo sapiens	96-100
35614996-0	2022	Retraction Notice to: Knockdown of KCNQ1OT1 Suppresses Cell Invasion and Sensitizes Osteosarcoma Cells to CDDP by Upregulating DNMT1-Mediated Kcnq1 Expression.	cddp	106-110	DNA methyltransferase 1	Homo sapiens	127-132
35614996-0	2022	Retraction Notice to: Knockdown of KCNQ1OT1 Suppresses Cell Invasion and Sensitizes Osteosarcoma Cells to CDDP by Upregulating DNMT1-Mediated Kcnq1 Expression.	cddp	106-110	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	142-147
35459153-6	2022	RESULTS: Sixty-five potential therapeutic targets of CDDP on CHD were identified and enriched in the PI3K/AKT and VEGF/VEGFR pathways.	cddp	53-57	vascular endothelial growth factor Aa	Danio rerio	114-118
34981536-4	2022	In this study, we investigate the effects of borneol on the pharmacokinetics of ginsenoside Rb1 (Rb1 ), ginsenoside Rg1 (Rg1 ) and notoginsenoside R1 (NR1 ) in CDDP.	cddp	160-164	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	151-154
35587162-3	2022	The present study found that ILK was highly expressed in ESCC cell lines, and the overexpression of ILK in ESCC cells reduced the incidence of cell apoptosis and alleviated the cytotoxicity on cells induced by cisplatin (CDDP).	cddp	221-225	integrin linked kinase	Homo sapiens	100-103
35587162-4	2022	Inversely, ILK knockdown increased CDDP-induced apoptosis and had an inhibitive effect on the malignant phenotype of ESCC, including cell proliferation, invasion, and migration.	cddp	35-39	integrin linked kinase	Homo sapiens	11-14
35587162-8	2022	In conclusion, ILK potentially reduced the CDDP sensitivity of ESCC cells by influencing the activity of the Wnt/beta-catenin signaling pathway.	cddp	43-47	integrin linked kinase	Homo sapiens	15-18
35587162-8	2022	In conclusion, ILK potentially reduced the CDDP sensitivity of ESCC cells by influencing the activity of the Wnt/beta-catenin signaling pathway.	cddp	43-47	catenin beta 1	Homo sapiens	113-125
35459153-8	2022	In addition, Vegfaa and Kdrl expression were significantly upregulated after CDDP treatment.	cddp	77-81	vascular endothelial growth factor Aa	Danio rerio	13-19
35459153-8	2022	In addition, Vegfaa and Kdrl expression were significantly upregulated after CDDP treatment.	cddp	77-81	kinase insert domain receptor like	Danio rerio	24-28
35459153-10	2022	CONCLUSIONS: CDDP has a proangiogenic effect, the mechanism of which involves the VEGF/VEGFR and PI3K/AKT signaling pathways.	cddp	13-17	vascular endothelial growth factor Aa	Danio rerio	82-86
35459212-6	2022	Genetic BNIP3 silencing or pharmacological inhibition of autophagosome formation re-sensitizes these cells to CDDP.	cddp	110-114	BCL2 interacting protein 3	Homo sapiens	8-13
35459212-7	2022	Our study identifies inhibition of BNIP3-driven mitophagy as a potential therapeutic strategy to counteract CDDP resistance in ovarian carcinoma and osteosarcoma.	cddp	108-112	BCL2 interacting protein 3	Homo sapiens	35-40
35280369-11	2022	Functional enrichment analysis showed that CDDP plays a pharmacological role in the treatment of epilepsy by regulating serotonergic synapses, morphine addiction, nicotine addiction and other pathways, as well as the NF-kappaB signaling pathway.	cddp	43-47	nuclear factor kappa B subunit 1	Homo sapiens	217-226
35465837-4	2022	Furthermore, FAM46A overexpression in ovarian cancer cells induces higher CDDP resistance.	cddp	74-78	terminal nucleotidyltransferase 5A	Homo sapiens	13-19
35465837-5	2022	However, inhibition of FAM46A sensitized ovarian cancer cell lines to CDDP cytotoxicity both in vitro and in vivo.	cddp	70-74	terminal nucleotidyltransferase 5A	Homo sapiens	23-29
2475556-6	1989	Combined chemotherapy with CDDP, VP16, and PEP brought the AFP and LDH 1 values down to 10 ng/ml and 27%, respectively.	cddp	27-31	alpha fetoprotein	Homo sapiens	59-62
2506819-2	1989	Concentration of the anti-cancer drug (CDDP) was measured in the specimen of cancer tissue obtained following intra-arterial infusion of the drug with angiotensin II.	cddp	39-43	angiotensinogen	Homo sapiens	151-165
2644935-3	1989	CDDP induces a dramatic change in both the testosterone level and the microsomal cytochrome P-450 concentration.	cddp	0-4	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-97
2658824-3	1989	The shortest t 1/2 alpha and the longest t 1/2 beta were observed in CDDP group, which correlated with the rate of protein binding (CDDP greater than DWA-2114R greater than NK-121 greater than CBDCA greater than 254-S).	cddp	69-73	brachyury, T-box transcription factor T	Mus musculus	13-24
2658824-3	1989	The shortest t 1/2 alpha and the longest t 1/2 beta were observed in CDDP group, which correlated with the rate of protein binding (CDDP greater than DWA-2114R greater than NK-121 greater than CBDCA greater than 254-S).	cddp	69-73	brachyury, T-box transcription factor T	Mus musculus	41-51
2658824-3	1989	The shortest t 1/2 alpha and the longest t 1/2 beta were observed in CDDP group, which correlated with the rate of protein binding (CDDP greater than DWA-2114R greater than NK-121 greater than CBDCA greater than 254-S).	cddp	132-136	brachyury, T-box transcription factor T	Mus musculus	41-51
3291772-11	1988	A synergistic increase in the cytotoxic effects of rH-TNF and anti-cancer drugs was demonstrated in vitro The cytotoxicity of rH-TNF against L-M cells in combination with MMC, ADM, Ara-C, ACD, DM, CDDP, VCR and 5-FU was 4 to 347 times as high as that of rH-TNF alone.	cddp	197-201	tumor necrosis factor	Homo sapiens	54-57
2729012-2	1989	In the present study, the acute changes of urinary beta-glucuronidase (beta-GL) and alkaline phosphatase (ALP) activities following CDDP administration as indicators of its toxicity were studied in 5 patients with urological malignant tumors.	cddp	132-136	glucuronidase beta	Homo sapiens	51-69
2729012-2	1989	In the present study, the acute changes of urinary beta-glucuronidase (beta-GL) and alkaline phosphatase (ALP) activities following CDDP administration as indicators of its toxicity were studied in 5 patients with urological malignant tumors.	cddp	132-136	glucuronidase beta	Homo sapiens	71-78
2729012-2	1989	In the present study, the acute changes of urinary beta-glucuronidase (beta-GL) and alkaline phosphatase (ALP) activities following CDDP administration as indicators of its toxicity were studied in 5 patients with urological malignant tumors.	cddp	132-136	alkaline phosphatase, placental	Homo sapiens	84-104
2848143-4	1988	After three sessions of one shot chemotherapy using ADM, MMC, and CDDP during the first admission, the AFP serum level decreased to 17,400 ng/ml, and tumor size regressed.	cddp	66-70	alpha fetoprotein	Homo sapiens	103-106
3291772-11	1988	A synergistic increase in the cytotoxic effects of rH-TNF and anti-cancer drugs was demonstrated in vitro The cytotoxicity of rH-TNF against L-M cells in combination with MMC, ADM, Ara-C, ACD, DM, CDDP, VCR and 5-FU was 4 to 347 times as high as that of rH-TNF alone.	cddp	197-201	tumor necrosis factor	Homo sapiens	129-132
3291772-11	1988	A synergistic increase in the cytotoxic effects of rH-TNF and anti-cancer drugs was demonstrated in vitro The cytotoxicity of rH-TNF against L-M cells in combination with MMC, ADM, Ara-C, ACD, DM, CDDP, VCR and 5-FU was 4 to 347 times as high as that of rH-TNF alone.	cddp	197-201	tumor necrosis factor	Homo sapiens	129-132
3355185-1	1988	The therapeutic effect of cis-1, 1-cyclobutane dicarboxylato-(2R)-2-methyl-1,4-butane diamine platinum (II) (NK 121) on 3 human yolk sac tumors of the ovary (YST-1, YST-2 and YST-3), which were transplanted into nude mice, was compared with that of cisplatin (CDDP).	cddp	260-264	suppressor of cytokine signaling 1	Homo sapiens	26-31
3048763-2	1988	The main cause for unresponsiveness of a tumor to CDDP is thought to be cellular drug resistance, which may be caused by (1) a decreased uptake of CDDP, (2) an increase in metallothioneins, (3) an increase in glutathione and/or glutathione-S-transferase, (4) increased DNA repair, or (5) increased tolerance to unrepaired lesions in DNA.	cddp	50-54	glutathione S-transferase mu 2	Homo sapiens	228-258
2895573-0	1987	[Relation of enzyme distribution in the kidney and increase pattern of urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma-GTP) activities following CDDP administration].	cddp	184-188	O-GlcNAcase	Homo sapiens	79-110
2895573-0	1987	[Relation of enzyme distribution in the kidney and increase pattern of urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma-GTP) activities following CDDP administration].	cddp	184-188	O-GlcNAcase	Homo sapiens	112-115
2895573-0	1987	[Relation of enzyme distribution in the kidney and increase pattern of urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma-GTP) activities following CDDP administration].	cddp	184-188	inactive glutathione hydrolase 2	Homo sapiens	121-150
2895573-0	1987	[Relation of enzyme distribution in the kidney and increase pattern of urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma-GTP) activities following CDDP administration].	cddp	184-188	inactive glutathione hydrolase 2	Homo sapiens	152-161
2895573-7	1987	On the other hand, two peaks of gamma-GTP activity were observed in many cases, the first peak during chemotherapy and the second peak soon after the completion of CDDP administration.	cddp	164-168	inactive glutathione hydrolase 2	Homo sapiens	32-41
2953096-8	1987	The only significant changes observed in this study were a rise in PRL and a decrease in beta-endorphin after CDDP administration.	cddp	110-114	proopiomelanocortin	Homo sapiens	89-103
3542253-1	1986	Carboplatin (JM8), a new cisdiamminodichloroplatin (CDDP) analogue, has exhibited the same antitumor as CDDP.	cddp	52-56	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	13-16
3542253-1	1986	Carboplatin (JM8), a new cisdiamminodichloroplatin (CDDP) analogue, has exhibited the same antitumor as CDDP.	cddp	104-108	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	13-16
2876605-1	1986	Acute change in urinary gamma-glutamyl transpeptidase (GTP) activity following cis-diamminedichloride platinum (CDDP) administration was studied in 12 patients who had malignant tumors.	cddp	112-116	inactive glutathione hydrolase 2	Homo sapiens	24-53
2880486-7	1986	The results showed that urinary NAG and gamma-GTP activities following CDDP administration were deeply influenced by these activities before CDDP administration and the combined therapy of FOM had tendency to reduce CDDP renal toxicity when urinary NAG and gamma-GTP activities before CDDP administration were in the normal range.	cddp	71-75	O-GlcNAcase	Homo sapiens	32-35
2880486-7	1986	The results showed that urinary NAG and gamma-GTP activities following CDDP administration were deeply influenced by these activities before CDDP administration and the combined therapy of FOM had tendency to reduce CDDP renal toxicity when urinary NAG and gamma-GTP activities before CDDP administration were in the normal range.	cddp	71-75	inactive glutathione hydrolase 2	Homo sapiens	40-49
2880486-7	1986	The results showed that urinary NAG and gamma-GTP activities following CDDP administration were deeply influenced by these activities before CDDP administration and the combined therapy of FOM had tendency to reduce CDDP renal toxicity when urinary NAG and gamma-GTP activities before CDDP administration were in the normal range.	cddp	141-145	O-GlcNAcase	Homo sapiens	32-35
2880486-7	1986	The results showed that urinary NAG and gamma-GTP activities following CDDP administration were deeply influenced by these activities before CDDP administration and the combined therapy of FOM had tendency to reduce CDDP renal toxicity when urinary NAG and gamma-GTP activities before CDDP administration were in the normal range.	cddp	141-145	inactive glutathione hydrolase 2	Homo sapiens	40-49
2880486-7	1986	The results showed that urinary NAG and gamma-GTP activities following CDDP administration were deeply influenced by these activities before CDDP administration and the combined therapy of FOM had tendency to reduce CDDP renal toxicity when urinary NAG and gamma-GTP activities before CDDP administration were in the normal range.	cddp	141-145	O-GlcNAcase	Homo sapiens	32-35
2880486-7	1986	The results showed that urinary NAG and gamma-GTP activities following CDDP administration were deeply influenced by these activities before CDDP administration and the combined therapy of FOM had tendency to reduce CDDP renal toxicity when urinary NAG and gamma-GTP activities before CDDP administration were in the normal range.	cddp	141-145	inactive glutathione hydrolase 2	Homo sapiens	40-49
2876605-1	1986	Acute change in urinary gamma-glutamyl transpeptidase (GTP) activity following cis-diamminedichloride platinum (CDDP) administration was studied in 12 patients who had malignant tumors.	cddp	112-116	inactive glutathione hydrolase 2	Homo sapiens	55-58
2876605-3	1986	In all cases, the gamma-GTP activity increased with CDDP administration and decreased after completion of chemotherapy.	cddp	52-56	inactive glutathione hydrolase 2	Homo sapiens	24-27
2876605-4	1986	Two peaks of gamma-GTP activity following CDDP administration were observed in many cases.	cddp	42-46	inactive glutathione hydrolase 2	Homo sapiens	19-22
2876605-5	1986	In cases presenting with high gamma-GTP activity and low creatinine clearance before CDDP administration, the increase in the activity was prominent.	cddp	85-89	inactive glutathione hydrolase 2	Homo sapiens	36-39
2876605-6	1986	The gamma-GTP activity before CDDP administration was significantly correlated with the gamma-GTP activity during the 10 days.	cddp	30-34	inactive glutathione hydrolase 2	Homo sapiens	10-13
2876605-6	1986	The gamma-GTP activity before CDDP administration was significantly correlated with the gamma-GTP activity during the 10 days.	cddp	30-34	inactive glutathione hydrolase 2	Homo sapiens	94-97
2876605-7	1986	This study suggests that the measurement of urinary gamma-GTP activity is important for the evaluation of CDDP nephrotoxicity, especially in cases of high gamma-GTP activity before CDDP administration.	cddp	106-110	inactive glutathione hydrolase 2	Homo sapiens	58-61
2876605-7	1986	This study suggests that the measurement of urinary gamma-GTP activity is important for the evaluation of CDDP nephrotoxicity, especially in cases of high gamma-GTP activity before CDDP administration.	cddp	106-110	inactive glutathione hydrolase 2	Homo sapiens	161-164
2876605-7	1986	This study suggests that the measurement of urinary gamma-GTP activity is important for the evaluation of CDDP nephrotoxicity, especially in cases of high gamma-GTP activity before CDDP administration.	cddp	181-185	inactive glutathione hydrolase 2	Homo sapiens	58-61
6439121-4	1984	Intra-arterial infusion of CDDP either alone or in combination with ADM or MMC seems to present an aggressive approach in dealing with other metastatic neoplasms without increasing toxicity, especially if intra-arterial angiotensin II is infused concomitantly.	cddp	27-31	angiotensinogen	Homo sapiens	220-234
33386467-9	2021	The change of PD-L1 expression in NCI-H1299 cells and xenografts induced by cisplatin (CDDP) was sensitively monitored by 68Ga-NOTA-Nb109.	cddp	87-91	CD274 molecule	Homo sapiens	14-19
33905957-9	2021	Thus, the ent-kaurane derivative showed potential application for sensitizing CDDP resistance by redox resetting destruction through dual inhibition of Prdx I/II and GSH in cancer chemotherapy.	cddp	78-82	peroxiredoxin 3	Homo sapiens	152-161
33894351-7	2021	The underlying immune mechanism demonstrated the combination of CDDP and pIL-12 activated immune effector cells to release IFN-gamma and induced M1-type differentiation of tumor-related macrophages, thereby generating synergistic chemoimmunotherapy effect.	cddp	64-68	interferon gamma	Mus musculus	123-132
34003591-10	2021	The EBI3/STAT3 pathway was implicated in the effect of alpha-M on SGC7901/CDDP cell development.	cddp	74-78	Epstein-Barr virus induced 3	Homo sapiens	4-8
34003591-10	2021	The EBI3/STAT3 pathway was implicated in the effect of alpha-M on SGC7901/CDDP cell development.	cddp	74-78	signal transducer and activator of transcription 3	Homo sapiens	9-14
33953309-5	2021	In addition, the direct inhibitory effect of CDDP on three kinases, AURKB, MET and PIM1 were observed both on biochemical level and cellular level, which could not only shed light on the mechanisms of action involved in CDDP, but also suggesting the potency of drug repositioning of CDDP.	cddp	45-49	aurora kinase B	Homo sapiens	68-73
33953309-5	2021	In addition, the direct inhibitory effect of CDDP on three kinases, AURKB, MET and PIM1 were observed both on biochemical level and cellular level, which could not only shed light on the mechanisms of action involved in CDDP, but also suggesting the potency of drug repositioning of CDDP.	cddp	45-49	SAFB like transcription modulator	Homo sapiens	75-78
33953309-5	2021	In addition, the direct inhibitory effect of CDDP on three kinases, AURKB, MET and PIM1 were observed both on biochemical level and cellular level, which could not only shed light on the mechanisms of action involved in CDDP, but also suggesting the potency of drug repositioning of CDDP.	cddp	45-49	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	83-87
33953309-5	2021	In addition, the direct inhibitory effect of CDDP on three kinases, AURKB, MET and PIM1 were observed both on biochemical level and cellular level, which could not only shed light on the mechanisms of action involved in CDDP, but also suggesting the potency of drug repositioning of CDDP.	cddp	220-224	aurora kinase B	Homo sapiens	68-73
33953309-5	2021	In addition, the direct inhibitory effect of CDDP on three kinases, AURKB, MET and PIM1 were observed both on biochemical level and cellular level, which could not only shed light on the mechanisms of action involved in CDDP, but also suggesting the potency of drug repositioning of CDDP.	cddp	220-224	SAFB like transcription modulator	Homo sapiens	75-78
33953309-5	2021	In addition, the direct inhibitory effect of CDDP on three kinases, AURKB, MET and PIM1 were observed both on biochemical level and cellular level, which could not only shed light on the mechanisms of action involved in CDDP, but also suggesting the potency of drug repositioning of CDDP.	cddp	220-224	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	83-87
33953309-5	2021	In addition, the direct inhibitory effect of CDDP on three kinases, AURKB, MET and PIM1 were observed both on biochemical level and cellular level, which could not only shed light on the mechanisms of action involved in CDDP, but also suggesting the potency of drug repositioning of CDDP.	cddp	220-224	aurora kinase B	Homo sapiens	68-73
33953309-5	2021	In addition, the direct inhibitory effect of CDDP on three kinases, AURKB, MET and PIM1 were observed both on biochemical level and cellular level, which could not only shed light on the mechanisms of action involved in CDDP, but also suggesting the potency of drug repositioning of CDDP.	cddp	220-224	SAFB like transcription modulator	Homo sapiens	75-78
33953309-5	2021	In addition, the direct inhibitory effect of CDDP on three kinases, AURKB, MET and PIM1 were observed both on biochemical level and cellular level, which could not only shed light on the mechanisms of action involved in CDDP, but also suggesting the potency of drug repositioning of CDDP.	cddp	220-224	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	83-87
33391428-0	2021	TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer.	cddp	45-49	tripartite motif containing 37	Homo sapiens	0-6
33784109-3	2021	By taking advantage of inherent CK2 specificity and CSC inhibition of HY1, a Pt(II) agent (HY1-Pt) was developed by conjugation of HY1 with an active Pt(II) unit to reverse cisplatin-induced resistance in A549/cDDP cell treatment.	cddp	210-214	RNA, Ro60-associated Y1	Homo sapiens	91-94
33784109-3	2021	By taking advantage of inherent CK2 specificity and CSC inhibition of HY1, a Pt(II) agent (HY1-Pt) was developed by conjugation of HY1 with an active Pt(II) unit to reverse cisplatin-induced resistance in A549/cDDP cell treatment.	cddp	210-214	RNA, Ro60-associated Y1	Homo sapiens	91-94
33784109-5	2021	Significantly, HY1-Pt presented an acceptable pharmacokinetic behavior and exhibited higher tumor growth inhibitory efficacy than cisplatin either in A549 or A549/cDDP xenograft models with low toxicity.	cddp	163-167	RNA, Ro60-associated Y1	Homo sapiens	15-18
33418444-11	2021	The gene and protein expression levels of CYP2B1, CYP2C6, and CYP2C11 were significantly reduced in the rat liver by CDDP.	cddp	117-121	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	42-48
33418444-11	2021	The gene and protein expression levels of CYP2B1, CYP2C6, and CYP2C11 were significantly reduced in the rat liver by CDDP.	cddp	117-121	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	50-56
33418444-11	2021	The gene and protein expression levels of CYP2B1, CYP2C6, and CYP2C11 were significantly reduced in the rat liver by CDDP.	cddp	117-121	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	62-69
33418444-12	2021	CDDP may diminish the AZ metabolism in vivo by suppressing the expression of the CYP2B1, CYP2C6, and CYP2C11 enzymes.	cddp	0-4	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	81-87
33418444-12	2021	CDDP may diminish the AZ metabolism in vivo by suppressing the expression of the CYP2B1, CYP2C6, and CYP2C11 enzymes.	cddp	0-4	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	89-95
33418444-12	2021	CDDP may diminish the AZ metabolism in vivo by suppressing the expression of the CYP2B1, CYP2C6, and CYP2C11 enzymes.	cddp	0-4	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	101-108
33086930-7	2020	CONCLUSIONS: Non-cytotoxic naringin reduced the expression of beta-catenin, c-Myc, and cyclin D1 in SKOV3/CDDP cells and partially reversed cisplatin resistance in SKOV3/CDDP CN 20 cells.	cddp	106-110	catenin beta 1	Homo sapiens	62-74
32687420-11	2020	Pre-treatment with CDDP significantly improved CFR (2.57 +- 0.29 vs. 1.84 +- 0.14), decreased the number of leukocytes adherent to microvascular wall (2500.00 +- 288.70 cells/mm2 vs. 4067.00 +- 581.20 cells/mm2) and down-regulated CD11b and FOXO1 expression.	cddp	19-23	integrin alpha M	Mus musculus	231-236
32687420-11	2020	Pre-treatment with CDDP significantly improved CFR (2.57 +- 0.29 vs. 1.84 +- 0.14), decreased the number of leukocytes adherent to microvascular wall (2500.00 +- 288.70 cells/mm2 vs. 4067.00 +- 581.20 cells/mm2) and down-regulated CD11b and FOXO1 expression.	cddp	19-23	forkhead box O1	Mus musculus	241-246
32687420-13	2020	Down-regulated FOXO1 and decreased leukocyte adhesion might play an important role in the mechanisms of CDDP"s efficacy.	cddp	104-108	forkhead box O1	Mus musculus	15-20
33275208-0	2020	MiR-129 reduces CDDP resistance in gastric cancer cells by inhibiting MAPK3.	cddp	16-20	mitogen-activated protein kinase 3	Homo sapiens	70-75
33192515-9	2020	Conclusion: This study found that GREB1 mutations may mediate the primary resistance and clinical prognosis of LUAD patients undergoing treatment with CDDP.	cddp	151-155	growth regulating estrogen receptor binding 1	Homo sapiens	34-39
33192515-10	2020	Further functional analysis showed that GREB1 mutations are related to the known mechanism of CDDP resistance.	cddp	94-98	growth regulating estrogen receptor binding 1	Homo sapiens	40-45
33192515-11	2020	These results suggest that GREB1 mutations are potential biomarkers for screening of CDDP resistance among LUAD patients.	cddp	85-89	growth regulating estrogen receptor binding 1	Homo sapiens	27-32
32901857-4	2020	Microarray analysis was conducted to analyze the miRNA expression profiles in exosomes isolated from A549 cells treated with or without CDDP, and miR-1273a was found to be the most prominently downregulated miRNA in CDDP-treated exosomes.	cddp	136-140	microRNA 1273a	Homo sapiens	146-155
32901857-4	2020	Microarray analysis was conducted to analyze the miRNA expression profiles in exosomes isolated from A549 cells treated with or without CDDP, and miR-1273a was found to be the most prominently downregulated miRNA in CDDP-treated exosomes.	cddp	216-220	microRNA 1273a	Homo sapiens	146-155
32901857-5	2020	Overexpression of miR-1273a significantly increased the cytotoxicity of CDDP and induced apoptosis in A549 cells.	cddp	72-76	microRNA 1273a	Homo sapiens	18-27
32831924-10	2020	RPPH1 overexpression increased the resistance of A549 and H1299 cells to CDDP.	cddp	73-77	ribonuclease P RNA component H1	Homo sapiens	0-5
32831924-15	2020	MiR-326 overexpression partially reduced the resistance of A549 cells to CDDP induced by RPPH1 overexpression.	cddp	73-77	microRNA 326	Homo sapiens	0-7
32831924-15	2020	MiR-326 overexpression partially reduced the resistance of A549 cells to CDDP induced by RPPH1 overexpression.	cddp	73-77	ribonuclease P RNA component H1	Homo sapiens	89-94
32831924-18	2020	miR-326 overexpression reduced CDDP resistance in A549 cells.	cddp	31-35	microRNA 326	Homo sapiens	0-7
32831924-19	2020	However, co-transfection with WNT2B partially enhanced CDDP resistance, compared with the mimic alone.	cddp	55-59	Wnt family member 2B	Homo sapiens	30-35
32831924-20	2020	In conclusion, RPPH1 promoted NSCLC progression and lung cancer cell resistance to CDDP through miR-326 and WNT2B.	cddp	83-87	ribonuclease P RNA component H1	Homo sapiens	15-20
32824929-10	2020	The response of NB cells to CDDP and poly(I:C) was potentiated by Dac in association with increased mtROS, which was blunted in rho0 cells.	cddp	28-32	arylacetamide deacetylase	Homo sapiens	66-69
32825798-2	2020	We have previously shown that p22phox, an endoplasmic reticulum (ER) membrane protein, confers CDDP resistance by blocking CDDP nuclear entry in oral squamous cell carcinoma (OSCC) cells; however, the underlying mechanism remains unresolved.	cddp	95-99	cytochrome b-245 alpha chain	Homo sapiens	30-37
32825798-2	2020	We have previously shown that p22phox, an endoplasmic reticulum (ER) membrane protein, confers CDDP resistance by blocking CDDP nuclear entry in oral squamous cell carcinoma (OSCC) cells; however, the underlying mechanism remains unresolved.	cddp	123-127	cytochrome b-245 alpha chain	Homo sapiens	30-37
32825798-3	2020	Using a fluorescent dye-labeled CDDP, here we show that CDDP can bind to p22phox in both cell-based and cell-free contexts.	cddp	32-36	cytochrome b-245 alpha chain	Homo sapiens	73-80
32825798-3	2020	Using a fluorescent dye-labeled CDDP, here we show that CDDP can bind to p22phox in both cell-based and cell-free contexts.	cddp	56-60	cytochrome b-245 alpha chain	Homo sapiens	73-80
32825798-4	2020	Subsequent detection of CDDP-peptide interaction by the Tris-Tricine-based electrophoresis revealed that GA-30, a synthetic peptide matching a region of the cytosolic domain of p22phox, could interact with CDDP.	cddp	24-28	cytochrome b-245 alpha chain	Homo sapiens	177-184
32825798-4	2020	Subsequent detection of CDDP-peptide interaction by the Tris-Tricine-based electrophoresis revealed that GA-30, a synthetic peptide matching a region of the cytosolic domain of p22phox, could interact with CDDP.	cddp	206-210	cytochrome b-245 alpha chain	Homo sapiens	177-184
32825798-6	2020	Amino acid substitutions at Cys50, Met65 and Met73, but not His72, significantly impaired the binding between CDDP and the GA-30 domain, thereby suggesting the potential CDDP-binding residues in p22phox protein.	cddp	110-114	cytochrome b-245 alpha chain	Homo sapiens	195-202
32825798-6	2020	Amino acid substitutions at Cys50, Met65 and Met73, but not His72, significantly impaired the binding between CDDP and the GA-30 domain, thereby suggesting the potential CDDP-binding residues in p22phox protein.	cddp	170-174	cytochrome b-245 alpha chain	Homo sapiens	195-202
32825798-7	2020	Consistently, the p22phox point mutations at Cys50, Met65 and Met73, but not His72, resensitized OSCC cells to CDDP-induced cytotoxicity and apoptosis.	cddp	111-115	cytochrome b-245 alpha chain	Homo sapiens	18-25
32825798-8	2020	Finally, p22phox might have binding specificity for the platinum drugs, including CDDP, carboplatin and oxaliplatin.	cddp	82-86	cytochrome b-245 alpha chain	Homo sapiens	9-16
32824929-12	2020	Dac can potentiate the cytotoxic effects of CDDP and poly(I:C) in NB cells.	cddp	44-48	arylacetamide deacetylase	Homo sapiens	0-3
32714408-4	2020	CDDP was found improving the impaired insulin signal sensitivity of ob/ob mice by ameliorating insulin and glucose tolerance, improving hepatic phosphorylation of the insulin receptor substrate-1 on Ser 307 (pIRS1) of ob/ob mice, and restoring hepatic function by decreasing serum ALT and AST, which increased in ob/ob mice serum.	cddp	0-4	insulin receptor substrate 1	Mus musculus	167-195
32632107-7	2020	Consistently, PAICS deficiency enhanced the sensitivity of GC cells to DNA damage agent, cisplatin (CDDP), both in vitro and in vivo.	cddp	100-104	phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase	Homo sapiens	14-19
32714408-4	2020	CDDP was found improving the impaired insulin signal sensitivity of ob/ob mice by ameliorating insulin and glucose tolerance, improving hepatic phosphorylation of the insulin receptor substrate-1 on Ser 307 (pIRS1) of ob/ob mice, and restoring hepatic function by decreasing serum ALT and AST, which increased in ob/ob mice serum.	cddp	0-4	glutamic pyruvic transaminase, soluble	Mus musculus	281-284
32714408-5	2020	Decreasing hepatic phosphorylation of pancreatic ER kinase (PERK) and inositol-requiring enzyme-1 (IRE1) regulating hepatic ER stress in the liver of ob/ob mice were increased by CDDP.	cddp	179-183	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	38-58
32714408-5	2020	Decreasing hepatic phosphorylation of pancreatic ER kinase (PERK) and inositol-requiring enzyme-1 (IRE1) regulating hepatic ER stress in the liver of ob/ob mice were increased by CDDP.	cddp	179-183	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	60-64
32714408-5	2020	Decreasing hepatic phosphorylation of pancreatic ER kinase (PERK) and inositol-requiring enzyme-1 (IRE1) regulating hepatic ER stress in the liver of ob/ob mice were increased by CDDP.	cddp	179-183	endoplasmic reticulum (ER) to nucleus signalling 2	Mus musculus	70-97
32714408-5	2020	Decreasing hepatic phosphorylation of pancreatic ER kinase (PERK) and inositol-requiring enzyme-1 (IRE1) regulating hepatic ER stress in the liver of ob/ob mice were increased by CDDP.	cddp	179-183	endoplasmic reticulum (ER) to nucleus signalling 2	Mus musculus	99-103
32714408-6	2020	Furthermore, CDDP was also found stimulating ob/ob mice hepatic autophagy by increasing the expression of Beclin1 and LC3B, while decreasing P62 expression.	cddp	13-17	beclin 1, autophagy related	Mus musculus	106-113
32714408-6	2020	Furthermore, CDDP was also found stimulating ob/ob mice hepatic autophagy by increasing the expression of Beclin1 and LC3B, while decreasing P62 expression.	cddp	13-17	microtubule-associated protein 1 light chain 3 beta	Mus musculus	118-122
32714408-6	2020	Furthermore, CDDP was also found stimulating ob/ob mice hepatic autophagy by increasing the expression of Beclin1 and LC3B, while decreasing P62 expression.	cddp	13-17	nucleoporin 62	Mus musculus	141-144
32192504-12	2020	In addition, the activation of JNK induced by CDDP was up-regulated and then decreased after the administration of ATX-LPN, while P38 stayed unchanged.	cddp	46-50	mitogen-activated protein kinase 8	Homo sapiens	31-34
32240302-3	2020	Here, using data mining and analysis on clinical samples, we show that expression of JUND, a core component of activator protein-1 (AP-1) family, was significantly induced in cisplatin (CDDP)-resistant MIBC.	cddp	186-190	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	85-89
32240302-5	2020	In both genetically engineered cell models and murine xenograft models, we provided evidence that BC cells with excessive JUND expression were less responsive to CDDP treatment.	cddp	162-166	jun D proto-oncogene	Mus musculus	122-126
32240302-6	2020	This CDDP resistance was further demonstrated to be mediated, at least in part, by transactivation of HMOX1 [the gene encoding heme oxygenase-1 (HO-1)], one of the most important antioxidant signaling pathways of cell adaptation to stress.	cddp	5-9	heme oxygenase 1	Homo sapiens	102-107
32240302-6	2020	This CDDP resistance was further demonstrated to be mediated, at least in part, by transactivation of HMOX1 [the gene encoding heme oxygenase-1 (HO-1)], one of the most important antioxidant signaling pathways of cell adaptation to stress.	cddp	5-9	heme oxygenase 1	Homo sapiens	127-143
32240302-6	2020	This CDDP resistance was further demonstrated to be mediated, at least in part, by transactivation of HMOX1 [the gene encoding heme oxygenase-1 (HO-1)], one of the most important antioxidant signaling pathways of cell adaptation to stress.	cddp	5-9	heme oxygenase 1	Homo sapiens	145-149
32240302-7	2020	One mutation within the HMOX1 promoter successfully abolished oxidative stress-enhanced and JUND-driven HMOX1 promoter activation, suggesting that this unique site synergized for maximal HO-1 induction in CDDP-challenged BC cells.	cddp	205-209	heme oxygenase 1	Homo sapiens	24-29
32240302-7	2020	One mutation within the HMOX1 promoter successfully abolished oxidative stress-enhanced and JUND-driven HMOX1 promoter activation, suggesting that this unique site synergized for maximal HO-1 induction in CDDP-challenged BC cells.	cddp	205-209	jun D proto-oncogene	Mus musculus	92-96
32240302-7	2020	One mutation within the HMOX1 promoter successfully abolished oxidative stress-enhanced and JUND-driven HMOX1 promoter activation, suggesting that this unique site synergized for maximal HO-1 induction in CDDP-challenged BC cells.	cddp	205-209	heme oxygenase 1	Homo sapiens	104-109
32240302-7	2020	One mutation within the HMOX1 promoter successfully abolished oxidative stress-enhanced and JUND-driven HMOX1 promoter activation, suggesting that this unique site synergized for maximal HO-1 induction in CDDP-challenged BC cells.	cddp	205-209	heme oxygenase 1	Homo sapiens	187-191
32240302-8	2020	Overall, our data highlight an indispensible role of JUND, both as a target as a modifier of the oxidative stress signaling, in conferring an adaptive response during the pathogenesis of CDDP resistance in MIBC.	cddp	187-191	jun D proto-oncogene	Mus musculus	53-57
32482981-8	2022	Subgroup analysis of overall survival with respect to positive RAD51 expression indicated preoperative chemotherapy (CDDP + 5-FU or docetaxel + CDDP + 5-FU) was superior to CRT.	cddp	117-121	RAD51 recombinase	Homo sapiens	63-68
32393433-3	2020	The result showed that the serum concentration of hepcidin in patients receiving CDDP-based chemotherapy was significantly increased after 4-6 days of treatment, in comparison to the baseline level, suggesting that aforementioned excessive systemic Fe was not explained by the change of serum hepcidin level.	cddp	81-85	hepcidin antimicrobial peptide	Homo sapiens	50-58
32101771-0	2020	Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism.	cddp	41-45	NFE2 like bZIP transcription factor 2	Homo sapiens	106-110
32101771-0	2020	Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism.	cddp	41-45	Yes1 associated transcriptional regulator	Homo sapiens	115-118
32101771-9	2020	Moreover, Aila treatment further reduced the superoxide anion content of CDDP-resistant cells in correlation with the reduction of Nrf2 and YAP proteins.	cddp	73-77	NFE2 like bZIP transcription factor 2	Homo sapiens	131-135
32101771-9	2020	Moreover, Aila treatment further reduced the superoxide anion content of CDDP-resistant cells in correlation with the reduction of Nrf2 and YAP proteins.	cddp	73-77	Yes1 associated transcriptional regulator	Homo sapiens	140-143
31669557-2	2019	The liver cancer cells developed the ability to tolerate CDDP treatment with the elevation of Bmi-1.	cddp	57-61	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	94-99
31930546-5	2020	Overexpression of cytoplasmic APE1 protected the osteosarcoma cells from CDDP-induced apoptosis.	cddp	73-77	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	30-34
32185607-4	2020	It has been found that MiR-26b may be involved in CDDP resistance.	cddp	50-54	microRNA 26b	Rattus norvegicus	23-30
32185607-9	2020	MAP3K9 partially reversed the effect of miR-26b-5p on ovarian granulosa cells induced by CDDP.	cddp	89-93	mitogen-activated protein kinase kinase kinase 9	Rattus norvegicus	0-6
32185607-9	2020	MAP3K9 partially reversed the effect of miR-26b-5p on ovarian granulosa cells induced by CDDP.	cddp	89-93	microRNA 26b	Rattus norvegicus	40-47
32185607-10	2020	miR-26b-5p has a protective effect on CDDP-induced ovarian granulosa cells via targeting MAP3K9.	cddp	38-42	mitogen-activated protein kinase kinase kinase 9	Rattus norvegicus	89-95
31399419-7	2019	Genetic depletion of USP22 inhibited liver cancer growth in an immune system-dependent manner, increased tumor immunogenicity and tumor-infiltrating lymphocytes, and improved therapeutic efficacy of CD274-targeted immunotherapy and CDDP-based chemotherapy in mice.	cddp	232-236	ubiquitin specific peptidase 22	Mus musculus	21-26
31493026-4	2019	Functional and molecular analysis showed that OCT1/2-/- mice are partially protected from CDDP-induced nephrotoxicity and peripheral neurotoxicity, whereas ototoxicity was not detectable.	cddp	90-94	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	46-50
31493026-7	2019	Consistent with functional protection, CDDP-induced proteome changes were more severe in WT mice than in OCT1/2-/- mice.	cddp	39-43	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	105-109
31263157-10	2019	Clinical investigation of matched pre- and post-CDDP-treated UC sections confirmed upregulation of TNFAIP2 expression in CDDP-treated tumors but downregulation of E-cadherin expression.	cddp	48-52	TNF alpha induced protein 2	Homo sapiens	99-106
31263157-10	2019	Clinical investigation of matched pre- and post-CDDP-treated UC sections confirmed upregulation of TNFAIP2 expression in CDDP-treated tumors but downregulation of E-cadherin expression.	cddp	121-125	TNF alpha induced protein 2	Homo sapiens	99-106
31263157-12	2019	The present results suggest a relationship between TNFAIP2 and EMT in cancers under the control of CDDP, in which MTDH expression levels in cancer cells are vital for promoting TNFAIP2-derived EMT acquisition.	cddp	99-103	TNF alpha induced protein 2	Homo sapiens	51-58
31263157-12	2019	The present results suggest a relationship between TNFAIP2 and EMT in cancers under the control of CDDP, in which MTDH expression levels in cancer cells are vital for promoting TNFAIP2-derived EMT acquisition.	cddp	99-103	metadherin	Homo sapiens	114-118
31263157-12	2019	The present results suggest a relationship between TNFAIP2 and EMT in cancers under the control of CDDP, in which MTDH expression levels in cancer cells are vital for promoting TNFAIP2-derived EMT acquisition.	cddp	99-103	TNF alpha induced protein 2	Homo sapiens	177-184
31077746-5	2019	Initially, we generated CDDP-resistant cells by a new protocol followed by checking the anticancer efficacy of salinomycin through MTT, clonogenic, annexin-V/PI and sub-G1 assay.	cddp	24-28	annexin A5	Homo sapiens	148-157
31255669-6	2019	Results documented that neferine/isoliensinine with CDDP augmented "intracellular uptake of cisplatin" consequently apoptosis in HCT-15 cells exemplified by "apoptotic morphological changes", "S phase cell cycle arrest", "ROS mediated oxidative stress" with the concomitant escalation in intracellular calcium & dissipation of MMP and activation of MAPK/PI3K/AKT pathway".	cddp	52-56	AKT serine/threonine kinase 1	Homo sapiens	363-366
31077746-8	2019	The analysis of nuclear translocation of pro-survival transcription factors by western blotting showed a distinct role of p65 (NF-kappaB) in CDDP-mediated resistance in breast cancer.	cddp	141-145	RELA proto-oncogene, NF-kB subunit	Homo sapiens	122-125
31077746-8	2019	The analysis of nuclear translocation of pro-survival transcription factors by western blotting showed a distinct role of p65 (NF-kappaB) in CDDP-mediated resistance in breast cancer.	cddp	141-145	nuclear factor kappa B subunit 1	Homo sapiens	127-136
31077746-9	2019	Salinomycin abrogated nuclear translocation of NF-kappaB proteins and also caused a concurrent reduction in NF-kappaB regulated expression of pro-survival proteins e.g., survivin, XIAP and BCL-2 in CDDP-resistant cells.	cddp	198-202	nuclear factor kappa B subunit 1	Homo sapiens	108-117
31077746-9	2019	Salinomycin abrogated nuclear translocation of NF-kappaB proteins and also caused a concurrent reduction in NF-kappaB regulated expression of pro-survival proteins e.g., survivin, XIAP and BCL-2 in CDDP-resistant cells.	cddp	198-202	BCL2 apoptosis regulator	Homo sapiens	189-194
31189612-6	2019	Mechanistically, vorinostat reverted 5FU/CDDP-induced EGFR phosphorylation and nuclear translocation, leading to the impairment of nuclear EGFR noncanonical induction of genes such as thymidylate synthase and cyclin D1.	cddp	41-45	cyclin D1	Homo sapiens	209-218
31189612-6	2019	Mechanistically, vorinostat reverted 5FU/CDDP-induced EGFR phosphorylation and nuclear translocation, leading to the impairment of nuclear EGFR noncanonical induction of genes such as thymidylate synthase and cyclin D1.	cddp	41-45	epidermal growth factor receptor	Homo sapiens	54-58
31036057-5	2019	RESULTS: In this study, we first demonstrated the elevated expression of oncogenic and stemenss markers such as Src, Notch1, macrophage inhibitory factor (MIF) and CD155 in trained cisplatin (CDDP)-resistant A549 and H460 cells (A549R and H460R cells).	cddp	192-196	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	112-115
31219617-1	2019	The protein binding rates (PBR) of platinum-containing agents cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin (L-OHP) have been reported as 98%, 25-50% and 98%, respectively.	cddp	73-77	translocator protein	Rattus norvegicus	27-30
30878903-2	2019	Numerous researches have proved that the dammarane type saponins including notoginsenoside R1 (NR1), ginsenoside Rg1 (GRg1) and ginsenoside Rb1 (GRb1) are the main bioactive components of PN in CDDP.	cddp	194-198	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	95-98
30878903-3	2019	An efficient, realiable and sensitive liquid chromatography tandem-mass spectrometry (LC-MS/MS) analysis method for simultaneously detecting NR1, GRg1 and GRb1 in human plasma was established and applied to the pharmacokinetics study of the three PN saponins after oral administration of CDDP.	cddp	288-292	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	141-144
30978440-5	2019	IL-8 increased the IC50 of cisplatin (CDDP) in AGS or MGC-803 in vitro.	cddp	38-42	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
31117440-3	2019	Then, the cisplatin (CDDP)-crosslinked CPT-prodrug micelles (CPTP/CDDP) with a hybrid complex as a stable structure were successfully established via the CDDP (Pt)-carboxyl (COOH) chelate interaction.	cddp	21-25	ceramide-1-phosphate transfer protein	Homo sapiens	61-65
31117440-7	2019	In addition, the CPTP/CDDP also exhibited a sustained reduction responsive release of CPT accompanied by the dissociation of the CDDP-COOH complex.	cddp	22-26	ceramide-1-phosphate transfer protein	Homo sapiens	17-21
31117440-7	2019	In addition, the CPTP/CDDP also exhibited a sustained reduction responsive release of CPT accompanied by the dissociation of the CDDP-COOH complex.	cddp	129-133	ceramide-1-phosphate transfer protein	Homo sapiens	17-21
31275988-2	2019	In the current study, we investigated the role of lncRNA HOMEOBOX A11 (HOXA11) antisense RNA (HOXA11-AS) in OSCC resistance to cisplatin (CDDP).	cddp	138-142	homeobox A11	Mus musculus	57-69
31275988-2	2019	In the current study, we investigated the role of lncRNA HOMEOBOX A11 (HOXA11) antisense RNA (HOXA11-AS) in OSCC resistance to cisplatin (CDDP).	cddp	138-142	homeobox A11	Mus musculus	71-77
31275988-2	2019	In the current study, we investigated the role of lncRNA HOMEOBOX A11 (HOXA11) antisense RNA (HOXA11-AS) in OSCC resistance to cisplatin (CDDP).	cddp	138-142	homeobox A11	Mus musculus	94-100
31275988-6	2019	HOXA11-AS expression was increased in OSCC clinical tissues and cell lines and upregulated in CDDP-resistant cells.	cddp	94-98	homeobox A11	Mus musculus	0-6
31275988-7	2019	Upregulation of HOXA11-AS promoted proliferation in CDDP-sensitive cells and inhibited CDDP-induced cytotoxicity.	cddp	52-56	homeobox A11	Mus musculus	16-22
31275988-7	2019	Upregulation of HOXA11-AS promoted proliferation in CDDP-sensitive cells and inhibited CDDP-induced cytotoxicity.	cddp	87-91	homeobox A11	Mus musculus	16-22
31275988-8	2019	In contrast, downregulation of HOXA11-AS decreased proliferation in CDDP-resistant cells and increased CDDP-induced cytotoxicity.	cddp	68-72	homeobox A11	Mus musculus	31-37
31275988-8	2019	In contrast, downregulation of HOXA11-AS decreased proliferation in CDDP-resistant cells and increased CDDP-induced cytotoxicity.	cddp	103-107	homeobox A11	Mus musculus	31-37
31275988-9	2019	Knockdown of HOXA11-AS inhibited the tumor growth in xenograft mice injected by CDDP.	cddp	80-84	homeobox A11	Mus musculus	13-19
31275988-10	2019	Downregulation of HOXA11-AS increased apoptosis and caspase 3 activities in CDDP-resistant OSCC cells.	cddp	76-80	homeobox A11	Mus musculus	18-24
31275988-10	2019	Downregulation of HOXA11-AS increased apoptosis and caspase 3 activities in CDDP-resistant OSCC cells.	cddp	76-80	caspase 3	Mus musculus	52-61
31275988-16	2019	In summary, HOXA11-AS was identified to facilitate CDDP-resistance in OSCC and miR-214-3p/PIM1 was found to be the downstream target of HOXA11-AS.	cddp	51-55	homeobox A11	Mus musculus	12-18
31036057-5	2019	RESULTS: In this study, we first demonstrated the elevated expression of oncogenic and stemenss markers such as Src, Notch1, macrophage inhibitory factor (MIF) and CD155 in trained cisplatin (CDDP)-resistant A549 and H460 cells (A549R and H460R cells).	cddp	192-196	notch receptor 1	Homo sapiens	117-123
31036057-5	2019	RESULTS: In this study, we first demonstrated the elevated expression of oncogenic and stemenss markers such as Src, Notch1, macrophage inhibitory factor (MIF) and CD155 in trained cisplatin (CDDP)-resistant A549 and H460 cells (A549R and H460R cells).	cddp	192-196	macrophage migration inhibitory factor	Homo sapiens	125-153
31036057-5	2019	RESULTS: In this study, we first demonstrated the elevated expression of oncogenic and stemenss markers such as Src, Notch1, macrophage inhibitory factor (MIF) and CD155 in trained cisplatin (CDDP)-resistant A549 and H460 cells (A549R and H460R cells).	cddp	192-196	macrophage migration inhibitory factor	Homo sapiens	155-158
31036057-5	2019	RESULTS: In this study, we first demonstrated the elevated expression of oncogenic and stemenss markers such as Src, Notch1, macrophage inhibitory factor (MIF) and CD155 in trained cisplatin (CDDP)-resistant A549 and H460 cells (A549R and H460R cells).	cddp	192-196	PVR cell adhesion molecule	Homo sapiens	164-169
30784875-3	2019	The NSAID-Pt(IV) prodrugs, especially Eto-Pt(IV), highly enhanced cellular uptake with amount up to 42-fold at 3 h compared with CDDP, and greatly increased DNA damage and cell apoptosis, showing much higher cytotoxicity than cisplatin in the tested cancer cells even in A549/cis cells.	cddp	129-133	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	38-41
29930276-6	2019	KLF4-overexpressed osteosarcoma cells displayed characteristics of OSCs: increased sphere-forming potential, enhanced levels of stemness-associated genes, great chemoresistance to adriamycin and CDDP, as well as more metastasis potential.	cddp	195-199	Kruppel like factor 4	Homo sapiens	0-4
29988075-4	2019	Instead, CDDP activates TAp63alpha through the ATR > CHEK1 pathway independent of TAp63alpha hyper-phosphorylation, whereas X-irradiation activates the ATM > CHEK2 > TAp63alpha-hyper-phosphorylation pathway.	cddp	9-13	ataxia telangiectasia and Rad3 related	Mus musculus	47-50
31040910-0	2019	Targeting claudin-4 enhances CDDP-chemosensitivity in gastric cancer.	cddp	29-33	claudin 4	Homo sapiens	10-19
29988075-4	2019	Instead, CDDP activates TAp63alpha through the ATR > CHEK1 pathway independent of TAp63alpha hyper-phosphorylation, whereas X-irradiation activates the ATM > CHEK2 > TAp63alpha-hyper-phosphorylation pathway.	cddp	9-13	checkpoint kinase 1	Mus musculus	56-61
29988075-4	2019	Instead, CDDP activates TAp63alpha through the ATR > CHEK1 pathway independent of TAp63alpha hyper-phosphorylation, whereas X-irradiation activates the ATM > CHEK2 > TAp63alpha-hyper-phosphorylation pathway.	cddp	9-13	checkpoint kinase 2	Mus musculus	164-169
29988075-5	2019	Furthermore, oocyte-specific deletion of Trp73 partially protects oocytes from CDDP but not from X-ray, highlighting the fundamental differences of two pathways.	cddp	79-83	transformation related protein 73	Mus musculus	41-46
29988075-6	2019	Nevertheless, temporary repression of DNA damage response by a kinase inhibitor that attenuates phosphorylation of ATM, ATR, CHEK1, and CHEK2 fully preserves fertility in female mice against CDDP as well as X-ray.	cddp	191-195	ataxia telangiectasia mutated	Mus musculus	115-118
29988075-6	2019	Nevertheless, temporary repression of DNA damage response by a kinase inhibitor that attenuates phosphorylation of ATM, ATR, CHEK1, and CHEK2 fully preserves fertility in female mice against CDDP as well as X-ray.	cddp	191-195	ataxia telangiectasia and Rad3 related	Mus musculus	120-123
29988075-6	2019	Nevertheless, temporary repression of DNA damage response by a kinase inhibitor that attenuates phosphorylation of ATM, ATR, CHEK1, and CHEK2 fully preserves fertility in female mice against CDDP as well as X-ray.	cddp	191-195	checkpoint kinase 1	Mus musculus	125-130
29988075-6	2019	Nevertheless, temporary repression of DNA damage response by a kinase inhibitor that attenuates phosphorylation of ATM, ATR, CHEK1, and CHEK2 fully preserves fertility in female mice against CDDP as well as X-ray.	cddp	191-195	checkpoint kinase 2	Mus musculus	136-141
30408550-6	2019	Functional studies demonstrated that miR-509-3p inhibitor decreased cell response to cisplatin (CDDP) and promoted cell survival in SKOV3 ovarian cancer cells.	cddp	96-100	microRNA 5093	Homo sapiens	37-47
30609256-3	2019	As compare to the parental cells, the doxorubicin and cisplatin (CDDP) resistant OS cells had greater levels of oestrogen-related receptors alpha (ERRalpha).	cddp	65-69	estrogen related receptor alpha	Homo sapiens	147-155
29964327-7	2019	We also found that the combination of CDDP and DAPT exhibit additive suppression on phosphorylated AKT and ERK, contributing to the anti-cancer effects.	cddp	38-42	AKT serine/threonine kinase 1	Homo sapiens	99-102
30741422-5	2019	Meanwhile, nicotine can reduce the sensitivity of H1299 cells to CDDP via enhancement of the binding of Mcl-1 to Bak, which inhibits the proapoptotic effect of Bak and ultimately leads to increased survival and drug resistance of lung cancer cells.	cddp	65-69	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	104-109
30741422-5	2019	Meanwhile, nicotine can reduce the sensitivity of H1299 cells to CDDP via enhancement of the binding of Mcl-1 to Bak, which inhibits the proapoptotic effect of Bak and ultimately leads to increased survival and drug resistance of lung cancer cells.	cddp	65-69	BCL2 antagonist/killer 1	Homo sapiens	113-116
30741422-5	2019	Meanwhile, nicotine can reduce the sensitivity of H1299 cells to CDDP via enhancement of the binding of Mcl-1 to Bak, which inhibits the proapoptotic effect of Bak and ultimately leads to increased survival and drug resistance of lung cancer cells.	cddp	65-69	BCL2 antagonist/killer 1	Homo sapiens	160-163
30336071-5	2019	LIVE/DEAD, MTT cell viability and colony formation assays did in fact demonstrate that FSTL1 is required for CDDP and DOX chemoresistance in breast cancer cell lines.	cddp	109-113	follistatin like 1	Homo sapiens	87-92
30668408-12	2019	Thirdly, DMC treatment markedly increased post-target CDDP resistance pathway including Bax and cytochrome c.	cddp	54-58	BCL2 associated X, apoptosis regulator	Homo sapiens	88-91
30668408-12	2019	Thirdly, DMC treatment markedly increased post-target CDDP resistance pathway including Bax and cytochrome c.	cddp	54-58	cytochrome c, somatic	Homo sapiens	96-108
30668408-15	2019	CONCLUSIONS: We concluded that enhancement of the cytotoxicity to CDDP by coadminstration with DMC was mediated by down-regulation of the expression of TP and ERCC1, regulated by PI3K-Akt-Snail pathway inactivation.	cddp	66-70	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	159-164
29964327-7	2019	We also found that the combination of CDDP and DAPT exhibit additive suppression on phosphorylated AKT and ERK, contributing to the anti-cancer effects.	cddp	38-42	mitogen-activated protein kinase 1	Homo sapiens	107-110
30367559-3	2018	Here, mapping the transcriptome of cancers treated with CDDP by scRNA-seq, we uncovered a novel gene, COX7B, associated with platinum-resistance, and surrogate marker, CD63.	cddp	56-60	cytochrome c oxidase subunit 7B	Homo sapiens	102-107
30662802-6	2018	Moreover, knockdown of YEATS4 improved chemosensitivity for CDDP and L-OHP.	cddp	60-64	YEATS domain containing 4	Homo sapiens	23-29
30367559-3	2018	Here, mapping the transcriptome of cancers treated with CDDP by scRNA-seq, we uncovered a novel gene, COX7B, associated with platinum-resistance, and surrogate marker, CD63.	cddp	56-60	CD63 molecule	Homo sapiens	168-172
30367559-4	2018	Knockdown of COX7B in cancer cells decreased the sensitivity of CDDP whereas overexpression recovered the sensitivity of CDDP.	cddp	64-68	cytochrome c oxidase subunit 7B	Homo sapiens	13-18
30367559-6	2018	Tumor samples from patients, who underwent CDDP therapy, showed decreased COX7B protein levels after the treatment.	cddp	43-47	cytochrome c oxidase subunit 7B	Homo sapiens	74-79
30367559-8	2018	This low-COX7B subclone behaved as cells with acquired platinum-resistance when challenged to CDDP.	cddp	94-98	cytochrome c oxidase subunit 7B	Homo sapiens	9-14
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	cddp	294-298	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	80-120
30106452-8	2018	Knockdown of integrin beta4 increased sensitivity to cisplatin (CDDP) in 3D cultures.	cddp	64-68	integrin subunit beta 4	Homo sapiens	13-27
29601666-4	2018	Our results demonstrated that Trps1 and MGMT expression both increased in drug-resistant lung cancer cell line (H446/CDDP).	cddp	117-121	transcriptional repressor GATA binding 1	Homo sapiens	30-35
29601666-4	2018	Our results demonstrated that Trps1 and MGMT expression both increased in drug-resistant lung cancer cell line (H446/CDDP).	cddp	117-121	O-6-methylguanine-DNA methyltransferase	Homo sapiens	40-44
29601666-5	2018	Silencing of Trps1 resulted in downregulation of MGMT expression and decrease in the multidrug sensitivity of H446/CDDP cells, while Trps1 overexpression exhibited the opposite effects in H446 cells.	cddp	115-119	transcriptional repressor GATA binding 1	Homo sapiens	13-18
29601666-6	2018	Ectopic expression of MGMT had no effect on Trps1 expression, but enhanced the IC50 values of H446 cells or rescued the IC50 values of Trps1-silenced H446/CDDP cells in treatment of multidrug.	cddp	155-159	O-6-methylguanine-DNA methyltransferase	Homo sapiens	22-26
29601666-6	2018	Ectopic expression of MGMT had no effect on Trps1 expression, but enhanced the IC50 values of H446 cells or rescued the IC50 values of Trps1-silenced H446/CDDP cells in treatment of multidrug.	cddp	155-159	transcriptional repressor GATA binding 1	Homo sapiens	135-140
30405447-13	2018	CDDP prevented the reduction in Bcl-2 expression and the increase in BCL-2 associated X (Bax) and caspase-3 (Casp3) expression in diabetic rats.	cddp	0-4	BCL2, apoptosis regulator	Rattus norvegicus	32-37
30405447-13	2018	CDDP prevented the reduction in Bcl-2 expression and the increase in BCL-2 associated X (Bax) and caspase-3 (Casp3) expression in diabetic rats.	cddp	0-4	BCL2 associated X, apoptosis regulator	Rattus norvegicus	69-87
30405447-13	2018	CDDP prevented the reduction in Bcl-2 expression and the increase in BCL-2 associated X (Bax) and caspase-3 (Casp3) expression in diabetic rats.	cddp	0-4	BCL2 associated X, apoptosis regulator	Rattus norvegicus	89-92
30405447-13	2018	CDDP prevented the reduction in Bcl-2 expression and the increase in BCL-2 associated X (Bax) and caspase-3 (Casp3) expression in diabetic rats.	cddp	0-4	caspase 3	Rattus norvegicus	98-107
30405447-13	2018	CDDP prevented the reduction in Bcl-2 expression and the increase in BCL-2 associated X (Bax) and caspase-3 (Casp3) expression in diabetic rats.	cddp	0-4	caspase 3	Rattus norvegicus	109-114
29887946-16	2018	Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bcl-2 mRNA level.	cddp	16-20	caspase 9	Homo sapiens	111-119
29887946-16	2018	Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bcl-2 mRNA level.	cddp	32-36	caspase 3	Homo sapiens	101-109
29887946-16	2018	Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bcl-2 mRNA level.	cddp	32-36	caspase 9	Homo sapiens	111-119
29887946-16	2018	Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bcl-2 mRNA level.	cddp	32-36	BCL2 associated X, apoptosis regulator	Homo sapiens	124-127
29887946-16	2018	Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bcl-2 mRNA level.	cddp	32-36	BCL2 apoptosis regulator	Homo sapiens	187-192
29731891-11	2018	In HeLa and CaSki cell lines, a combination index <1 for CDDP and CFC indicated the synergistic growth inhibition; the combination of the two also significantly increased expression of caspase-3, -7 and -9.	cddp	60-64	caspase 3	Homo sapiens	188-208
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	cddp	294-298	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-127
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	cddp	294-298	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	169-174
29765522-9	2018	Gene expression analysis of the ATP-binding cassette transporters revealed that ATP binding cassette subfamily B member1 (ABCB1) was conspicuously expressed in A99, and ABCB1 and ATP binding cassette subfamily C member2 (ABCC2) were deficient in TYUC-1, which might explain a part of different CDDP susceptibilities between cell lines.	cddp	294-298	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	221-226
29427302-8	2018	Levels of PDPN-high tumor basal cells and of expression of genes for DNA repair and antioxidant enzymes were reduced in stable transfectants, and they showed high CDDP and H2 O2 sensitivities, and their xenografts showed a well-differentiated histology.	cddp	163-167	podoplanin	Homo sapiens	10-14
29808689-11	2018	We have demonstrated a reduced sensitivity of MT-3 transfected cells to CDDP (24h IC50 of 7.48 +- 0.97 and 19.81 +- 1.2 mug/ml), a higher number of colonies after incubation with CDDP, reduced caspase 3 after incubation with CDDP and lower free oxygen radicals after induction of CDDP.	cddp	72-76	metallothionein 3	Homo sapiens	46-50
29808689-11	2018	We have demonstrated a reduced sensitivity of MT-3 transfected cells to CDDP (24h IC50 of 7.48 +- 0.97 and 19.81 +- 1.2 mug/ml), a higher number of colonies after incubation with CDDP, reduced caspase 3 after incubation with CDDP and lower free oxygen radicals after induction of CDDP.	cddp	179-183	metallothionein 3	Homo sapiens	46-50
29808689-11	2018	We have demonstrated a reduced sensitivity of MT-3 transfected cells to CDDP (24h IC50 of 7.48 +- 0.97 and 19.81 +- 1.2 mug/ml), a higher number of colonies after incubation with CDDP, reduced caspase 3 after incubation with CDDP and lower free oxygen radicals after induction of CDDP.	cddp	179-183	metallothionein 3	Homo sapiens	46-50
29808689-11	2018	We have demonstrated a reduced sensitivity of MT-3 transfected cells to CDDP (24h IC50 of 7.48 +- 0.97 and 19.81 +- 1.2 mug/ml), a higher number of colonies after incubation with CDDP, reduced caspase 3 after incubation with CDDP and lower free oxygen radicals after induction of CDDP.	cddp	179-183	metallothionein 3	Homo sapiens	46-50
29808689-13	2018	CONCLUSION: We have demonstrated the relationship between MT-3 and senescence-induced oncogene genes and some other genes relevant to cell fate (glutathione S-transferase M3, caspase 4 and DNAJB6) and a significant proportion of MT-3 on CDDP resistance.	cddp	237-241	metallothionein 3	Homo sapiens	58-62
29394666-0	2017	[The Case of HER2 Positive Advanced Gastric Cancer with Para-Aorta Lymph Node Recurrence Responding to Capecitabine plus CDDP plus Trastuzumab Chemotherapy].	cddp	121-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-17
28864226-9	2017	Expression of renal organic cation transporter 2 (rOct2) and multidrug and toxin extrusion protein 1 (rMate1), which are involved in CDDP transport, did not differ between the groups.	cddp	133-137	solute carrier family 47 member 1	Rattus norvegicus	102-108
30110677-12	2018	Furthermore, CDDP increased the expression of Bax and decreased Bcl-2 expression in renal tissue.	cddp	13-17	BCL2-associated X protein	Mus musculus	46-49
30110677-12	2018	Furthermore, CDDP increased the expression of Bax and decreased Bcl-2 expression in renal tissue.	cddp	13-17	B cell leukemia/lymphoma 2	Mus musculus	64-69
29268977-0	2017	Reverse effect of curcumin on CDDP-induced drug-resistance via Keap1/p62-Nrf2 signaling in A549/CDDP cell.	cddp	30-34	kelch like ECH associated protein 1	Homo sapiens	63-68
29268977-0	2017	Reverse effect of curcumin on CDDP-induced drug-resistance via Keap1/p62-Nrf2 signaling in A549/CDDP cell.	cddp	30-34	nucleoporin 62	Homo sapiens	69-72
29268977-0	2017	Reverse effect of curcumin on CDDP-induced drug-resistance via Keap1/p62-Nrf2 signaling in A549/CDDP cell.	cddp	30-34	NFE2 like bZIP transcription factor 2	Homo sapiens	73-77
29268977-0	2017	Reverse effect of curcumin on CDDP-induced drug-resistance via Keap1/p62-Nrf2 signaling in A549/CDDP cell.	cddp	96-100	kelch like ECH associated protein 1	Homo sapiens	63-68
29268977-0	2017	Reverse effect of curcumin on CDDP-induced drug-resistance via Keap1/p62-Nrf2 signaling in A549/CDDP cell.	cddp	96-100	nucleoporin 62	Homo sapiens	69-72
29268977-0	2017	Reverse effect of curcumin on CDDP-induced drug-resistance via Keap1/p62-Nrf2 signaling in A549/CDDP cell.	cddp	96-100	NFE2 like bZIP transcription factor 2	Homo sapiens	73-77
29268977-6	2017	Meanwhile, curcumin combination attenuated autophagy and Nrf2 activation induced by CDDP, and reversed the drug-resistant phenotype.	cddp	84-88	NFE2 like bZIP transcription factor 2	Homo sapiens	57-61
29268977-9	2017	CONCLUSIONS: The present findings demonstrate that CDDP promotes abnormal activation of Nrf2 pathway and autophagy, leading to drug resistance of A549/CDDP cell.	cddp	51-55	NFE2 like bZIP transcription factor 2	Homo sapiens	88-92
29394772-8	2017	After conducting 3 courses of S-1/CDDP(SP)therapy as adjuvant chemotherapy, the serum level of AFP had decreased to normal levels.	cddp	34-38	alpha fetoprotein	Homo sapiens	95-98
29394666-3	2017	Since HER2 protein was overexpressed in primary tumor immunostaining, he was treated with capecitabine plus CDDP plus trastuzumab therapy.After the chemotherapy, CEA levels decreased to the normal range and the enlarged lymph node was remarkably decreased in size in May, 2015.T he patient is alive 24 months after the chemotherapy with no evidence of recurrence.	cddp	108-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-10
29394666-3	2017	Since HER2 protein was overexpressed in primary tumor immunostaining, he was treated with capecitabine plus CDDP plus trastuzumab therapy.After the chemotherapy, CEA levels decreased to the normal range and the enlarged lymph node was remarkably decreased in size in May, 2015.T he patient is alive 24 months after the chemotherapy with no evidence of recurrence.	cddp	108-112	pregnancy specific beta-1-glycoprotein 2	Homo sapiens	162-165
29158814-9	2017	Our experimental results strongly support the direct regulation of MAFG through miR-7 and their involvement in the development of CDDP resistance in human tumor cells.	cddp	130-134	MAF bZIP transcription factor G	Homo sapiens	67-71
28978336-8	2017	GOLPH3L overexpression confers CDDP resistance on ovarian cancer cells; however, inhibition of GOLPH3L sensitized ovarian cancer cell lines to CDDP cytotoxicity both in vitro and in vivo.	cddp	31-35	golgi phosphoprotein 3 like	Homo sapiens	0-7
28978336-8	2017	GOLPH3L overexpression confers CDDP resistance on ovarian cancer cells; however, inhibition of GOLPH3L sensitized ovarian cancer cell lines to CDDP cytotoxicity both in vitro and in vivo.	cddp	143-147	golgi phosphoprotein 3 like	Homo sapiens	95-102
28982859-5	2017	RESULTS: Some CDDP-resistant HepG2 cell lines exhibited changes in the expression of copper transporter 1, multidrug resistant protein (MRP)2, and/or MRP3, resulting in decreased intracellular platinum amounts, while others showed no change in platinum accumulation.	cddp	14-18	ATP binding cassette subfamily C member 2	Homo sapiens	136-141
28982859-5	2017	RESULTS: Some CDDP-resistant HepG2 cell lines exhibited changes in the expression of copper transporter 1, multidrug resistant protein (MRP)2, and/or MRP3, resulting in decreased intracellular platinum amounts, while others showed no change in platinum accumulation.	cddp	14-18	ATP binding cassette subfamily C member 3	Homo sapiens	150-154
28760781-6	2017	Overexpression of miR-432-3p resulted in a decreased sensitivity of esophageal squamous cell carcinoma (ESCC) cells to chemotherapy drugs including cisplatin (CDDP).	cddp	159-163	microRNA 432	Homo sapiens	18-25
28760781-7	2017	Conversely, the inhibition of miR-432-3p expression by the CRISPR/Cas9 system resulted in an increased sensitivity of ESCC cells to CDDP.	cddp	132-136	microRNA 432	Homo sapiens	30-37
28529140-8	2017	The expressions of the renal organic cation transporter 2 (rOct2) and renal multidrug and toxin extrusion protein 1 (rMate1) were downregulated and upregulated, respectively following co-administration with Mg, which significantly reduced the renal Pt accumulation in the 2.5mg/kg CDDP-treated group.	cddp	281-285	solute carrier family 22 member 2	Rattus norvegicus	59-64
28529140-8	2017	The expressions of the renal organic cation transporter 2 (rOct2) and renal multidrug and toxin extrusion protein 1 (rMate1) were downregulated and upregulated, respectively following co-administration with Mg, which significantly reduced the renal Pt accumulation in the 2.5mg/kg CDDP-treated group.	cddp	281-285	solute carrier family 47 member 1	Rattus norvegicus	117-123
29158814-9	2017	Our experimental results strongly support the direct regulation of MAFG through miR-7 and their involvement in the development of CDDP resistance in human tumor cells.	cddp	130-134	leukocyte immunoglobulin like receptor B1	Homo sapiens	80-85
29158814-10	2017	Conclusion: The basal methylation status of miR-7 before treatment may be a potential clinical epigenetic biomarker, predictor of the chemotherapy outcome to CDDP in ovarian cancer patients.	cddp	158-162	leukocyte immunoglobulin like receptor B1	Homo sapiens	44-49
29158814-11	2017	To the best of our knowledge, this is the first report linking the regulation of MAFG by miRNA-7 and its role in chemotherapy response to CDDP.	cddp	138-142	MAF bZIP transcription factor G	Homo sapiens	81-85
28819442-10	2017	IFNalpha-primed enhanced the cytotoxic inhibition effect of CDDP, erlotinib and nimotuzumab on OSCC cells.	cddp	60-64	interferon alpha 1	Homo sapiens	0-8
28537902-3	2017	Increasing concentrations of tunicamycin and CDDP activated ERS in SKOV3 cells, reduced cell viability and proliferation, increased apoptosis and autophagy, enhanced expression of ERS-related proteins, and inhibited expression of PI3K/AKT/mTOR pathway-related proteins.	cddp	45-49	AKT serine/threonine kinase 1	Homo sapiens	235-238
28537902-3	2017	Increasing concentrations of tunicamycin and CDDP activated ERS in SKOV3 cells, reduced cell viability and proliferation, increased apoptosis and autophagy, enhanced expression of ERS-related proteins, and inhibited expression of PI3K/AKT/mTOR pathway-related proteins.	cddp	45-49	mechanistic target of rapamycin kinase	Homo sapiens	239-243
28927087-9	2017	Western blotting demonstrated that the expression levels of Ku70, DNA-PKcs, Rad50 and Rad51 were downregulated in cells treated with CDHP and CDDP combination treatment.	cddp	142-146	X-ray repair cross complementing 6	Homo sapiens	60-64
28927087-9	2017	Western blotting demonstrated that the expression levels of Ku70, DNA-PKcs, Rad50 and Rad51 were downregulated in cells treated with CDHP and CDDP combination treatment.	cddp	142-146	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	66-74
28927087-9	2017	Western blotting demonstrated that the expression levels of Ku70, DNA-PKcs, Rad50 and Rad51 were downregulated in cells treated with CDHP and CDDP combination treatment.	cddp	142-146	RAD50 double strand break repair protein	Homo sapiens	76-81
28927087-9	2017	Western blotting demonstrated that the expression levels of Ku70, DNA-PKcs, Rad50 and Rad51 were downregulated in cells treated with CDHP and CDDP combination treatment.	cddp	142-146	RAD51 recombinase	Homo sapiens	86-91
28619508-5	2017	MTT, colony formation, and DAPI staining assays further revealed that miR-129-5p inhibits NSCLC chemoresistance when the cells are treated with varying doses of CDDP.	cddp	161-165	microRNA 1295a	Homo sapiens	70-80
28653877-4	2017	Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol.	cddp	95-99	tumor suppressor candidate 7	Homo sapiens	28-33
28386750-3	2017	Although it was shown that FASN inhibition induced apoptosis by enhancing the cytotoxicity of certain drugs in breast cancer, its role in regulating the chemosensitivity of different types of breast cancer cells to CDDP-induced apoptosis is not established yet.	cddp	215-219	fatty acid synthase	Homo sapiens	27-31
28386750-8	2017	CDDP decreased FASN expression and increased apoptosis in TNBC cells.	cddp	0-4	fatty acid synthase	Homo sapiens	15-19
28386750-10	2017	We also illustrate that the inhibition of FASN by either siRNA or exogenous inhibitor decreased CDDP-induced apoptosis in TPBC cells suggesting its role as an apoptotic factor, while an opposite finding was observed in TNBC cells when siRNA and fatty acids were used, suggesting its role as a survival factor.	cddp	96-100	fatty acid synthase	Homo sapiens	42-46
28386750-11	2017	To our knowledge, we are the first to demonstrate a dual role of FASN in CDDP-induced apoptosis in breast cancer cells and how it can modulate their chemosensitivity.	cddp	73-77	fatty acid synthase	Homo sapiens	65-69
28648300-6	2017	Additionally, both dimercapto-compounds restored the CDDP-reduced mRNA levels of transporter proteins (OCT2 and MATE1), and apparently suppressed the CDDP-induced apoptosis.	cddp	53-57	POU domain, class 2, transcription factor 2	Mus musculus	103-107
28648300-6	2017	Additionally, both dimercapto-compounds restored the CDDP-reduced mRNA levels of transporter proteins (OCT2 and MATE1), and apparently suppressed the CDDP-induced apoptosis.	cddp	53-57	solute carrier family 47, member 1	Mus musculus	112-117
28052414-0	2017	MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer.	cddp	69-73	branched chain amino acid transaminase 1	Homo sapiens	97-102
28052414-7	2017	Importantly, overexpression of BCAT1 decreased the chemosensitivity to CDDP treatment of PC3 and DU145 cells.	cddp	71-75	branched chain amino acid transaminase 1	Homo sapiens	31-36
28052414-7	2017	Importantly, overexpression of BCAT1 decreased the chemosensitivity to CDDP treatment of PC3 and DU145 cells.	cddp	71-75	proprotein convertase subtilisin/kexin type 1	Homo sapiens	89-92
28653877-4	2017	Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol.	cddp	95-99	tumor suppressor candidate 7	Homo sapiens	214-219
28653877-4	2017	Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol.	cddp	336-340	tumor suppressor candidate 7	Homo sapiens	28-33
28653877-4	2017	Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol.	cddp	336-340	tumor suppressor candidate 7	Homo sapiens	214-219
28653877-5	2017	TUSC7 upregulation inhibited proliferation, blocked cells at G1 phase, and advanced apoptosis and chemotherapy sensitivity to CDDP and Taxol in HEC1A/CR cell line.	cddp	126-130	tumor suppressor candidate 7	Homo sapiens	0-5
28340724-7	2017	Notably, Cyt c-CDDP adducts were stable through all the above conditions while Cyt c-RAPTA-C adducts turned out unstable in the ammonium bicarbonate buffer.	cddp	15-19	cytochrome c, somatic	Homo sapiens	9-14
28469960-3	2017	In cell models, p62/SQSTM1 levels affected the Nrf2-Keap1 pathway, ROS levels, GSH/GSSG ratios and cell growth, especially under irradiation rather than under CDDP exposure, which was toxic despite p62/SQSTM1 status.	cddp	159-163	sequestosome 1	Homo sapiens	16-19
28206967-6	2017	Treatment of neuroblastoma cells with increasing concentrations of CDDP (0.1-10 muM) or TOPO (0.1 nM-1 muM) induced cytotoxicity and increased apoptosis in a concentration- and time-dependent manner.	cddp	67-71	latexin	Homo sapiens	80-83
28469960-3	2017	In cell models, p62/SQSTM1 levels affected the Nrf2-Keap1 pathway, ROS levels, GSH/GSSG ratios and cell growth, especially under irradiation rather than under CDDP exposure, which was toxic despite p62/SQSTM1 status.	cddp	159-163	sequestosome 1	Homo sapiens	20-26
27787693-6	2016	Results of co-exposure with the transport inhibitors ouabain, tetraethylammonium, and cimetidine indicated that the intracellular uptake of CDDP was dependent on Na+/K+-ATPase and that of 4M-PzPt was dependent on organic cation transporters (OCTs), probably OCT1.	cddp	140-144	solute carrier family 22 member 1	Homo sapiens	258-262
28955993-9	2017	Cells with high expression of LSD1+8a were resistant to CDDP and LSD1 inhibitor.	cddp	56-60	lysine demethylase 1A	Homo sapiens	30-34
27882231-2	2016	Recently, we found that a decreased OCT6 expression is associated with a reduced intracellular uptake of cisplatin (CDDP), and concomitant resistance to CDDP.	cddp	116-120	solute carrier family 22 member 16	Homo sapiens	36-40
27882231-2	2016	Recently, we found that a decreased OCT6 expression is associated with a reduced intracellular uptake of cisplatin (CDDP), and concomitant resistance to CDDP.	cddp	153-157	solute carrier family 22 member 16	Homo sapiens	36-40
26331585-6	2016	The expression levels of the GPR40 gene was elevated by the long-term CDDP treatment in HT1080 cells, while the GPR120 gene expression remained unchanged.	cddp	70-74	free fatty acid receptor 1	Homo sapiens	29-34
28133204-5	2016	Chemoradiotherapy(CRT) (5-FU and CDDP with 50 Gy of radiation)was administered.	cddp	33-37	calcitonin receptor	Homo sapiens	18-21
26331585-8	2016	In gelatin zymography, the activities of matrix metalloproteinase-2 (MMP-2) and MMP-9 of HT1080 cells were enhanced by the long-term CDDP treatment.	cddp	133-137	matrix metallopeptidase 2	Homo sapiens	41-67
26331585-8	2016	In gelatin zymography, the activities of matrix metalloproteinase-2 (MMP-2) and MMP-9 of HT1080 cells were enhanced by the long-term CDDP treatment.	cddp	133-137	matrix metallopeptidase 2	Homo sapiens	69-74
26331585-8	2016	In gelatin zymography, the activities of matrix metalloproteinase-2 (MMP-2) and MMP-9 of HT1080 cells were enhanced by the long-term CDDP treatment.	cddp	133-137	matrix metallopeptidase 9	Homo sapiens	80-85
26331585-9	2016	In addition, GW9508 which is an agonist of GPR40 and GPR120 suppressed the cell motile and invasive activities of HT1080 cells treated with CDDP as well as the MMP activation.	cddp	140-144	free fatty acid receptor 1	Homo sapiens	43-48
26331585-9	2016	In addition, GW9508 which is an agonist of GPR40 and GPR120 suppressed the cell motile and invasive activities of HT1080 cells treated with CDDP as well as the MMP activation.	cddp	140-144	free fatty acid receptor 4	Homo sapiens	53-59
27411790-3	2016	The purpose of this study was to investigate the ability of EHD1 [Eps15 homology (EH) domain - containing protein 1] to confer CDDP resistance in NSCLC cells and to investigate mechanisms of this resistance.	cddp	127-131	EH domain containing 1	Homo sapiens	60-64
27411790-3	2016	The purpose of this study was to investigate the ability of EHD1 [Eps15 homology (EH) domain - containing protein 1] to confer CDDP resistance in NSCLC cells and to investigate mechanisms of this resistance.	cddp	127-131	epidermal growth factor receptor pathway substrate 15	Homo sapiens	66-71
27411790-3	2016	The purpose of this study was to investigate the ability of EHD1 [Eps15 homology (EH) domain - containing protein 1] to confer CDDP resistance in NSCLC cells and to investigate mechanisms of this resistance.	cddp	127-131	EH domain containing 1	Homo sapiens	82-115
27411790-10	2016	Moreover, DNA microarrays indicated that the EHD1 gene was upregulated in CDDP- resistant NSCLC cells.	cddp	74-78	EH domain containing 1	Homo sapiens	45-49
27411790-11	2016	The IC50 value of CDDP in cells that overexpressed EHD1 was 3.3-fold greater than that in the A549-control line, and the IC50 value of EHD1 knockdown cells was at least 5.2-fold lower than that of the control cells, as evidenced by a CCK-8 assay.	cddp	18-22	EH domain containing 1	Homo sapiens	51-55
27411790-13	2016	High-performance liquid chromatography (HPLC) showed that the total platinum level was lower in A549-EHD1 cells than in control cells, and the concentration of CDDP was higher in the EHD1 knockdown cells than in the A549/DDP control cells.	cddp	160-164	EH domain containing 1	Homo sapiens	183-187
27411790-14	2016	CONCLUSION: We conclude that EHD1 is required for tumour growth and that it is a regulator of CDDP accumulation and cytotoxicity.	cddp	94-98	EH domain containing 1	Homo sapiens	29-33
27411790-15	2016	The selective knockdown of EHD1 in tumours offers a strategy for enhancing the efficacy of CDDP.	cddp	91-95	EH domain containing 1	Homo sapiens	27-31
27040953-2	2016	X-ray structures were also solved for the adducts formed at 20 and 55  C. Data demonstrate that high temperature facilitates the formation of CDDP-HEWL adducts, where Pt atoms bind ND1 atom of His15 or NE2 atom of His15 and NH1 atom of Arg14.	cddp	142-146	mitochondrially encoded NADH dehydrogenase 1	Homo sapiens	181-184
27065457-2	2016	We demonstrated previously that unexpectedly ovarian cancer cells are sensitised to cisplatin (CDDP) by the hepatocyte growth factor (HGF), usually considered an anti-apoptotic factor.	cddp	95-99	hepatocyte growth factor	Homo sapiens	108-132
27310703-10	2016	GPC1 expression levels positively correlated with chemo-sensitivity against cis-Diammineplatinum (II) dichloride (CDDP), and are potentially associated with anti-apoptotic function based on alterations in the MAPK downstream signalling pathway and Bcl-2 family member proteins.	cddp	114-118	glypican 1	Homo sapiens	0-4
27310703-11	2016	CONCLUSIONS: GPC1 is an independent prognostic factor in ESCC and is a critical molecule for altering the threshold of chemoresistance to CDDP.	cddp	138-142	glypican 1	Homo sapiens	13-17
27065457-2	2016	We demonstrated previously that unexpectedly ovarian cancer cells are sensitised to cisplatin (CDDP) by the hepatocyte growth factor (HGF), usually considered an anti-apoptotic factor.	cddp	95-99	hepatocyte growth factor	Homo sapiens	134-137
27065457-4	2016	RESULTS: In ovarian cancer cells, CDDP induced the phosphorylation, i.e. the activation, of the p90RSK.	cddp	34-38	ribosomal protein S6 kinase A1	Homo sapiens	96-102
27065457-7	2016	Conversely, CDDP down-modulated ILKAP expression.	cddp	12-16	ILK associated serine/threonine phosphatase	Homo sapiens	32-37
27065457-8	2016	This impaired CDDP efficacy, as ILKAP silencing protected cells from CDDP-induced death.	cddp	14-18	ILK associated serine/threonine phosphatase	Homo sapiens	32-37
27065457-8	2016	This impaired CDDP efficacy, as ILKAP silencing protected cells from CDDP-induced death.	cddp	69-73	ILK associated serine/threonine phosphatase	Homo sapiens	32-37
27065457-9	2016	In line, the biochemical inhibition of the p90RSK or the combined silencing of the most expressed RSK isoforms, namely RSK1 and RSK2, increased the efficacy of CDDP.	cddp	160-164	ribosomal protein S6 kinase A1	Homo sapiens	43-49
27065457-9	2016	In line, the biochemical inhibition of the p90RSK or the combined silencing of the most expressed RSK isoforms, namely RSK1 and RSK2, increased the efficacy of CDDP.	cddp	160-164	ribosomal protein S6 kinase A1	Homo sapiens	46-49
27065457-9	2016	In line, the biochemical inhibition of the p90RSK or the combined silencing of the most expressed RSK isoforms, namely RSK1 and RSK2, increased the efficacy of CDDP.	cddp	160-164	ribosomal protein S6 kinase A1	Homo sapiens	119-123
27065457-9	2016	In line, the biochemical inhibition of the p90RSK or the combined silencing of the most expressed RSK isoforms, namely RSK1 and RSK2, increased the efficacy of CDDP.	cddp	160-164	ribosomal protein S6 kinase A3	Homo sapiens	128-132
26492332-6	2016	This study aimed to investigate the role of miR-26a in CDDP resistance in NSCLC as well as the underlying mechanisms.	cddp	55-59	microRNA 26a-1	Homo sapiens	44-51
26733163-12	2016	The activity of LDHA was also abrogated in ABCC3-deficient UBC cells, and the blockade of LDHA increased UBC cells sensitivity to Cis-diamine dichloroplatinum (CDDP).	cddp	160-164	lactate dehydrogenase A	Homo sapiens	16-20
26733163-12	2016	The activity of LDHA was also abrogated in ABCC3-deficient UBC cells, and the blockade of LDHA increased UBC cells sensitivity to Cis-diamine dichloroplatinum (CDDP).	cddp	160-164	lactate dehydrogenase A	Homo sapiens	90-94
26492332-12	2016	Overexpression of miR-26a in A549 cells inhibited G1-S transition, increased cell death in response to CDDP treatment, and decreased the colony formation of A549 cells.	cddp	103-107	microRNA 26a-1	Homo sapiens	18-25
26492332-15	2016	CONCLUSION: MiR-26a is responsible for A549 cell sensitivity in the treatment of CDDP through regulating HMGA2-mediated E2F1-Akt pathway.	cddp	81-85	microRNA 26a-1	Homo sapiens	12-19
26492332-15	2016	CONCLUSION: MiR-26a is responsible for A549 cell sensitivity in the treatment of CDDP through regulating HMGA2-mediated E2F1-Akt pathway.	cddp	81-85	high mobility group AT-hook 2	Homo sapiens	105-110
26492332-15	2016	CONCLUSION: MiR-26a is responsible for A549 cell sensitivity in the treatment of CDDP through regulating HMGA2-mediated E2F1-Akt pathway.	cddp	81-85	E2F transcription factor 1	Homo sapiens	120-124
26724920-1	2016	The interaction of antitumor drug, cisplatin (cis-[PtCl2(NH3)2], CDDP) with insulin from porcine pancreas has been investigated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and high resolution hybrid ion trap/time-of-flight mass spectrometry (MALIDI-TOF/TOF-MS and ESI-IT/TOF MS).	cddp	65-69	insulin	Homo sapiens	76-83
26805233-10	2015	Combination therapy using TS-1 plus CDDP plus trastuzumab resulted in a good response, and the leukocytosis and elevated serum G-CSF gradually improved.	cddp	36-40	colony stimulating factor 3	Homo sapiens	127-132
26647656-6	2016	Regarding SAS, CD44v3+/CD24- cells also showed a higher drug resistance for CDDP, 5-FU and cetuximab and expressed higher mRNA levels of CSC property-related genes than the other cell fractions.	cddp	76-80	CD24 molecule	Homo sapiens	23-27
26165741-0	2015	Dissociation of E-cadherin/beta-catenin complex by MG132 and bortezomib enhances CDDP induced cell death in oral cancer SCC-25 cells.	cddp	81-85	cadherin 1	Homo sapiens	16-26
26165741-0	2015	Dissociation of E-cadherin/beta-catenin complex by MG132 and bortezomib enhances CDDP induced cell death in oral cancer SCC-25 cells.	cddp	81-85	catenin beta 1	Homo sapiens	27-39
26254540-9	2015	The synergistic effect of SSZ and CDDP was reversed by antioxidant N-acetyl-L-cysteine (NAC).	cddp	34-38	X-linked Kx blood group	Homo sapiens	88-91
26398317-9	2015	Treatment with anti-CD20-hIFNalpha sensitized the cells to apoptosis by CDDP, doxorubicin and Treanda.	cddp	72-76	keratin 20	Homo sapiens	20-24
26398317-9	2015	Treatment with anti-CD20-hIFNalpha sensitized the cells to apoptosis by CDDP, doxorubicin and Treanda.	cddp	72-76	interferon alpha 1	Homo sapiens	25-34
26398317-12	2015	Treatment with SB203580 enhanced the sensitization of the resistant clone by anti-CD20-hIFNalpha to CDDP apoptosis.	cddp	100-104	keratin 20	Homo sapiens	82-86
26398317-12	2015	Treatment with SB203580 enhanced the sensitization of the resistant clone by anti-CD20-hIFNalpha to CDDP apoptosis.	cddp	100-104	interferon alpha 1	Homo sapiens	87-96
25154814-4	2015	We have established that Protein Phosphatase Magnesium-dependent 1 D (PPM1D) confers CDDP resistance in gynecological cancer cells by deactivating p53.	cddp	85-89	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	25-68
25154814-4	2015	We have established that Protein Phosphatase Magnesium-dependent 1 D (PPM1D) confers CDDP resistance in gynecological cancer cells by deactivating p53.	cddp	85-89	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	70-75
25154814-4	2015	We have established that Protein Phosphatase Magnesium-dependent 1 D (PPM1D) confers CDDP resistance in gynecological cancer cells by deactivating p53.	cddp	85-89	tumor protein p53	Homo sapiens	147-150
25154814-5	2015	However, whether CDDP regulates intra-cellular PPM1D localization and whether this regulation is different between chemosensitive and chemoresistant cancer cells is unknown.	cddp	17-21	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	47-52
25154814-6	2015	Moreover, whether Akt regulates PPM1D in the context of CDDP resistance has not been studied.	cddp	56-60	AKT serine/threonine kinase 1	Homo sapiens	18-21
25154814-8	2015	In conclusion, we have established that PPM1D plays an important role in promoting CDDP resistance and as a novel downstream target of Akt, PPM1D mediates its action in conferring CDDP resistance in gynecological cancer cells.	cddp	83-87	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	40-45
25154814-8	2015	In conclusion, we have established that PPM1D plays an important role in promoting CDDP resistance and as a novel downstream target of Akt, PPM1D mediates its action in conferring CDDP resistance in gynecological cancer cells.	cddp	83-87	AKT serine/threonine kinase 1	Homo sapiens	135-138
25154814-8	2015	In conclusion, we have established that PPM1D plays an important role in promoting CDDP resistance and as a novel downstream target of Akt, PPM1D mediates its action in conferring CDDP resistance in gynecological cancer cells.	cddp	180-184	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	40-45
25154814-8	2015	In conclusion, we have established that PPM1D plays an important role in promoting CDDP resistance and as a novel downstream target of Akt, PPM1D mediates its action in conferring CDDP resistance in gynecological cancer cells.	cddp	180-184	AKT serine/threonine kinase 1	Homo sapiens	135-138
25154814-8	2015	In conclusion, we have established that PPM1D plays an important role in promoting CDDP resistance and as a novel downstream target of Akt, PPM1D mediates its action in conferring CDDP resistance in gynecological cancer cells.	cddp	180-184	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	140-145
26283082-10	2015	RESULTS: Oral administration of ZMYL prior to the CDDP treatment could prevent the CDDP-induced in lifting of ALT and AST, reduction of T-GSH, R-GSH and GST, and some histopathological alterations in ICR mice.	cddp	83-87	glutamic pyruvic transaminase, soluble	Mus musculus	110-113
26283082-10	2015	RESULTS: Oral administration of ZMYL prior to the CDDP treatment could prevent the CDDP-induced in lifting of ALT and AST, reduction of T-GSH, R-GSH and GST, and some histopathological alterations in ICR mice.	cddp	83-87	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	118-121
25772757-5	2015	RESULTS: Both gene and protein expression of OCT6 were decreased in both CDDP-resistant cell lines compared with their expression in their respective parental cells.	cddp	73-77	solute carrier family 22 member 16	Homo sapiens	45-49
26088228-0	2015	Re: The PDGFRbeta-AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors.	cddp	45-49	platelet derived growth factor receptor beta	Homo sapiens	8-17
26088228-0	2015	Re: The PDGFRbeta-AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors.	cddp	45-49	AKT serine/threonine kinase 1	Homo sapiens	18-21
25359574-5	2015	Furthermore, in NSCLC cell lines, ATF2 expression levels were evaluated and correlated to platinum (CDDP) resistance.	cddp	100-104	activating transcription factor 2	Homo sapiens	34-38
25359574-8	2015	CDDP-resistant NSCLC cell lines expressed high levels of ATF2 protein.	cddp	0-4	activating transcription factor 2	Homo sapiens	57-61
25359574-9	2015	By contrast, Celastrol-mediated ATF2/cJUN functional inhibition restored the response to CDDP.	cddp	89-93	activating transcription factor 2	Homo sapiens	32-36
25359574-9	2015	By contrast, Celastrol-mediated ATF2/cJUN functional inhibition restored the response to CDDP.	cddp	89-93	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	37-41
25359574-10	2015	Moreover, ATF2 protein activation correlates with worse outcome in advanced CDDP-treated patients.	cddp	76-80	activating transcription factor 2	Homo sapiens	10-14
25359574-12	2015	In addition, we reported that in NSCLC cell lines a correlation between ATF2 protein expression and CDDP resistance occurs.	cddp	100-104	activating transcription factor 2	Homo sapiens	72-76
25359574-13	2015	Altogether, our results indicate a potential increase in CDDP sensitivity, on Celastrol-mediated ATF2/cJUN inhibition.	cddp	57-61	activating transcription factor 2	Homo sapiens	97-101
25359574-13	2015	Altogether, our results indicate a potential increase in CDDP sensitivity, on Celastrol-mediated ATF2/cJUN inhibition.	cddp	57-61	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	102-106
25359574-14	2015	These data suggest a possible involvement of ATF2 in NSCLC CDDP-resistance.	cddp	59-63	activating transcription factor 2	Homo sapiens	45-49
25529533-7	2015	Experiments to measure the pharmacokinetics and biodistribution demonstrated that the selected CDDP/PLG-g-mPEG nanoparticles, NP10, had a long blood circulation time and could achieve selective and significant accumulation in Lewis lung carcinoma (LLC) tumors.	cddp	95-99	nuclear receptor subfamily 4, group A, member 1	Mus musculus	126-130
25529533-8	2015	The platinum plasma concentrations in the LLC tumor-bearing mice receiving NP10 remained up to 46-fold higher than that of mice receiving equivalent doses of free CDDP.	cddp	163-167	nuclear receptor subfamily 4, group A, member 1	Mus musculus	75-79
25529533-9	2015	In addition, the plasma area under the concentration time curve (AUC) of NP10 was 31-fold higher than that of free CDDP in 48h.	cddp	115-119	nuclear receptor subfamily 4, group A, member 1	Mus musculus	73-77
25529533-10	2015	The platinum concentration ratio of NP10 to free CDDP in tumors reached as high as 9.4.	cddp	49-53	nuclear receptor subfamily 4, group A, member 1	Mus musculus	36-40
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	cddp	127-131	solute carrier family 22 member 16	Homo sapiens	13-17
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	cddp	127-131	solute carrier family 22 member 16	Homo sapiens	64-68
25772757-7	2015	Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.	cddp	127-131	solute carrier family 22 member 16	Homo sapiens	75-83
25927922-3	2015	It is hypothesized that increased CTR1 expression would enhance the sensitivity of cancer cells to cisplatin (cDDP).	cddp	110-114	solute carrier family 31 member 1	Homo sapiens	34-38
25927922-5	2015	EGCG inhibits the rapid degradation of CTR1 induced by cDDP.	cddp	55-59	solute carrier family 31 member 1	Homo sapiens	39-43